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In the nervous system, rapidly occuring processes such as neuronal transmission and 
calcium signaling are afected by short-term inhibition of proteasome function. It is unclear how 
proteasomes are able to acutely regulate such processes, as this action is inconsistent with their 
canonical role in proteostasis. We discovered a mammalian nervous-system-specific membrane 
20S proteasome complex that directly and rapidly modulates neuronal function by degrading 
intracelular proteins into extracelular peptides that can stimulate neuronal signaling. This 
proteasome complex is closely associated with neuronal plasma membranes, exposed to the 
extracelular space, and catalyticaly active. Selective inhibition of the membrane proteasome 
complex by a cel-impermeable proteasome inhibitor blocked the production of extracelular 
peptides and atenuated neuronal-activity-induced calcium signaling. Moreover, we observed that 
membrane-proteasome-derived peptides were suficient to induce neuronal calcium signaling.  
Analyzing the composition of the neuronal membrane proteasome (NMP), we did not 
find canonical ubiquitin-proteasome components required for recognizing a ubiquitiylated 
protein. This raised the fundamental question of how substrates were being targeted to the NMP 
for degradation into extracelular peptides. Remarkably, we observed newly synthesized 
polypeptides were rapidly turned over by the NMP in a stimulation-dependent manner. This 
turnover corelated with enhanced production of NMP-derived peptides in the extracelular space. 
Using parameters determined in these experiments, we constructed Markov process chain models 
in silico which predicted that the kinetics of this process necessitate coordination of translation 
and degradation. In a series of biochemical analyses, this predicted coordination was instantiated 
by NMP-mediated and ubiquitin-independent degradation of ribosome-associated nascent 
polypeptides. Using in-depth, global, and unbiased mass spectrometry, we identified the nascent 
protein substrates of the NMP. Among these substrates, we found that immediate-early gene 




synthesis, prior to activity-induced transcriptional responses. Our findings chalenge the 
prevailing notion that proteasomes function primarily to maintain proteostasis, and highlight a 
form of neuronal communication that takes place through the NMP. Together, these findings 
generaly define an activity-dependent protein quality control program unique to the nervous 
system through the neuronal membrane proteasome. 
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 The ability to interact and communicate with the environment around us relies on 
fundamental intracelular events within neurons that enable robust and rapid neuronal 
communication. Neuronal communication takes place over multiple timescales, from rapid 
neurotransmission events (~1ms) to long-scale peptide and hormone communication (~hrs). This 
large variation in timescales is determined by an accompanying diversity in the molecular 
underpinnings of neuronal communication. Analyzing these molecular mechanisms, there are 
some contributors to neuronal communication that remain unexplored. For example, inhibition of 
the proteasome, the major machine and pathway that enables intracelular protein degradation, 
has previously been shown to afect the speed and intensity of neuronal transmission within 
seconds to minutes. This remains entirely inconsistent with what is known about the function for 
proteasomes in degrading proteins and regulating protein homeostasis over hours to days. This 
fundamental contradiction provided the rationale to explore unidentified functions for 
proteasomes in the nervous system to rapidly regulate neuronal signaling. 
1.1 Protein homeostasis 
Over their lifetime, cels experience a huge number of extracelular and intracelular cues. 
A smal subset of examples include hormone and growth signals, cel-cel communication or 
contact-based signals, extracelular remodeling, organelar or DNA damage events, or generaly 
aging-induced changes. In most cel types, these perturbations modulate gene and protein 
expression, which eventualy leads to changes in both the identity and abundance of synthesized 
proteins. Such large-scale events generate stress on an already busy and dynamic system. Over 
the past few decades, a substantial number of studies have demonstrated that these fluctuations 
and stresses can have detrimental consequences for cel viability and outcomes. These efects are 
largely bufered by a series of intracelular pathways that regulate translation, protein folding, and 
protein degradation(Sontag, Samant, and Frydman 2017; Brehme et al. 2014; Labbadia and 
Morimoto 2015). We define protein homeostasis as the colective set of inter and intracelular 




large changes in gene and protein expression. Protein homeostasis (or proteostasis) permits a 
system to maintain biochemical homeostasis when chalenged with various stimuli. 
Neurons display a particular and unique sensitivity to alterations in proteostasis(Brehme 
et al. 2014). Such vulnerabilities are most clearly demonstrated by the vast number of genetic 
disorders of protein aggregation that are characterized by severe phenotypes in the nervous 
system. Examples include Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral 
Sclerosis, Huntington’s disease, Frontotemporal Dementia, and so on. Moreover, disorders such 
as Autism spectrum disorder, Angelman Syndrome, Fragile X mental retardation disorder, and 
others have been linked to dysfunctions in both the protein synthesis or protein degradation 
machinery. Mechanisms that dictate the sensitivity of the nervous system over other tissues are 
only beginning to be uncovered and require far more investigation. There is a plethora of 
information regarding general mechanisms of proteostasis. For the purposes of providing 
background for my work, I wil focus on core mechanisms of regulating protein synthesis and 
protein degradation.  
 The ribosome is the center of protein synthesis in al cels, generating the proteome that 
defines celular composition and function(Alberts B 2002). At the ribosome, newly synthesized 
polypeptides leave the exit tunnel and must undergo the complex task of folding into the proper 
conformation. Al the while, the remainder of the protein is continuing to be synthesized. This 
makes the ribosome an ideal platform for ensuring that protein synthesis occurs properly, without 
aggregation or misfolding(Pechmann, Wilmund, and Frydman 2013). Nascent polypeptides are 
also therefore one of the most vulnerable populations in the cel to cellular 
perturbations(Dimitrova et al. 2009; Kramer et al. 2009; Ito et al. 2011; Pechmann, Wilmund, 
and Frydman 2013; Gloge et al. 2014; Balchin, Hayer-Hartl, and Hartl 2016). As nascent 
polypeptides emerge from the exit tunnel, they begin folding co-translationaly. A set of 
eukaryotic chaperones regulate this process, such as the nascent polypeptide-associated complex 




chains can be detected from within the exit tunnel prior to exit, and the appropriate machinery 
recruited to the ribosome and the new nascent chain. Folowing synthesis, some substrates 
continue to need assistance in achieving the corect folded state. Prefoldin, TRiC/CCT, Hsp90, 
and a few other factors assist with complex proteins that cannot just be dealt with by ribosome-
bound chaperones(Kirstein-Miles et al. 2013; Frydman et al. 1992; Frydman et al. 1994; Melvile 
et al. 2003; Kim et al. 2010; Albanese, Reissmann, and Frydman 2010). For topologicaly 
chalenging proteins, substrates need to be shutled to complex chaperonins such as TRiC for 
sustained and protected folding. For other substrates such as Endoplasmic Reticulum (ER)-
destined proteins, the signal sequence is recognized by signal recognition particle SRP. SRP 
competes or interacts with NAC, and trafics nascent chains to the appropriate fate(Thrift et al. 
1991; Ng and Walter 1994; Ogg and Walter 1995; Powers and Walter 1996; Wiedmann et al. 
1994; Siegel 1995; Gamerdinger et al. 2015). 
 Despite this large and robust repertoire of mechanisms to ensure polypeptide fidelity, a 
portion of synthesized proteins wil contain translation or folding defects. These defects are only 
exaggerated by celular stresses, and therefore, mechanisms to eliminate these improper proteins 
are critical to celular viability. Two major systems of protein degradation are employed to ensure 
the fidelity of the proteome – 1) proteasome-mediated protein degradation and 2) autophagy or 
lysosome-mediate protein degradation. 
First, the ubiquitin-proteasome system is the dominant form of protein degradation in 
almost al cels. First, a protein is tagged for degradation through an enzymatic cascade of E1 
ubiquitin-activating enzymes that transfer ubiquitin to an E2. These E2 conjugate the ubiquitin to 
the E3 ubiquitin ligase, which finaly marks a candidate substrate for ubiquitylation and 
subsequent degradation by the proteasome(Coux, Tanaka, and Goldberg 1996; Ciechanover 1998; 
Grol et al. 2000; Tsai 2014; Colins and Goldberg 2017). Proteasomes are large multisubunit 
catalytic machines that are made of a core 20S particle and a 19S cap. The 19S cap contains a 




deubiquitinases that remove the ubiquitylated protein, and then ATPases that use ATP hydrolysis 
to unfold the candidate substrate for its subsequent degradation. This step is thought to be 
necessary prior to degradation by the core 20S proteasome, because the pore of the 20S is fairly 
narow (~6Ao), which requires a substrate to be nearly linearized(Coux, Tanaka, and Goldberg 
1996; Ciechanover 1998; Grol et al. 2000; Tsai 2014; Colins and Goldberg 2017). The core 20S 
degrades these proteins into peptide fragments. Typicaly, these peptides are turned over by exo- 
and endopeptidases within a few seconds and converted into single amino acids for reuse. This is 
why the proteasome is generaly considered to be a degradation machine responsible for the 
ubiquitin-dependent turnover of proteins and sometimes to regenerate free amino acids.  
The ubiquitin-proteasome system is the canonical system for degrading proteins, though 
there are cases where the proteasome is thought to have functions that are independent of 
ubiquitylation. Historicaly, there have been dozens of reports of ubiquitin-independent 
degradation of particular protein substrates. In particular, substrates such as c-Fos, p21, and 
ornithine decarboxylase have al been shown to be degraded without requiring tagging by 
ubiquitin(Hoyt, Zhang, and Cofino 2003; Asher et al. 2005; Bodenstein, Sunahara, and Neubig 
2007; Tsvetkov, Reuven, and Shaul 2009; Tsvetkov et al. 2009; Adler et al. 2010). This has been 
shown to be driven through just the 20S proteasome, without the 19S cap. However, most 
scenarios in cels have focused on the capped 26S proteasome. Rising evidence does suggest that 
20S proteasomes exist without 19S caps in cels, though these data are stil actively debated and 
in progress(Ben-Nissan and Sharon 2014). In general, 20S proteasome-mediated ubiquitin-
independent degradation is thought to be of unstructured or intrinsicaly disordered 
proteins(Coux, Tanaka, and Goldberg 1996; Asher et al. 2005; Tsvetkov et al. 2008; Rabl et al. 
2008; Adler et al. 2010; Ben-Nissan and Sharon 2014). This seems likely since the 20S cannot 
itself unfold a substrate or recognize a ubiquitylated protein, and there must be some structure 




These structural constraints on what can enter the 20S therefore dictates that the majority 
of proteasome substrates must be processed through the ubiquitin pathway. How then do cels 
handle large aggregates, which are chalenging to unfold using proteasomal ATPases? Typicaly, 
autophagy and lysosomal degradation handle such large cargo which can range from groups of 
proteins to entire organeles(Jiang et al. 2013; Yang and Klionsky 2010; Kaushik and Cuervo 
2012; Wickner, Maurizi, and Gotesman 1999; Doyle, Genest, and Wickner 2013). In some cases, 
proteins are released from aggregates through chaperones and targeted to the autophagy 
machinery, and in other cases, the machinery is recruited to the aggregates. Regardless of how the 
autophagy machinery sees its cargo, the cargo is then loaded into a double-membrane vesicle and 
traficked to the lysosome. This is thought to be driven by the concerted actions of over 40 
autophagy-releated genes which function at the various steps of this process. While the 
progression through autophagy has largely been thought to be vectorial and sequential, recent 
data runs contradictory to this paradigm. Certainly, the pathways is criticaly important over 
longer timescales (~hrs to days) to determine protein turnover or that of large aggregates. 
However, because of the complexity and intrinsic speed of the mechanisms involved, autophagy 
is unlikely to provide major contributions to rapid celular events, such as neuronal 
communication. Both the protein synthesis and protein degradation machinery are far more 
poised to participate in such mechanisms. While seemingly contradictory to their canonical role 
in regulating global protein homeostasis, such rapid mechanisms are tantalizing to consider and 
could open new domains in biology. 
1.2 Protein synthesis and proteasome-mediated protein degradation in the nervous system 
Mounting evidence suggests that both ribosomes and proteasomes are regulated in tissue-
specific manners. For example, recent reports reveal the expression of tRNAs that are unique to 
the nervous system. Interfering with or mutations in this tRNA leads to severe neurodegenerative 
phenotypes(Ishimura et al. 2014). In addition, components that regulate the translation life cycle 




Translation is even regulated at the level of codon usage across tissues, which have clear efects 
on translation eficiency(Plotkin, Robins, and Levine 2004; Ditmar, Goodenbour, and Pan 2006). 
How these diferent modes of translational regulation come together to modulate a tissue-specific 
outcome is largely unexplored. Finaly, while older studies suggest that the composition of 
ribosomes themselves may be diferent in diferent tissues, these studies have not been rigorously 
folowed up using modern approaches. 
What about tissue-specific proteasome expression? There are many modes of regulation 
of the UPS to focus on. For example, TRIM32 is a tissue-specific ubiquitin ligase that is restricted 
to skeletal muscle(Lazzari and Meroni 2016). This serves as a way of modulating substrate 
selectivity in diferent tissues. There are also a number of situations where the proteasome 
composition itself is altered. First and foremost, three major types of core 20S proteasomes have 
been identified in diferent tissues. The most classic example for tissue-specific proteasome 
expression is in the immune system. Here, the so-caled immunoproteasome contains three unique 
subunits that are highly enriched in the immune system that swap places into the normal 
proteasome(Rock et al. 2014; Etari et al. 2017; Freudenburg et al. 2013; Basler, Kirk, and 
Groetrup 2013; Johnston-Carey, Pomato, and Davies 2015; Winter et al. 2017). This subunit 
replacement results in a proteasome that is more finely tuned towards generating longer peptides. 
In fact, these peptides go on to be processed and presented as antigenic peptides that alow cels 
to dictate self vs non-self. Therefore, this tissue-specific proteasome degradation system lies at 
the heart of how the immune system functions. In addition, the thymoproteasome has shown to 
utilize a diferent b5 subunit, the production of CD4+ T cels that are generated in the 
thymus(Murata, Takahama, and Tanaka 2008). These cels are necessary for mounting a strong 
antigenic response against viral infections and other chalenges to the immune system. Finaly, 
the most extensive modulation in proteasome composition has been observed in 




Yokota, Harada, and Sawada 2010; D'Amours et al. 2010; Sanchez et al. 2011; Rosales et al. 
2011; Sasanami et al. 2012; Uechi, Hamazaki, and Murata 2014; Richburg, Myers, and Braton 
2014). These proteasome subunits undergo extensive alternative splicing, generating a series of 
diferent types of proteasomes in diferent parts of the sperm. Studies looking into this further 
have shown diferent capping structures in diferent regions of sperm. For example, nuclear 
spermatoproteasomes have been shown to be capped by PA200 which enables eficient 
degradation of histones. Perhaps the most unusual and intriguing observation of 
spermatoproteasomes is their localization to plasma membranes. A few groups have made this 
observation, though they have not at al been folowed up on or studied in great detail. 
Indeed, such tissue-specific regulation is also observed in the nervous system. This seems 
logical as neurons, as large polarized and spatialy segregated cels, need to solve the chalenging 
problem of local protein synthesis and degradation near sites of activity without relying on 
transcriptional responses. Local protein synthesis has been detected over the past two deacdes 
using chemical reporters of protein synthesis. Initialy, these studies were motivated by 
observations that ribosomes were localized at the base of dendritic spines, and even in axon 
terminals(Steward and Levy 1982; Steward and Falk 1991; Steward and Worley 2001). Later 
studies developed reporters which typicaly utilize either unnatural amino acid incorporation and 
detection by mass spectrometry, or incorporation of puromycin to disrupt the translating nascent 
polypeptide and subsequent detection using antibodies against puromycin(Aakalu et al. 2001; 
Dieterich et al. 2010; Landgraf et al. 2015). These techniques have al suggested that translation 
occurs both pre- and post-synapticaly, though there continues to be debate about 
this(Tcherkezian et al. 2010). In addition to spatial regulation of protein synthesis, there is also 
evidence of the role for neuronal activity to modulate protein synthesis. Based on some of the 
puromycin-based reporters, the Schuman group has reported that neuronal activity bi-
directionaly modulates the amount of protein synthesis(Aakalu et al. 2001; Bingol and Schuman 




pharmacological experiments reveals that neuronal activity relieves ribosomal staling on 
dendritic mRNAs(Graber et al. 2013). This suggests that a large portion of mRNAs in dendrites 
are held in translationaly repressed states, such as in stress granules(Ramaswami, Taylor, and 
Parker 2013; Wheeler et al. 2016; Proter and Parker 2016; Proter et al. 2018). Somehow, 
neuronal activity may play a critical role in activating or translating these transcripts. Regardless, 
the role for activity in protein translation seems to be an emerging modality of post-
transcriptional regulation of the proteome. 
Another mechanism by which the proteome can be remodeled is through proteasome-
mediated protein degradation. Proteasomes have been shown to be distributed al across the 
neuron, from the nucleus, soma, dendrites, axons, and even in dendritic spines(Asano et al. 2015; 
Campbel and Holt 2001; Ehlers 2003; Bingol and Schuman 2006; Tai and Schuman 2008b). 
Components of the UPS do exist at spines as wel, such as the E3 ubiquitin ligases IDOL, Trim3, 
and Ube3A(Liu et al. 2008; Albrecht et al. 1997; Tai et al. 2010; Schreiber et al. 2015; Lazzari 
and Meroni 2016). Other components have been shown to be enriched in the brain such as the 
ligase RNF182(Liu et al. 2008). Unusualy, the initiating components of the ubiquitin cascade 
(E1s and E2s) have not been studied in dendrites or axons. Some investigation has also gone into 
biochemical separation of neuronal cultures, and purification of proteasome complexes to 
determine whether these proteasomes are 20S or single- or double-capped 26S proteasomes(Tai et 
al. 2010). These data surprisingly revealed that a significant fraction of proteasomes are 20S. In 
support of the diferent types of proteasomes in the nervous system, cryo-electron tomography 
analysis of proteasomes in intact hippocampal neurons reveals proteasomes in diferent capping 
states(Asano et al. 2015). In contrast to the biochemical methods, the majority of proteasomes 
detected by Cryo-ET methods are singly or doubly capped. These data are interpreted to mean 
that the the majority of proteasomes are in substrate processing modes. However, these data 
should be re-evaluated in the context of the significant amount of work on 20S proteasome-




fairly dynamic, where some proteasomes are capped and uncapped depending on the activity state 
of the neuron. In response to excitatory neuronal stimuli, a large fraction of singly- and doubly-
capped proteasomes have been shown to disassemble into uncapped 20S proteasomes. Again, 
much like protein synthesis, components of the protein degradation machinery seem to be 
modulated by neuronal activity(Ehlers 2003; Bingol and Schuman 2006). This extends to both the 
localization of proteasomes segregating to dendritic spines, and enzymatic activity of proteasome-
mediated protein degradation increasing in response to stimulation. 
Therefore, neuronal activity-dependent biochemical programs drive the enzymatic 
activity of both ribosomes and proteasomes. In addition, activity promotes the localization of both 
complexes to the same subcelular compartments. This leaves a fundamental but outstanding 
question: do the ribosome and proteasome coordinate their actions in any manner? Such a 
coordination could result in either or both ubiquitylation and degradation of polypeptides 
undergoing translation. Indeed, such co-translational mechanisms have been both postulated and 
observed(Robertson and Wheatley 1979; Wheatley, Giddings, and Inglis 1980; Wheatley, 
Grisolia, and Hernandez-Yago 1982; Wheatley and Inglis 1980). Historical studies on the fate of 
newly synthesized proteins have been extensively conducted and folowed up on, though not in 
neuronal tissues. A major conclusion of these studies is that newly synthesized proteins can be 
incredibly susceptible to rapid turnover, potentialy through co-translational mechanisms. 
However, compeling evidence for such turnover is largely lacking, with a few major exceptions. 
In contrast, substantial evidence has recently emerged for co-translational ubiquitylation. This is 
largely driven by Listerin1 (Ltn1) and the Ribosome Quality Control (RQC) complex(Brandman 
et al. 2012; von der Malsburg, Shao, and Hegde 2015; Yonashiro et al. 2016; Bengtson and 
Joazeiro 2010). Ltn1 is a ubiquitin ligase that is a component of the RQC complex. These 
proteins mediate a protein quality control response to recognize staled ribosomes, separate the 
ribosomes, and eliminate the partial polypeptide through the ubiquitin-proteasome system. As a 




variety of substrates in yeast that depends on a large series of ubiquitin ligases(Dutler, 
Pechmann, and Frydman 2013). A few studies have even gone on to show that some substrates 
are co-translationaly degraded, potentialy without the need for ubiquitylation. Beyond these 
types of near-direct interactions between UPS components and the ribosome, secondary 
consequences of signaling pathways have linked protein synthesis and degradation together. Of 
note, mammalian Target of Rapamycin (mTOR), a key metabolic sensor in mammalian cels, has 
clearly been shown to be involved in both proteasomal degradation and protein 
synthesis(Keleher, Govindarajan, and Tonegawa 2004; Wu, Volta, et al. 2009; Zhao et al. 2015; 
Zhao, Garcia, and Goldberg 2016). Though interplay was posited by a few studies, these studies 
have come under question based on methodologies that they employ. More general mechanisms 
have also been proposed for the interplay between proteasomes and ribosomes. Proteasome 
inhibition has reproducibly shown to inhibit protein synthesis(Ding et al. 2006; Obeng et al. 
2006). This likely occurs through the activation of the unfolded protein response, leading to 
phosphorylation of elongation initiation factor 2 alpha (eIF2α) and subsequent inhibition of 
protein synthesis. 
The overal functions of protein synthesis and degradation in the nervous system have 
been studied for the beter half of a century. Initialy, this work was done using inhibitors against 
protein synthesis, and in particular, Puromycin. Puromycin is an aminoacyl-tRNA mimic that 
modified the growing nascent polypeptide and prematurely releases the nascent chain from the 
ribosome(Nathans and Neidle 1963; Nathans 1964). The earliest experiments with Puromycin in 
the nervous system injected tritiated radiolabeled Puromycin into the brains of mice, and 
monitored the fate of puromycylated peptides in the brain(Flexner et al. 1962; Flexner, Flexner, 
and Stelar 1963; Flexner et al. 1964; Flexner and Flexner 1967; Flexner and Flexner 1968; 
Roberts and Flexner 1969; Flexner et al. 1971). These studies revealed an unusualy long lifetime 
of these radiopeptides, and that these peptides spread from the site of injection far into other 




learning and memory, no folow up experiments were done for more than two decades. The next 
major set of experiments to address these questions injected Puromycin and cycloheximide into 
the brains of mice undergoing behavior tasks. These and many subsequent experiments 
determined the requirement for protein synthesis in learning and memory using a variety of 
paradigms in both amygdala and hippocampus. A coresponding plethora of data has been 
generated using inhibitors of protein degradation, which by and large have similar consequences 
in similar brain regions in similar behavioral tasks. Based on some fairly uncompeling data, these 
changes have been corelated to changes in the ubiquitylation state of proteins. However, changes 
in substrate levels in response to neuronal activity or under diferent behavioral paradigms needs 
to be clearly demonstrated. 
Outside of behavioral contexts, many compeling studies on protein synthesis and 
degradation have been done. These have largely focused on the use of inhibitors of the synthesis 
and degradation machinery on long-term potentiation (LTP) and depression (LTD). These 
mechanisms are thought to be fundamental to the core function of the nervous system to encode 
information. LTP is defined as a stimulation-dependent sustained increase in synaptic strength 
that is thought to underlie learning and memory, while LTD is the opposite phenomenon(Nicol 
and Roche 2013). Protein synthesis and protein degradation have been shown to be critical for the 
maintenance of LTP and LTD(Keleher, Govindarajan, and Tonegawa 2004; Fonseca et al. 2006; 
Fonseca, Nagerl, and Bonhoefer 2006; Klein, Castilo, and Jordan 2015). Intriguingly, neither 
have been shown to be involved in the induction of LTP (early-LTP). This is likely because 
calcium influx and the resulting receptor insertion events are critical for short LTP. However, the 
mechanisms underlying late-LTP and late-LTD are unknown. In addition, both protein synthesis 
and protein degradation have been shown to be critical for synaptic tagging and capture(Cai et al. 
2010). This is thought to be a phenomenon underlying heterosynaptic plasticity, where one set of 
inputs influence the dynamic range of plasticity of an alternate set of inputs. The primary inputs 




tags”. The tags are likely protein in origin, as they rely on protein synthesis to be 
established(Ding, Cecarini, and Keler 2007). Intriguingly though, they also rely on protein 
degradation. This seems unusual since if they were simply a set of proteins that were made, then 
protein degradation should not be necessary. Therefore, there seems to be a more complex 
phenomenon underlying synaptic tagging that may depend on the coordination of protein 
synthesis and degradation. 
1.3 Neuronal communication and smal peptides 
Neuronal communication takes place over multiple timescales, from rapid 
neurotransmission events (~1ms) to long-scale peptide and hormone communication (~hrs). This 
diversity in timescale is driven by diversity in the molecular underpinnings of these events. 
Neurotransmission is dictated by fast and transient release of specific neurotransmiters which act 
on specific receptors(Hyman 2005). The duration of action for these molecules act is determined 
and regulated by specific reuptake mechanisms in both neurons and glial cels. The action of 
neurotransmiters tends to be fairly transient, and gives a short and directed signal in a determined 
manner. In contrast, hormone signaling begins with a series of signaling events, which drives the 
transcription of genes encoding the hormone products(Nestler et al. 2015). Subsequently, the pre-
peptide neuropeptides must be processed to their active forms, and eventualy exported and 
transported to their targets. The relative timescales of these actions provides critical information 
about their functions in the nervous system: while fast neurotransmission underlies fast 
membrane depolarization events, slow peptide hormone signaling is largely used for slow 
neuromodulation. 
Blockade of the classic neurotransmiter receptors such as AMPA, NMDA, and 
GABAergic receptors inhibits miniature and evoked excitatory and inhibitory postsynaptic 
curents. This is the primary basis for the understanding that these receptors, and classic 
neurotransmission, is the dominant form of neuronal communication. In addition, neurotrophic 




neurotrophic factor (BDNF) can modulate the magnitude and type of LTP, though the exact role 
for and magnitude of this modulation is debated(Lu, Christian, and Lu 2008; Mei et al. 2011). 
These are largely considered to be in the class of neurotrophic factors, many of which modulate 
neurotransmiter release or function in unique circuits and perform particular functions. Other 
such factors include nerve growth factor (NGF), Ephrins, Insulin growth factor-1 (IGF-1), and 
many others(Bergado et al. 1997; Bozdagi, Tavassoli, and Buxbaum 2013; Ivanov et al. 2015). 
Many of these factors play important roles in the development of the nervous system, learning 
and memory, and molecular mechanisms underlying LTP and LTD. In addition to neurotrophic 
factors, a large class of neuromodulatory factors caled neuropeptides are expressed in unique 
circuits to modulate behavior and circuit function. A classic example of a neuropeptide is 
Enkephalin, a 30 amino acid neuropeptide that largely regulates pain sensing. Another wel-
studied neuropeptide is oxytocin, which regulates a variety of social behaviors. Finaly, there are 
classes of neuropeptides that regulate feeding and thirst, such as Gastrin, Ghrelin, and Agouti-
related peptide (AGRP)(Nestler et al. 2015). Finaly, smal molecules are also capable of 
modulating neurotransmission. The most wel studied and rigorous example of this is through 
endocannabinoids, which are released from the postsynaptic site and act at the presynaptic 
terminal to modulate neurotransmiter release. Al of these types of atypical neurotransmiters, 
neuropeptides, and neuromodulators are derived from specific gene transcripts. This propeptides 
or prohormones are extensively post-translationaly modified and cleaved to generate the active 
form, which are then released. There are exceptions to these rules, for molecules such as 
gasotransmiters such as nitric oxide, carbon monoxide, and hydrogen sulfide. Each of these can 
individualy modify LTP, LTD, and a host of intracelular signaling pathways(Nestler et al. 
2015). In addition, the endocannabinoids are also synthesized through regulated metabolic 
pathways and eventualy released. The classic examples are the eicosanoids anandamide and 2-




retrograde signal to modulate presynaptic synaptic release and overal neuronal 
excitability(Nestler et al. 2015). 
Al of these systems rely on transcriptional responses, cleavage of particular proproteins, 
or metabolic signaling mechanisms to generate functional neuropeptides and neuromodulators. 
However, inhibition of certain pathways that do not afect either of these canonical neuronal 
communication mechanisms can lead to changes in neuronal function and neuronal firing. The 
biochemical mechanisms that generate proteins and peptides within cels have extraordinary 
capacity to influence neuronal function. These mechanisms constitutively generate an enormous 
amount of proteins and peptides, and are necessary for the overal protein homeostasis of the cel. 
However, separating the contributions of these biochemical mechanisms to just protein 
homeostasis versus signaling remains to be clearly elucidated. This needs to be elaborated in light 
of data demonstrating that inhibition of these pathways can very rapidly modulate neuronal 
signaling. Therefore, the goal of my thesis work was to determine what the roles of protein 
synthesis and protein degradation were in rapid neuronal signaling. By investigating these 
mechanisms, I revealed a coordination between protein synthesis and degradation through a 
neuronal-specific plasma membrane 20S proteasome complex. This coordination and degradation 

























































































































































































































PRS10 44 0 0  11 22 0 0 0 44.00% 27.80% 
PRS4 49   0   0  6 16   0   0   0 31.80% 13.90% 
PRS6A 50 0 0  10 16 0 0 0 30.80% 23.05% 
PRS6B 47   0   0  18 27   0   0   0 58.40% 33.80% 
PRS7 49 0 0  15 20 0 0 0 36.70% 25.80% 
PRS8 46   0   0  9 21   0   0   0 51.00% 20.90% 
PSMD1 106 0 0  20 48 0 0 0 29.98% 18.60% 
PSD11 47 22   6  14 19   0 48.81% 11.85% 43.10% 31.80% 
PSD12 53 0 0  8 24 0 0 0 52.19% 15.57% 




PSDE 35 0 0  2 11 0 0 0 28.40% 4.52% 
PSMD2 100 85   8  27 61   0 44.63% 7.71% 39.00% 24.64% 
PSMD3 61 0 0  11 35 0 0 0 54.38% 18.88% 
PSMD4 41   0   0  3   5   0   0   0 12.76% 6.91% 
PSMD5 56 0 0  2 4 0 0 0 6.15% 3.77% 
PSMD6 46   0   0  12 22   0   0   0 42.20% 29.00% 
PSMD7 37 0 0  8 14 0 0 0 32.70% 19.90% 
PSME4 211   0   0  16   3   0   0   0 17.30% 1.84% 
PSMG1 33 0 0  4 4 0 0 0 13.50% 14.50% 
PSMG2 30   0   0  4   7   0   0   0 15.20% 20.80% 
PSA1 30 13 13  30 39 100.00% 42.22% 39.20% 51.69% 77.23% 
PSA2 26 10   6  36 29 100.00% 45.70% 41.50% 58.70% 58.10% 




PSA4 29   9   9  29 24 100.00% 27.95% 19.50% 82.40% 67.81% 
PSA5 26 11 7  22 17 100.00% 56.04% 38.60% 55.80% 74.70% 
PSA6 27 13   6  36 29 100.00% 58.70% 27.65% 71.20% 66.40% 
PSA7 28 7 3  34 20 100.00% 25.80% 14.10% 57.56% 60.90% 
PSB1 26   8   4  27 17 100.00% 30.80% 13.75% 64.60% 55.80% 
PSB2 23 17 6  33 26 100.00% 48.26% 29.90% 52.06% 63.10% 
PSB3 23   7   3  26 19 100.00% 34.10% 20.00% 50.80% 68.80% 
PSB4 29 5 8  15 16 100.00% 14.40% 33.30% 37.88% 53.00% 
PSB5 29 23 20  39 31 100.00% 54.74% 52.70% 64.80% 43.70% 
PSB6 25 5 7  12 14 100.00% 16.80% 32.30% 44.90% 51.00% 
PSB7 30   3   5  28 15 100.00% 15.20% 25.70% 39.70% 35.79% 


































































































































































































AT1A3 112 201 186  0 0 100.00% 38.42% 31.37% 0 0 
CMC1 75 93 57  0   0 100.00% 36.67% 49.70%   0   0 
AT1A1 113 73 76  0 0 100.00% 62.00% 49.30% 0 0 
AT1A2 112 41 63  0   0 98.40% 34.00% 38.10%   0   0 
PLXA1 211 38 37  0 0 100.00% 18.88% 16.74% 0 0 
PLXA4 213 29 42  0 0 100.00% 14.31% 18.68% 0 0 
AT1B1 35 21 43  0 0 99.80% 54.26% 77.60% 0 0 
GPM6A 31 16 13  0   0 100.00% 18.30% 32.05%   0   0 
4F2 58 14 10  0 0 100.00% 22.95% 18.10% 0 0 
EAA1 60 12   7  0   0 99.10% 19.51% 10.50%   0   0 
SFXN3 35 11 20  0 0 99.80% 35.80% 53.30% 0 0 




LPP3 35 9 10  0 0 99.20% 31.70% 25.30% 0 0 
RTN1 84 8 8  0 0 97.00% 7.94% 5.64% 0 0 
GRIA3 101 7 14  0 0 100.00% 6.98% 11.90% 0 0 
PLTP 54 7 5  0 0 100.00% 15.66% 10.34% 0 0 
VDAC2 32 6 9  0 0 100.00% 16.95% 31.19% 0 0 




































Rgs4 10.000 3.924 46.829 23.200 1.102 0.000 0.001 
Npas4 3.000 0.501 4.988 87.200 0.809 0.000 0.002 
1190005I06
Rik 
2.000 2.162 26.126 11.900 0.801 0.002 0.083 
Wbscr22 3.000 0.995 15.302 31.600 0.779 0.002 0.086 
Snurf 1.000 0.778 19.718 8.400 0.731 0.000 0.015 
Hnrnpd 22.000 204.353 51.961 32.700 0.664 0.005 0.104 
Bex2 3.000 0.874 27.907 15.400 0.623 0.000 0.006 
Fos 5.000 3.329 15.000 40.800 0.619 0.000 0.010 
Myo6 59.000 6.743 49.268 149.500 0.596 0.007 0.121 
Fosl2 2.000 0.425 7.362 35.300 0.510 0.000 0.048 
Anxa5 24.000 12.183 82.759 35.700 0.486 0.007 0.115 
Lix1 3.000 0.638 13.830 31.900 0.474 0.006 0.112 
Mgme1 1.000 0.145 3.254 38.400 0.435 0.005 0.110 
Odc1 4.000 0.492 9.544 51.100 0.402 0.000 0.013 




Creg2 2.000 0.292 9.028 31.700 0.363 0.001 0.064 
Slc39a9 1.000 0.389 2.540 33.200 0.360 0.005 0.105 
Ubc 15.000 0.988 92.234 82.500 0.351 0.000 0.027 
Egr1 7.000 2.831 14.447 56.600 0.328 0.001 0.068 
Plk2 6.000 0.431 10.411 77.800 0.326 0.007 0.121 
Svs1 2.000 0.101 2.195 93.500 0.313 0.003 0.097 
Smpd4 13.000 1.228 21.219 96.700 0.313 0.000 0.048 
Rbm18 3.000 0.778 20.526 21.600 0.309 0.006 0.114 
Sox4 2.000 0.359 5.682 45.000 0.306 0.000 0.044 
Slc18b1 1.000 0.212 2.407 48.800 0.300 0.000 0.053 
Tmem130 3.000 0.350 10.979 46.600 0.288 0.001 0.083 
Rexo1 6.000 0.215 7.573 132.400 0.287 0.004 0.100 
6330403K0
7Rik 
2.000 3.642 33.058 13.400 0.283 0.000 0.013 
Enc1 18.000 2.252 33.277 66.100 0.279 0.000 0.001 
Casd1 8.000 0.490 11.987 101.300 0.270 0.006 0.112 
Jund 1.000 0.292 4.106 34.900 0.264 0.004 0.100 
Ggcx 6.000 0.711 9.775 87.100 0.260 0.001 0.083 
Supt20 4.000 0.301 7.755 94.200 0.253 0.005 0.105 
Hmgcr 15.000 1.268 18.952 98.100 0.250 0.000 0.013 
Tmem117 2.000 0.202 4.475 60.300 0.248 0.002 0.086 




Gnl3l 12.000 1.581 25.650 65.200 0.246 0.001 0.083 
Ahctf1 16.000 0.382 10.194 254.600 0.242 0.000 0.048 
Tcof1 27.000 1.414 24.926 138.500 0.242 0.003 0.096 
Tpm1 22.000 17.233 54.577 32.800 0.241 0.005 0.110 
Nfx1 8.000 0.362 7.899 123.700 0.241 0.001 0.072 
Soat1 6.000 0.905 11.481 63.800 0.235 0.001 0.068 
Trpc4ap 14.000 1.121 24.216 90.700 0.235 0.000 0.039 
COX2 7.000 25.827 30.837 25.900 0.233 0.003 0.097 
Junb 7.000 2.728 34.884 35.700 0.232 0.001 0.083 
Sft2d3 2.000 0.425 13.208 21.900 0.231 0.004 0.099 
Fads1 9.000 2.981 22.595 52.300 0.228 0.001 0.066 
Ccnd1 8.000 1.818 38.486 35.900 0.226 0.001 0.083 
Wnt7b 13.000 3.062 39.943 39.300 0.224 0.001 0.068 
Zfp871 3.000 0.218 4.228 71.500 0.223 0.004 0.100 
Prodh 11.000 0.983 21.202 68.000 0.222 0.008 0.126 
Mbtps2 1.000 0.179 1.748 56.900 0.218 0.000 0.061 
4930433I11
Rik 
2.000 0.129 1.108 69.800 0.216 0.006 0.114 
Mpnd 2.000 0.334 7.828 55.900 0.215 0.005 0.106 
Clcc1 7.000 0.630 19.669 61.200 0.214 0.001 0.080 
Ndn 11.000 2.675 38.769 36.800 0.213 0.000 0.013 




Cox7c 3.000 9.000 38.095 7.300 0.212 0.003 0.090 
Fads2 12.000 2.481 25.225 52.400 0.211 0.002 0.083 
Cadps 54.000 8.412 50.300 150.800 0.211 0.002 0.088 
Atp2b4 50.000 11.969 40.355 136.900 0.209 0.005 0.104 
Sil1 12.000 2.775 37.634 52.400 0.208 0.002 0.086 
Ccdc91 12.000 2.311 28.054 50.000 0.204 0.000 0.044 
Olig1 7.000 3.394 40.385 27.100 0.203 0.003 0.099 
Galnt18 6.000 0.682 13.023 71.100 0.203 0.006 0.114 
Nog 2.000 0.668 11.638 25.800 0.203 0.000 0.059 
Tm9sf1 4.000 0.468 9.241 68.900 0.202 0.005 0.106 
Prkcd 10.000 0.778 15.000 80.200 0.199 0.000 0.059 
Tmem135 3.000 0.269 6.332 52.300 0.197 0.001 0.064 
Gas2l1 2.000 0.110 3.097 72.400 0.197 0.006 0.110 
Fzd2 3.000 0.318 7.193 64.000 0.197 0.001 0.083 
Ppp1r37 16.000 3.299 29.073 77.500 0.196 0.001 0.064 
Tmem209 8.000 0.848 21.228 64.000 0.196 0.000 0.031 
Apitd1 1.000 0.233 7.042 16.300 0.196 0.009 0.127 
Gbp6 4.000 0.266 3.857 80.300 0.192 0.008 0.126 
Scn1b 5.000 1.848 33.028 24.600 0.189 0.001 0.066 
Gm21949 3.000 0.292 9.302 61.900 0.189 0.004 0.100 
Smim14 2.000 2.162 19.192 10.700 0.187 0.000 0.032 




Mzt2 2.000 1.154 22.013 16.500 0.186 0.006 0.114 
Csrp2 5.000 1.424 32.642 20.900 0.185 0.009 0.127 
Polr3a 15.000 0.486 17.254 158.600 0.184 0.001 0.066 
Tmem109 2.000 0.585 8.642 26.300 0.181 0.001 0.068 
Virma 24.000 0.769 20.097 207.000 0.181 0.002 0.088 
Pcmtd2 9.000 2.162 25.627 40.700 0.181 0.001 0.080 
0610009B2
2Rik 
6.000 6.743 43.571 16.400 0.180 0.002 0.086 
Mxra7 4.000 5.813 23.179 16.200 0.178 0.005 0.105 
Sqle 13.000 1.955 25.874 63.700 0.178 0.009 0.128 
Cdkn2c 5.000 2.511 45.238 18.100 0.177 0.006 0.110 
Rab13 8.000 2.981 44.059 22.800 0.177 0.007 0.121 
Utp15 13.000 1.297 26.705 59.300 0.176 0.002 0.086 
Jam2 9.000 3.160 34.808 37.500 0.176 0.003 0.099 
Abcb10 10.000 0.805 17.343 77.100 0.176 0.002 0.083 
Scd2 5.000 1.371 11.732 40.900 0.175 0.008 0.121 
Cspg4 35.000 1.783 23.034 252.200 0.175 0.001 0.083 
Pomt1 5.000 0.389 8.981 85.200 0.175 0.001 0.064 
Gtf2e2 10.000 1.610 41.017 33.400 0.174 0.000 0.059 
Dtx1 4.000 0.359 6.973 68.500 0.172 0.000 0.048 
Slco1c1 8.000 0.748 15.105 78.300 0.170 0.004 0.102 




Nat14 6.000 6.499 31.068 21.800 0.169 0.001 0.080 
Cyp20a1 10.000 1.712 27.489 52.100 0.168 0.004 0.100 
Capn1 8.000 0.492 16.690 82.100 0.167 0.002 0.086 
Amfr 13.000 3.047 33.177 72.700 0.165 0.006 0.112 
Far1 15.000 2.652 34.563 59.400 0.165 0.008 0.121 
Lage3 4.000 1.783 24.324 15.800 0.165 0.009 0.128 
Klhl7 9.000 0.833 23.720 65.900 0.165 0.007 0.121 
Bnip3l 4.000 1.512 16.972 23.800 0.164 0.001 0.083 
Mrpl20 5.000 2.511 38.255 17.600 0.164 0.010 0.130 
Srebf2 13.000 0.759 15.310 122.800 0.162 0.009 0.127 
Fam69a 7.000 0.957 25.701 48.900 0.162 0.001 0.080 
Kat8 7.000 0.978 18.341 52.500 0.161 0.001 0.066 
Akap11 14.000 0.474 9.024 208.700 0.160 0.000 0.048 
B230219D2
2Rik 
5.000 2.162 38.298 20.100 0.160 0.009 0.128 
Alg9 10.000 1.395 17.349 69.500 0.159 0.001 0.068 
Rabac1 5.000 14.849 27.568 20.600 0.159 0.009 0.128 
Ppp4r3b 14.000 1.485 21.341 93.900 0.159 0.000 0.061 
Fmo1 3.000 0.218 6.579 59.900 0.159 0.008 0.126 
Chd4 86.000 9.228 49.103 221.400 0.158 0.001 0.082 
Lman1 20.000 5.529 46.422 57.800 0.158 0.003 0.098 




Saraf 10.000 3.281 33.884 38.700 0.157 0.001 0.083 
Abcf1 35.000 7.577 51.732 94.900 0.156 0.004 0.100 
Pxmp2 5.000 1.610 21.762 22.100 0.155 0.002 0.086 
Agap2 28.000 1.832 23.845 142.200 0.154 0.002 0.085 
Syne2 80.000 0.546 14.984 782.200 0.154 0.000 0.055 
Fbxl20 16.000 2.857 43.578 48.400 0.153 0.004 0.102 
Tnk2 5.000 0.318 6.919 116.900 0.153 0.005 0.110 
Gamt 8.000 11.328 46.825 27.900 0.152 0.009 0.128 
Ephx1 25.000 9.000 60.659 52.500 0.152 0.008 0.122 
Tmem55a 7.000 2.875 36.576 28.000 0.151 0.002 0.083 
Lyst 28.000 0.431 9.977 430.500 0.151 0.002 0.086 
Hira 19.000 1.399 27.087 113.100 0.150 0.001 0.083 
Cpt1a 20.000 2.675 28.947 90.600 0.150 0.005 0.107 
Pgap1 25.000 4.289 28.416 104.500 0.149 0.006 0.111 
Metl7a1 5.000 1.929 27.459 28.100 0.148 0.010 0.129 
Ptpn13 21.000 0.420 11.016 270.100 0.148 0.004 0.100 
Nol3 6.000 4.995 38.182 24.600 0.147 0.007 0.121 
Gpc1 21.000 7.620 53.479 55.500 0.146 0.007 0.121 
Utp6 8.000 0.567 14.573 70.400 0.145 0.002 0.088 
Dlx2 2.000 1.683 7.229 34.700 0.145 0.009 0.128 
Gpc6 18.000 3.748 45.664 64.300 0.145 0.009 0.127 




Tmem100 2.000 1.512 11.940 14.500 0.142 0.001 0.083 
Rbm15b 13.000 0.647 19.842 97.000 0.141 0.003 0.094 
Kctd18 7.000 0.905 14.219 46.900 0.140 0.000 0.061 
Nek6 6.000 1.081 12.570 40.800 0.140 0.007 0.120 
Iqgap1 54.000 3.827 43.486 191.300 0.140 0.009 0.127 
Tspyl4 15.000 3.924 46.059 44.800 0.140 0.002 0.083 
Cbx4 8.000 0.995 17.604 60.500 0.139 0.004 0.100 
Maged1 22.000 4.179 29.419 85.600 0.139 0.005 0.104 
Pes1 17.000 2.490 24.829 67.800 0.139 0.002 0.086 
Timp3 5.000 2.162 27.962 24.200 0.137 0.010 0.131 
Pomp 4.000 2.511 43.972 15.800 0.137 0.002 0.086 
Top2b 95.000 15.596 59.739 181.800 0.137 0.003 0.095 
Tmem56 3.000 0.701 11.957 31.200 0.136 0.002 0.088 
Fdft1 21.000 13.125 50.481 48.100 0.136 0.000 0.059 
Atp13a1 35.000 3.823 34.505 135.000 0.135 0.003 0.095 
Abcb7 18.000 3.072 29.787 82.500 0.134 0.001 0.083 
Tmpo 14.000 5.422 42.920 50.300 0.134 0.001 0.066 
Abcb8 22.000 2.814 36.541 78.000 0.133 0.010 0.131 
Mrfap1 5.000 14.849 47.200 14.200 0.132 0.006 0.111 
Rab33b 10.000 6.356 38.428 25.800 0.131 0.003 0.094 
Kdm5b 25.000 1.233 20.013 175.400 0.131 0.002 0.083 




Ppfibp1 13.000 0.647 16.667 115.900 0.130 0.007 0.115 
Lemd3 22.000 1.619 33.660 100.100 0.127 0.007 0.121 
Gtf3c1 53.000 2.162 33.079 237.300 0.127 0.002 0.083 
Serac1 13.000 1.154 26.603 70.600 0.127 0.007 0.121 
Alg11 8.000 1.565 21.341 55.200 0.126 0.004 0.100 
Rnf114 7.000 2.384 41.921 25.700 0.122 0.003 0.093 
Tst 10.000 3.281 36.364 33.400 0.122 0.007 0.121 
Mospd1 4.000 1.031 16.929 28.800 0.122 0.009 0.127 
Galnt2 25.000 6.326 48.070 64.500 0.122 0.006 0.112 
Lemd2 14.000 2.282 29.550 57.500 0.121 0.004 0.100 
Abca1 47.000 1.903 26.823 253.800 0.121 0.003 0.096 
Utp14a 10.000 0.802 18.905 87.200 0.120 0.009 0.127 
Pnpla6 19.000 0.947 17.734 149.900 0.120 0.007 0.121 
Rbbp5 18.000 4.179 42.600 55.000 0.120 0.008 0.126 
Tnks 8.000 0.311 6.894 140.900 0.120 0.000 0.053 
4933434E2
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8.000 2.162 36.364 28.700 0.120 0.009 0.127 
Tmem214 17.000 1.818 27.365 76.400 0.119 0.005 0.105 
Rab24 9.000 4.412 45.320 23.100 0.118 0.001 0.068 
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17.000 9.000 63.354 35.300 0.118 0.006 0.110 




Nsdhl 15.000 9.000 55.525 40.700 0.117 0.009 0.127 
Pip5k1a 8.000 1.096 16.636 60.500 0.116 0.006 0.110 
Lrrc59 17.000 30.623 57.003 34.900 0.116 0.005 0.104 
Vangl2 13.000 2.433 26.679 59.700 0.116 0.004 0.100 
Nup205 59.000 3.239 36.164 232.100 0.115 0.005 0.110 
Wipi1 6.000 1.637 22.646 48.700 0.115 0.010 0.130 
Rlbp1 10.000 3.833 42.271 36.400 0.114 0.009 0.128 
Prpf8 111.000 8.237 54.133 273.400 0.114 0.002 0.083 
Tpbg 5.000 1.154 14.789 46.400 0.114 0.004 0.100 
Ncln 16.000 4.109 28.826 62.700 0.113 0.008 0.126 
Ccdc177 12.000 1.254 18.130 79.800 0.113 0.004 0.100 
Tmem43 16.000 6.197 43.750 44.800 0.113 0.006 0.111 
Smpd2 11.000 1.894 32.697 47.400 0.113 0.004 0.100 
Lactb2 10.000 5.310 46.528 32.700 0.112 0.002 0.086 
Atp2a2 54.000 41.622 53.161 114.800 0.112 0.005 0.108 
Acbd5 15.000 4.179 29.615 58.000 0.112 0.004 0.100 
Ints8 11.000 0.628 12.663 113.300 0.111 0.008 0.127 
Pcdhga12 9.000 1.106 12.554 100.800 0.111 0.008 0.126 
Abhd16a 20.000 6.880 42.473 63.000 0.110 0.001 0.068 
Pqlc1 2.000 1.371 7.380 30.600 0.110 0.005 0.108 
Rims4 7.000 4.878 38.662 29.300 0.110 0.003 0.094 




"March2" 18.000 9.000 42.899 38.200 0.109 0.009 0.128 
Cxx1c 5.000 4.623 55.357 13.600 0.109 0.002 0.086 
Gprin3 14.000 1.434 22.850 89.700 0.108 0.000 0.057 
Pisd 9.000 1.276 20.690 45.900 0.107 0.007 0.121 
Bri3bp 5.000 2.831 19.763 28.200 0.107 0.002 0.086 
Sbk1 2.000 0.334 5.036 45.700 0.106 0.006 0.110 
Alkbh5 5.000 0.874 18.987 44.400 0.105 0.005 0.104 
Glg1 54.000 9.680 46.809 133.600 0.105 0.003 0.095 
Fam69b 10.000 3.642 29.930 48.800 0.105 0.001 0.080 
Commd4 7.000 3.642 36.181 21.800 0.104 0.004 0.102 
Trmt10c 14.000 2.728 43.478 48.400 0.104 0.010 0.131 
Kif1b 57.000 3.453 42.126 204.000 0.104 0.004 0.100 
Metl9 7.000 2.162 34.906 36.400 0.103 0.006 0.110 
Cyb5r4 14.000 1.322 31.439 59.700 0.102 0.004 0.100 
Wdr36 14.000 1.260 20.912 99.700 0.102 0.009 0.127 
Rhot2 16.000 5.210 37.742 69.000 0.100 0.001 0.080 
Gpaa1 11.000 2.162 18.035 67.900 0.096 0.007 0.121 
Lbr 10.000 1.395 18.211 71.400 0.095 0.002 0.083 
Cpt1c 17.000 2.162 24.656 90.100 0.094 0.003 0.098 
Ubtf 27.000 2.802 35.094 93.000 0.093 0.002 0.086 
Nlgn3 20.000 8.211 38.061 91.100 0.092 0.006 0.110 




Stk3 17.000 4.298 44.064 56.800 0.091 0.004 0.100 
Exosc10 23.000 1.404 31.960 102.000 0.090 0.001 0.083 
Spg7 22.000 1.894 33.803 85.900 0.087 0.009 0.128 
Atp8a2 31.000 2.325 28.451 133.500 0.086 0.006 0.110 
Surf4 4.000 1.848 14.870 30.400 0.086 0.007 0.121 
Slc30a9 13.000 2.162 23.810 62.800 0.085 0.005 0.108 
Casc4 17.000 4.754 37.931 49.400 0.083 0.002 0.083 
Sec62 9.000 1.818 13.819 45.600 0.082 0.006 0.110 
Chd8 29.000 0.733 13.822 291.600 0.080 0.010 0.130 
Ktn1 69.000 7.799 51.380 149.700 0.080 0.009 0.128 
Use1 6.000 1.081 19.298 32.300 0.077 0.004 0.102 
Pbrm1 43.000 1.591 29.884 197.400 0.076 0.007 0.121 
Jmy 25.000 3.642 29.400 110.500 0.076 0.007 0.121 
Mrps30 20.000 11.115 58.824 49.900 0.076 0.008 0.126 
Abi2 11.000 4.012 22.509 58.800 -0.072 0.009 0.127 
Ptprd 65.000 6.909 45.336 215.100 -0.073 0.004 0.100 
Rpp25l 4.000 1.610 22.321 24.300 -0.073 0.009 0.128 
Matr3 49.000 29.858 55.674 94.600 -0.078 0.006 0.110 
Erc2 51.000 6.068 45.089 123.100 -0.078 0.003 0.097 
Hnrnpa3 25.000 88.125 53.826 39.600 -0.078 0.008 0.123 
Csnk1e 18.000 14.199 51.202 47.300 -0.078 0.006 0.113 




Epn2 17.000 9.000 36.875 68.300 -0.079 0.005 0.110 
Gdap1l1 14.000 6.848 38.692 41.900 -0.079 0.009 0.128 
Ap2a2 49.000 15.103 56.397 104.000 -0.080 0.007 0.121 
Psmc6 23.000 15.681 66.067 44.100 -0.080 0.003 0.099 
Vat1l 19.000 17.233 59.952 45.800 -0.081 0.005 0.105 
Tcerg1 37.000 5.367 29.742 126.500 -0.084 0.010 0.129 
Ctsd 16.000 38.811 48.537 44.900 -0.085 0.006 0.110 
Dbn1 30.000 77.137 47.808 77.400 -0.085 0.008 0.123 
Raph1 38.000 4.125 36.950 142.500 -0.086 0.010 0.130 
Ap3d1 63.000 25.827 52.294 135.000 -0.086 0.009 0.128 
Atp6v1d 20.000 162.789 59.919 28.400 -0.090 0.003 0.095 
Shank1 41.000 2.442 25.336 225.200 -0.090 0.006 0.110 
Add1 39.000 39.842 57.107 87.100 -0.090 0.008 0.123 
Tolip 11.000 7.577 57.299 30.300 -0.090 0.004 0.102 
Tubb3 30.000 2564.02
1 
73.556 50.400 -0.091 0.009 0.127 
Tfg 14.000 48.239 46.348 43.000 -0.091 0.004 0.100 
Nsf 54.000 27.368 69.220 82.600 -0.093 0.009 0.128 
Stx1a 22.000 76.426 63.194 33.000 -0.093 0.005 0.107 
Ppp5c 32.000 24.929 58.717 56.800 -0.093 0.005 0.104 
Purb 14.000 17.957 56.481 33.900 -0.094 0.009 0.127 




Ran 11.000 27.480 51.852 24.400 -0.095 0.008 0.124 
Calb2 19.000 25.367 69.004 31.400 -0.096 0.005 0.108 
Mpped2 8.000 6.197 45.238 33.400 -0.097 0.004 0.102 
Syn1 35.000 43.367 70.963 74.100 -0.097 0.003 0.095 
Edil3 24.000 15.681 51.458 53.700 -0.098 0.006 0.112 
Slc7a14 8.000 1.424 16.602 83.900 -0.098 0.004 0.100 
Crmp1 40.000 126.427 74.490 74.200 -0.098 0.002 0.086 
Psmb5 17.000 55.234 64.015 28.500 -0.098 0.002 0.088 
Syp 7.000 5.105 27.707 34.000 -0.099 0.005 0.110 
Atxn2l 30.000 9.000 34.033 115.200 -0.100 0.009 0.128 
Pde1b 17.000 4.520 36.075 61.200 -0.100 0.004 0.100 
Wbp11 19.000 4.736 30.577 69.800 -0.101 0.004 0.100 
Htra1 26.000 22.101 58.542 51.200 -0.101 0.006 0.110 
Metap1 19.000 11.217 64.767 43.200 -0.101 0.009 0.127 
Eef1d 34.000 16.508 51.105 74.800 -0.102 0.006 0.113 
Ppp2r1a 36.000 40.246 66.044 65.300 -0.104 0.008 0.127 
Rbm8a 9.000 73.989 61.494 19.900 -0.104 0.002 0.086 
Lysmd1 9.000 3.394 39.823 24.800 -0.106 0.003 0.097 
Ash2l 17.000 2.371 33.068 68.700 -0.106 0.003 0.090 
Homer2 19.000 8.006 48.588 40.500 -0.107 0.005 0.106 
Zkscan3 5.000 0.417 13.743 62.600 -0.107 0.006 0.110 




Rtn3 36.000 12.503 47.822 103.800 -0.107 0.006 0.110 
Map2 134.000 110.706 66.434 202.300 -0.109 0.008 0.126 
Rps3 27.000 111.884 79.424 26.700 -0.110 0.008 0.126 
Pclo 154.000 5.039 39.740 550.500 -0.110 0.007 0.121 
Lrrn1 16.000 2.924 29.749 80.500 -0.112 0.009 0.127 
Actr3b 22.000 27.480 62.679 47.500 -0.112 0.004 0.100 
Irf2bpl 20.000 3.833 32.774 80.500 -0.112 0.004 0.099 
Cpeb2 21.000 4.532 27.317 108.700 -0.113 0.001 0.066 
Camk2a 26.000 42.940 53.556 54.100 -0.114 0.010 0.130 
Sirpa 15.000 6.356 44.401 56.000 -0.115 0.003 0.093 
Wasf1 21.000 58.948 41.503 61.500 -0.117 0.006 0.110 
Pcyt2 18.000 6.743 56.218 43.400 -0.117 0.009 0.127 
Ubap2l 25.000 13.030 32.863 119.900 -0.117 0.008 0.127 
Camkk2 26.000 7.209 56.633 64.600 -0.118 0.001 0.083 
Ahsa1 22.000 12.335 73.077 38.100 -0.118 0.003 0.094 
Snx27 26.000 9.000 57.699 61.000 -0.119 0.002 0.086 
Rpl38 5.000 214.443 47.143 8.200 -0.119 0.001 0.080 
Lamtor5 4.000 6.499 51.034 15.300 -0.119 0.002 0.086 
Ywhag 20.000 128.155 81.377 28.300 -0.119 0.004 0.100 
Ube2z 12.000 7.577 31.180 38.300 -0.120 0.009 0.128 
Nt5c 11.000 16.783 55.500 23.100 -0.120 0.005 0.110 




Cplx1 10.000 99.000 69.403 15.100 -0.122 0.003 0.097 
Adprh 16.000 10.159 53.591 40.000 -0.123 0.002 0.083 
Dgkg 22.000 2.008 34.532 93.900 -0.123 0.006 0.112 
Aak1 47.000 26.977 65.240 103.200 -0.125 0.001 0.083 
Bag4 8.000 5.105 19.475 49.100 -0.125 0.001 0.066 
Nectin1 19.000 9.000 50.097 57.000 -0.127 0.006 0.113 
Wasf3 14.000 9.000 37.325 55.200 -0.127 0.005 0.108 
Rap1gap 27.000 8.397 41.265 80.500 -0.127 0.004 0.100 
Kctd12 17.000 15.681 47.706 35.900 -0.127 0.001 0.066 
Eif4a1 33.000 145.780 68.473 46.100 -0.128 0.006 0.112 
Pcp4l1 3.000 5.310 58.824 7.500 -0.128 0.004 0.101 
Sf3a1 34.000 14.849 50.695 88.500 -0.129 0.002 0.083 
R3hdm2 13.000 2.054 17.337 114.500 -0.129 0.008 0.126 
Cyb5a 4.000 2.162 38.060 15.200 -0.131 0.001 0.071 
Itsn2 27.000 1.038 21.246 191.600 -0.131 0.002 0.088 
Nova2 17.000 12.895 42.886 49.000 -0.132 0.006 0.112 
Ppp4r2 16.000 5.422 49.880 46.400 -0.133 0.004 0.100 
Calb1 15.000 19.535 57.471 30.000 -0.134 0.007 0.115 
Camk2b 29.000 27.804 47.376 72.900 -0.134 0.008 0.126 
Gpd1 26.000 14.317 77.077 37.500 -0.141 0.005 0.110 
Eloc 7.000 11.915 55.224 14.900 -0.142 0.002 0.086 




Mrpl55 4.000 3.217 35.075 15.800 -0.142 0.008 0.127 
Sez6 12.000 1.246 18.567 107.400 -0.145 0.006 0.110 
Atxn2 29.000 5.190 26.594 136.400 -0.146 0.001 0.080 
Fam49a 17.000 18.953 65.944 37.300 -0.149 0.004 0.100 
Mrps21 6.000 6.197 63.218 10.600 -0.153 0.009 0.128 
Traf3 20.000 2.758 41.799 64.300 -0.153 0.001 0.083 
Smap2 16.000 18.684 39.019 46.500 -0.154 0.006 0.110 
Ctsl 9.000 6.356 41.317 37.500 -0.156 0.002 0.088 
Wipi2 14.000 6.197 49.213 48.400 -0.157 0.000 0.061 
Lsm8 4.000 6.197 68.750 10.400 -0.157 0.006 0.112 
Tra2a 11.000 4.817 40.129 35.500 -0.163 0.004 0.103 
Klc1 40.000 50.795 61.887 62.700 -0.164 0.008 0.127 
Limd2 5.000 2.594 28.906 14.200 -0.166 0.009 0.127 
Polr2k 2.000 0.931 8.081 11.700 -0.166 0.002 0.083 
Mapre2 19.000 68.519 73.620 36.900 -0.169 0.002 0.083 
Mrps18b 4.000 1.610 21.654 28.700 -0.171 0.007 0.121 
Pla2g7 15.000 4.623 36.136 49.200 -0.174 0.002 0.083 
Eif6 9.000 17.738 54.286 26.500 -0.175 0.004 0.099 
Tnc 52.000 5.310 48.338 172.100 -0.177 0.005 0.108 
Mfge8 24.000 45.416 56.371 51.200 -0.186 0.000 0.048 
Hp1bp3 25.000 6.197 37.005 63.800 -0.189 0.000 0.044 




Arpp19 6.000 4.995 41.379 16.100 -0.192 0.002 0.085 
Acbd7 3.000 2.162 29.545 10.000 -0.196 0.002 0.083 
Mug2 3.000 0.113 1.678 166.400 -0.203 0.005 0.110 
Mdk 8.000 11.915 47.143 15.400 -0.214 0.001 0.066 
Ppil3 8.000 3.125 60.248 18.100 -0.219 0.002 0.085 
Rps27 4.000 14.849 39.286 9.500 -0.222 0.000 0.032 
Gemin4 12.000 0.842 13.800 120.100 -0.225 0.009 0.127 
Mapre3 15.000 14.013 59.774 30.300 -0.226 0.009 0.127 
Clstn3 23.000 4.012 30.021 105.800 -0.233 0.004 0.100 
Fam135a 6.000 0.222 4.427 170.000 -0.234 0.002 0.083 
Ss18l1 4.000 9.000 16.667 43.700 -0.246 0.008 0.121 
Cnbp 6.000 1.929 41.808 19.500 -0.249 0.002 0.084 
Kdelr1 3.000 1.154 20.755 24.500 -0.256 0.007 0.121 
Cadm1 11.000 20.544 44.136 35.500 -0.258 0.009 0.127 
Ank2 217.000 23.302 65.394 434.500 -0.261 0.004 0.100 
Aplp1 19.000 2.793 33.333 72.800 -0.262 0.010 0.131 
Sparcl1 26.000 8.345 45.846 72.200 -0.267 0.007 0.121 
Serpind1 2.000 0.172 3.975 54.500 -0.284 0.001 0.066 
Aox1 14.000 0.585 14.254 146.600 -0.290 0.009 0.127 
Cyb5b 5.000 2.594 45.205 16.300 -0.295 0.008 0.121 
Ccdc92b 5.000 0.896 18.395 33.300 -0.317 0.000 0.012 




A2m 15.000 0.742 12.687 164.200 -0.329 0.003 0.099 
Nel2 20.000 2.639 32.967 91.400 -0.341 0.003 0.095 
Clstn1 25.000 4.854 33.504 108.800 -0.350 0.004 0.099 
Cst3 8.000 18.953 62.857 15.500 -0.359 0.003 0.091 
Cwf19l1 7.000 1.783 35.959 33.200 -0.361 0.003 0.094 
Pzp 4.000 0.222 3.144 165.700 -0.363 0.003 0.096 
Timp2 11.000 12.895 57.727 24.300 -0.367 0.001 0.066 
Cycs 13.000 315.228 69.524 11.600 -0.373 0.003 0.095 
Ecm1 2.000 0.136 2.773 64.600 -0.375 0.002 0.083 
 
14.000 1.728 19.309 85.600 -0.396 0.005 0.109 
Itih1 3.000 0.170 2.744 101.600 -0.396 0.004 0.100 
Igfbp2 9.000 4.275 41.967 32.800 -0.409 0.001 0.080 
Ambp 2.000 0.413 5.444 39.000 -0.415 0.001 0.083 
Usp27x 2.000 0.202 5.708 49.600 -0.415 0.006 0.110 
Serpinc1 15.000 2.924 29.892 52.000 -0.416 0.004 0.102 
C3 13.000 0.418 8.118 186.400 -0.431 0.003 0.099 
Csnk1a1 18.000 11.452 62.769 37.500 -0.435 0.002 0.083 
 
18.000 4.412 28.448 52.600 -0.442 0.003 0.094 
 
45.000 41.453 64.900 77.000 -0.474 0.004 0.100 
Sncaip 3.000 0.148 3.316 105.900 -0.476 0.002 0.083 
 
3.000 0.778 19.608 15.800 -0.478 0.003 0.097 




Ces1g 1.000 0.202 2.124 62.600 -0.533 0.002 0.086 
Hp 3.000 0.551 8.357 38.700 -0.598 0.004 0.100 
 



































Rgs4 10.000 3.924 46.829 23.200 1.102 0.000 0.001 
Npas4 3.000 0.501 4.988 87.200 0.809 0.000 0.002 
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2.000 2.162 26.126 11.900 0.801 0.002 0.083 
Wbscr22 3.000 0.995 15.302 31.600 0.779 0.002 0.086 
Snurf 1.000 0.778 19.718 8.400 0.731 0.000 0.015 
Bex2 3.000 0.874 27.907 15.400 0.623 0.000 0.006 
Fos 5.000 3.329 15.000 40.800 0.619 0.000 0.010 
Fosl2 2.000 0.425 7.362 35.300 0.510 0.000 0.048 
Odc1 4.000 0.492 9.544 51.100 0.402 0.000 0.013 
Fosb 4.000 1.783 15.385 36.000 0.402 0.000 0.048 
Creg2 2.000 0.292 9.028 31.700 0.363 0.001 0.064 
Ubc 15.000 0.988 92.234 82.500 0.351 0.000 0.027 
Egr1 7.000 2.831 14.447 56.600 0.328 0.001 0.068 
Svs1 2.000 0.101 2.195 93.500 0.313 0.003 0.097 
Smpd4 13.000 1.228 21.219 96.700 0.313 0.000 0.048 
Sox4 2.000 0.359 5.682 45.000 0.306 0.000 0.044 
Slc18b1 1.000 0.212 2.407 48.800 0.300 0.000 0.053 
Tmem130 3.000 0.350 10.979 46.600 0.288 0.001 0.083 
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2.000 3.642 33.058 13.400 0.283 0.000 0.013 
Enc1 18.000 2.252 33.277 66.100 0.279 0.000 0.001 
Ggcx 6.000 0.711 9.775 87.100 0.260 0.001 0.083 
Hmgcr 15.000 1.268 18.952 98.100 0.250 0.000 0.013 
Tmem117 2.000 0.202 4.475 60.300 0.248 0.002 0.086 
Cic 17.000 0.607 11.425 258.200 0.246 0.000 0.039 
Gnl3l 12.000 1.581 25.650 65.200 0.246 0.001 0.083 
Ahctf1 16.000 0.382 10.194 254.600 0.242 0.000 0.048 
Tcof1 27.000 1.414 24.926 138.500 0.242 0.003 0.096 
Nfx1 8.000 0.362 7.899 123.700 0.241 0.001 0.072 
Soat1 6.000 0.905 11.481 63.800 0.235 0.001 0.068 




COX2 7.000 25.827 30.837 25.900 0.233 0.003 0.097 
Junb 7.000 2.728 34.884 35.700 0.232 0.001 0.083 
Sft2d3 2.000 0.425 13.208 21.900 0.231 0.004 0.099 
Fads1 9.000 2.981 22.595 52.300 0.228 0.001 0.066 
Ccnd1 8.000 1.818 38.486 35.900 0.226 0.001 0.083 
Wnt7b 13.000 3.062 39.943 39.300 0.224 0.001 0.068 
Mbtps2 1.000 0.179 1.748 56.900 0.218 0.000 0.061 
Clcc1 7.000 0.630 19.669 61.200 0.214 0.001 0.080 
Ndn 11.000 2.675 38.769 36.800 0.213 0.000 0.013 
Tmem246 6.000 0.931 21.588 46.600 0.212 0.002 0.083 
Cox7c 3.000 9.000 38.095 7.300 0.212 0.003 0.090 
Fads2 12.000 2.481 25.225 52.400 0.211 0.002 0.083 
Cadps 54.000 8.412 50.300 150.800 0.211 0.002 0.088 
Sil1 12.000 2.775 37.634 52.400 0.208 0.002 0.086 
Ccdc91 12.000 2.311 28.054 50.000 0.204 0.000 0.044 
Olig1 7.000 3.394 40.385 27.100 0.203 0.003 0.099 
Nog 2.000 0.668 11.638 25.800 0.203 0.000 0.059 
Prkcd 10.000 0.778 15.000 80.200 0.199 0.000 0.059 
Tmem135 3.000 0.269 6.332 52.300 0.197 0.001 0.064 
Fzd2 3.000 0.318 7.193 64.000 0.197 0.001 0.083 
Ppp1r37 16.000 3.299 29.073 77.500 0.196 0.001 0.064 
Tmem209 8.000 0.848 21.228 64.000 0.196 0.000 0.031 
Scn1b 5.000 1.848 33.028 24.600 0.189 0.001 0.066 
Smim14 2.000 2.162 19.192 10.700 0.187 0.000 0.032 
Polr3a 15.000 0.486 17.254 158.600 0.184 0.001 0.066 
Tmem109 2.000 0.585 8.642 26.300 0.181 0.001 0.068 
Virma 24.000 0.769 20.097 207.000 0.181 0.002 0.088 
Pcmtd2 9.000 2.162 25.627 40.700 0.181 0.001 0.080 
0610009B2
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6.000 6.743 43.571 16.400 0.180 0.002 0.086 
Utp15 13.000 1.297 26.705 59.300 0.176 0.002 0.086 
Jam2 9.000 3.160 34.808 37.500 0.176 0.003 0.099 
Abcb10 10.000 0.805 17.343 77.100 0.176 0.002 0.083 
Cspg4 35.000 1.783 23.034 252.200 0.175 0.001 0.083 
Pomt1 5.000 0.389 8.981 85.200 0.175 0.001 0.064 
Gtf2e2 10.000 1.610 41.017 33.400 0.174 0.000 0.059 
Dtx1 4.000 0.359 6.973 68.500 0.172 0.000 0.048 
Nat14 6.000 6.499 31.068 21.800 0.169 0.001 0.080 




Bnip3l 4.000 1.512 16.972 23.800 0.164 0.001 0.083 
Fam69a 7.000 0.957 25.701 48.900 0.162 0.001 0.080 
Kat8 7.000 0.978 18.341 52.500 0.161 0.001 0.066 
Akap11 14.000 0.474 9.024 208.700 0.160 0.000 0.048 
Alg9 10.000 1.395 17.349 69.500 0.159 0.001 0.068 
Ppp4r3b 14.000 1.485 21.341 93.900 0.159 0.000 0.061 
Chd4 86.000 9.228 49.103 221.400 0.158 0.001 0.082 
Lman1 20.000 5.529 46.422 57.800 0.158 0.003 0.098 
Saraf 10.000 3.281 33.884 38.700 0.157 0.001 0.083 
Pxmp2 5.000 1.610 21.762 22.100 0.155 0.002 0.086 
Agap2 28.000 1.832 23.845 142.200 0.154 0.002 0.085 
Syne2 80.000 0.546 14.984 782.200 0.154 0.000 0.055 
Tmem55a 7.000 2.875 36.576 28.000 0.151 0.002 0.083 
Lyst 28.000 0.431 9.977 430.500 0.151 0.002 0.086 
Hira 19.000 1.399 27.087 113.100 0.150 0.001 0.083 
Utp6 8.000 0.567 14.573 70.400 0.145 0.002 0.088 
Nme3 7.000 3.642 28.994 19.100 0.142 0.001 0.066 
Tmem100 2.000 1.512 11.940 14.500 0.142 0.001 0.083 
Rbm15b 13.000 0.647 19.842 97.000 0.141 0.003 0.094 
Kctd18 7.000 0.905 14.219 46.900 0.140 0.000 0.061 
Tspyl4 15.000 3.924 46.059 44.800 0.140 0.002 0.083 
Pes1 17.000 2.490 24.829 67.800 0.139 0.002 0.086 
Pomp 4.000 2.511 43.972 15.800 0.137 0.002 0.086 
Top2b 95.000 15.596 59.739 181.800 0.137 0.003 0.095 
Tmem56 3.000 0.701 11.957 31.200 0.136 0.002 0.088 
Fdft1 21.000 13.125 50.481 48.100 0.136 0.000 0.059 
Atp13a1 35.000 3.823 34.505 135.000 0.135 0.003 0.095 
Abcb7 18.000 3.072 29.787 82.500 0.134 0.001 0.083 
Tmpo 14.000 5.422 42.920 50.300 0.134 0.001 0.066 
Rab33b 10.000 6.356 38.428 25.800 0.131 0.003 0.094 
Kdm5b 25.000 1.233 20.013 175.400 0.131 0.002 0.083 
Kcnj3 4.000 0.688 13.772 56.500 0.130 0.001 0.066 
Gtf3c1 53.000 2.162 33.079 237.300 0.127 0.002 0.083 
Rnf114 7.000 2.384 41.921 25.700 0.122 0.003 0.093 
Abca1 47.000 1.903 26.823 253.800 0.121 0.003 0.096 
Tnks 8.000 0.311 6.894 140.900 0.120 0.000 0.053 
Rab24 9.000 4.412 45.320 23.100 0.118 0.001 0.068 
Alg10b 8.000 1.310 14.557 55.400 0.117 0.002 0.086 




Lactb2 10.000 5.310 46.528 32.700 0.112 0.002 0.086 
Abhd16a 20.000 6.880 42.473 63.000 0.110 0.001 0.068 
Rims4 7.000 4.878 38.662 29.300 0.110 0.003 0.094 
Cxx1c 5.000 4.623 55.357 13.600 0.109 0.002 0.086 
Gprin3 14.000 1.434 22.850 89.700 0.108 0.000 0.057 
Bri3bp 5.000 2.831 19.763 28.200 0.107 0.002 0.086 
Glg1 54.000 9.680 46.809 133.600 0.105 0.003 0.095 
Fam69b 10.000 3.642 29.930 48.800 0.105 0.001 0.080 
Rhot2 16.000 5.210 37.742 69.000 0.100 0.001 0.080 
Lbr 10.000 1.395 18.211 71.400 0.095 0.002 0.083 
Cpt1c 17.000 2.162 24.656 90.100 0.094 0.003 0.098 
Ubtf 27.000 2.802 35.094 93.000 0.093 0.002 0.086 
Trim35 16.000 2.384 38.372 58.700 0.092 0.003 0.095 
Exosc10 23.000 1.404 31.960 102.000 0.090 0.001 0.083 























Al animal procedures were performed under protocols compliant and approved by the 
Institutional Animal Care and Use Commitees of The Johns Hopkins University School of 
Medicine. No diference was observed in experiments performed distinguishing between sexes. 
As such, both male and female mice were considered for analyses for this study. For al 
experiments, we use wild-type C57BL/6 mice (stock number 027 from Charles River 
Laboratories). These are general-use animals that are used by many laboratories in the field. The 
specific age of animal used is listed in the experimental procedure sections. For the majority of 
experiments, mice were euthanized with carbon dioxide-induced anoxia and decapitated as a 
secondary method of euthanasia. For in vivo experiments, animals were anesthetized with 
Isofluorane and then decapitated. 
2.2 Antibodies 
Chapter 3: The folowing were used according to manufacturer’s and/or published suggestions 
for western bloting and immunocytochemistry: anti-α1-7 proteasome subunit (Enzo), anti-a2 
proteasome subunit (Cel Signaling), anti-α5 proteasome subunit (Santa Cruz), anti-β1 
proteasome subunit (Santa Cruz), anti-β2 proteasome subunit (Santa Cruz), anti-β2 proteasome 
subunit (Enzo), anti-β2 proteasome subunit (Novus), anti-β2 proteasome subunit (Santa Cruz), 
anti-β5 proteasome subunit (Santa Cruz), anti-β5 proteasome subunit (Enzo), anti-Rpt5 
proteasome subunit (Enzo), anti-calregulin (Santa Cruz), anti-β-Actin (Abcam), anti-Biotin (Cel 
Signaling), Streptavidin-AF647 (Invitrogen), anti-Tubulin (Milipore), anti-GluR1 (Cel 
Signaling), anti-Myc (Abcam), anti-Transferin (Invitrogen), anti-EphB2 (M. 
Greenberg)(Margolis et al. 2010), anti-NGluR1 (R. Huganir), cleaved Caspase-3 (Cel Signaling), 
anti-Kv1.3 (NeuroMab), anti-S2 (Milipore), anti-PA200 (Novus), anti-11Sa (Cel Signaling), 
anti-11Sb (Cel Signaling). Antibodies obtained from commercial vendors were verified for 




those antibodies with a continued record of use in multiple independent studies (Supplementary 
Table 2). For proteasome antibodies, many antibodies used recognize a single band or set of 
bands at the known molecular weight. Genetic validation of these antibodies is impossible as al 
proteasome subunits are essential and no knockout controls can be obtained. 
Chapter 4: The folowing were used according to manufacturer’s and/or published suggestions 
for immunobloting: anti-β-Actin (Abcam), anti-Biotin (Cel Signaling), Streptavidin-AF647 
(Invitrogen), anti-Arc (Gift from P. Worley, Johns Hopkins, verified against knockout), anti-Fos 
(Cel Signaling), anti-Npas4 (Gift from Y. Lin, MIT, verified against knockout), anti-PSD-95 
(Pierce), anti-Ube3A (Sigma, verified against knockout), anti-Ubiquitin (FK2, Enzo), anti-S6 
ribosomal subunit (Cel Signaling), standard secondary antibodies were purchased. We atempted 
to use antibodies that were verified by knockout controls in either our study, or by other groups. 
We only used antibodies that provided a signal at the appropriate molecular weight, and where 
minimal nonspecific bands were observed. 
2.3 Mice 
Al animal procedures were performed under protocols compliant and approved by the 
Institutional Animal Care and Use Commitees of The Johns Hopkins University School of 
Medicine. No diference was observed in experiments performed distinguishing between sexes. 
As such, both male and female mice were considered for analyses for this study. For al 
experiments, we use wild-type C57BL/6 mice (stock number 027 from Charles River 
Laboratories). These are general-use animals that are used by many laboratories in the field. The 
specific age of animal used is listed in the experimental procedure sections. For the majority of 
experiments, mice were euthanized with carbon dioxide-induced anoxia and decapitated as a 
secondary method of euthanasia. For in vivo experiments, animals were anesthetized with 





P30 WT C57Bl/6 Mice were anesthetized with Isoflourane and rapidly perfused with phosphate 
bufer and 0.5% paraformaldehyde/1.0% glutaraldehyde and brains were thin-sectioned for 
Immuno-EM analysis. 
2.5 Immuno-electron microscopy analysis 
Brain slices from perfused mice and neuronal cultures were fixed and processed for Electron 
Microscopy. EM Grids were incubated in the primary antibody overnight at 4 °C folowed by 
secondary antibodies for 2 hours at room temperature. Al grids were viewed with a Philips CM 
120 TEM operating at 80 Kv and images were captured with an XR 80-8 Megapixel CCD camera 
by AMT. Neuronal cultures were fixed in 1.5% glutaraldehyde (EM grade, Pela) bufered with 
70 mM sodium cacodylate containing 3 mM MgCl2 (356 mOsmols pH 7.2), for 1 hour at room 
temperature. Thin-sectioned fixed brain slices and neuronal cultures were processed using the 
folowing protocol. Folowing a 30 minute bufer rinse (100 mM cacodylate, 3% sucrose, 3 mM 
MgCl2, 316 mOsmols, pH 7.2), samples were post-fixed in 1.5% potassium ferocyanide reduced 
1% osmium tetroxide in 100 mM cacodylate containing 3 mM MgCl2, for 1 hr in the dark at 4C. 
After en-bloc staining with filtered 0.5% uranyl acetate (aq.), neurons were dehydrated through 
graded series of ethanols and embedded/cured with Eponate 12 (Pela). LR-white procedural 
staining was used for HEK293 cels as wel as neuronal cultures (Supplementary Fig. 4C). A 
metal hole punch was used to remove 5 mm discs from the polymerized plates. Discs were 
mounted onto epon blanks and trimmed. Sections were cut on a Reichert Ultra cut E with a 
Diatome diamond knife. 80 nm sections were picked up on formvar coated 200 mesh nickel grids 
and treated for antigen removal folowed by on grid immunolabeling. Grids were floated on 95 
°C citrate bufer pH 6.0 in a porcelain staining dish for 25 minutes, and then alowed to cool on 
the same solution for 20 min. After a brief series of 50 mM TBS rinses, grids were floated on 50 




incubated in primary antibody diluted in blocking solution (1-50 Goat, mouse, rabbit antibody). 
Grids incubated on blocking solutions served as negative controls. Sections were alowed to 
come to room temperature (1 hour) on antibody solutions and placed on appropriated blocking 
solutions for 10 min. After further TBS rinses, grids were floated upon 12 nm Au conjugated 
donkey anti-goat, 12 nm Au conjugated goat anti-rabbit, 12 nm Au conjugated donkey anti-
mouse, or Au conjugated streptavidin (Jackson Immunoresearch) at 1-40 dilutions in TBS for 2 
hours at room temperature. Grids were then rinsed in TBS, floated upon 1% glutaraldehyde for 
5min, rinsed again and stained with 2% filtered uranyl acetate. Al grids were viewed with a 
Philips CM 120 TEM operating at 80 Kv and images were captured with an XR 80-8 Megapixel 
CCD camera by AMT. 
2.6 Cel Lines 
For primary mouse neuronal cultures, pregnant wild-type C57/B6 mice were obtained from 
Charles River Laboratories, and sacrificed at E17.5. Whole cortices were dissected, processed 
into a single cel suspension, and plated as previously described58. Primary cel lines isolated in 
our laboratory from mouse brains are identified by surface markers that are unique to neuronal 
cels. These approaches have high sensitivity to accurately identify specific cels. Alternatively, 
for biochemical studies analysis of primary cel lines can be done using western bloting with 
wel-validated antibodies to neuronal specific markers. Human Embryonic Kidney (HEK293) 
and Neuro-2A neuroblastoma cels were obtained from ATCC and maintained and expanded and 
frozen down in a series of aliquots. These aliquots are cultured for a limited number of passages 
(<10). They are regularly tested for any infection. The lab maintains strict guidelines for cel 
culture and monitoring of cel health in order to minimize biological variability and to prevent 





2.7 Cel Culture and Transfections 
Chapter 3: HEK293 and Neuro2A cels were cultured in DMEM supplemented with 10% fetal 
bovine serum, 2 mM glutamine (Sigma), and penicilin/streptomycin (100 U/mL and 100 µg/mL, 
respectively; Sigma). Mouse cortical neurons were prepared from E17.5 C57Bl/6 mouse embryos 
as previously described (Margolis et al. 2010). Neurons were maintained in Neurobasal Medium 
(Invitrogen) supplemented with 2% B-27 (Invitrogen), penicilin/streptomycin (100 U/mL and 
100 µg/mL, respectively), and 2 mM glutamine. Dissociated neurons were transfected using the 
Lipofectamine method (Invitrogen) according to the manufacturer’s suggestions. 
Chapter 4: For primary mouse neuronal cultures, pregnant wild-type C57/B6 mice were obtained 
from Charles River Laboratories (stock number 027 from Charles River Laboratories), and 
sacrificed at E17.5. Whole cortices were dissected, processed into a single cel suspension, and 
plated as previously described(Ramachandran and Margolis 2017). Human Embryonic Kidney 
(HEK293) cels were maintained as previously described. Each cel line is maintained in its own 
culture medium. Neurons were maintained in Neurobasal Medium (Invitrogen) supplemented 
with 2% B-27 (Invitrogen), penicilin/streptomycin (100 U/mL and 100 µg/mL, respectively), and 
2 mM glutamine. HEK293 cels were cultured in DMEM supplemented with 10% fetal bovine 
serum, 2 mM glutamine (Sigma), and penicilin/streptomycin (100 U/mL and 100 µg/mL, 
respectively; Sigma). 
For analyzing the expression of immediate-early gene products, unique care was taken to ensure 
that neurons had reduced activity at baseline as measured by the expression of immediate early 
genes. After switching 500K neurons/wel in 12 wel format of cultured cortical neurons into 
1mL Neurobasal/B27 at DIV3, neurons were maintained in that medium, with only one 100ul 
media exchange at DIV9. At DIV15, neurons were treated with pharmacological agents as 
indicated. Great caution was taken to minimize physical perturbation of these cultures so as not to 




growth media (media in which neurons were growing in) before addition, so cultures did not have 
to be shaken to treat neurons. 
2.8 Antibody feeding and immunocytochemistry 
Cultured cortical neurons were plated on glass coverslips coated with poly-L lysine overnight. 
Neurons were alowed to mature to DIV 14 for feeding experiments. DIV 14 cortical neurons 
were slowly washed twice with cold PBS supplemented with 1 mM CaCl2 and 2 mM MgCl2 to 
slow recycling and internalization. Care was taken not to shear cel bodies from the neuron, and 
to maintain neuronal morphology. Cold neurons, while alive, were treated with Chicken anti-
MAP2 antibodies (1:100), Goat anti-β5 proteasome subunit antibodies (1:50), and Rabbit anti-
GluR1 (1:100) in PBS supplemented with 1mM CaCl2 and 2 mM MgCl2 for 30 minutes at 4°C. 
Antibodies were washed of, and neurons were rinsed twice in cold PBS, 1 minute each. 
Neurons with bound antibodies were fixed in 4% paraformaldehyde/4% sucrose in PBS for 75 
seconds, so not to destroy the antibody itself but to maintain neuronal morphology. Samples 
were visualized using donkey anti-goat AF-488, donkey anti-chicken AF-55, and donkey anti-
rabbit AF-647 (1:250 each) in 1× non-permeabilizing GDB (30 mM phosphate bufer pH 7.4 
containing 0.2% gelatin, and 0.8 M NaCl) for 1 hour at 25 °C. Samples on coverslips were 
mounted on glass slides using Fluoromount-G (Southern Biotech). Neurons were imaged using 
a laser scanning Zeiss LSM780 FCS microscope. Images are representative maximal Z 
projections of multiple optical sections.  
2.9 Protease protection assay 
Cortical neuronal cultures were treated for the indicated times with 1 µg/mL of Proteinase K 
(NEB) in HBSSM (Hank’s Balanced Salt Solution without CaCl2 or phenol red, supplemented 
with 1 mM MgCl2). Excess Proteinase K was quickly washed away three times in HBSSM, and 




Neurons were then fractionated into cytosolic and membrane fractions as described above, and 
samples were prepared for SDS-PAGE and western analysis. 
2.10 Surface biotinylation, cel lysis, streptavidin puldown, western blots 
Chapter 3: Surface biotin-labeling was performed as previously described (Lin et al. 2009). 
Whole mouse brains, cultured cels or whole animal tissue were obtained where indicated and 
each sample was labeled using Sulfo-NHS-LC-Biotin (ThermoFisher). Cultured cels were 
washed in pH 8.0 PBS (Gibco) with 1 mM CaCl2 and 2 mM MgCl2 (PBSCM) and treated with 1 
mg/mL Sulfo-NHS-LC-Biotin dissolved in PBSCM for 20 minutes at 4 °C before the reaction 
was quenched for 10 minutes in 50 mM glycine in PBSCM. Intact tissue was quickly and 
manualy chopped, folowing biotinylation for only 10 minutes at 4 °C in 0.5 mg/mL Sulfo-NHS-
LC-Biotin prior to quenching the reaction. Whole mouse tissues and cultured neurons were 
colected and homogenized in RIPA bufer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-
100, 0.5% Sodium Deoxycholate, 0.1% SDS, 5 mM EDTA, complete protease inhibitor cocktail 
tablet (Roche), 1 mM β-glycerophosphate). Where indicated, the salt concentration in our RIPA 
lysis bufer was increased up to 300mM NaCl. Primary, human central nervous system (CNS) 
tissue, gestational weeks 19–21, were obtained under surgical writen consent folowing protocols 
approved by the Johns Hopkins Institutional Review Board, based on its designation as biological 
waste. Tissue was mechanicaly chopped at 4°C, and immediately processed for surface 
biotinylation. For streptavidin puldown experiments, lysed cels were incubated with high-
capacity streptavidin agarose beads (ThermoFisher) overnight and then washed thrice with RIPA 
bufer before elution in SDS sample bufer. Western blots were performed using conventional 
approaches. Gels were run either on 4-15% SDS-PAGE gradient gels (Bio-Rad) or on 10% gels 
made in the laboratory. Proteins were transfered to nitrocelulose membranes at 100V for 1.5 
hours in 20% methanol containing transfer bufer. Al antibodies were made up in 5% BSA in 




Horseradish Peroxidase, extensively washed, and incubated with ECL. Images were exposed on 
film, and were scanned in and quantified using ImageJ by standard densitometry analysis. 
Chapter 4: Immunoblots were performed using conventional approaches. Tris/Glycine gels were 
run on either 10% or 12% gels made in the laboratory. Proteins were transfered to nitrocelulose 
membranes at 100V for 2 hours in 20% methanol containing transfer bufer. Al antibodies were 
made up in 5% BSA in 0.1% TBST, except for Arc antibody which was made up in 5% Milk in 
0.1% TBST. Immunoblots were incubated with appropriate secondary antibodies coupled to 
Horseradish Peroxidase, extensively washed, and incubated with ECL. Blots were exposed on 
film, and were scanned in and quantified using ImageJ by standard densitometry analysis. 
2.11 Celular fractionation and integral membrane protein determination 
For celular fractionation experiments to determine the membrane atachment of the proteasome, 
cultured neurons were lysed in either a sucrose bufer (0.32 M sucrose, 5 mM HEPES, 0.1 mM 
EDTA, 0.25 mM DTT) or hypotonic lysis bufer (5 mM HEPES, 2 mM ATP, 1 mM MgCl2) 
colected. Nuclei were peleted at 800 RPM for 5 minutes, and the supernatant containing 
membranes was peleted at 55000 RPM for 1 hour. Peleted membranes were washed twice by 
homogenizing in lysis bufer and re-peleted. Folowing two washes, membranes were processed 
for appropriate application. Supernatants containing the cytosolic extracts were concentrated 
down to the same volume that membranes were eventualy resuspended in. Membrane association 
was determined by classic methods of sodium carbonate extraction. Briefly, purified neuronal 
membranes were resuspended in 50 mM sodium carbonate, pH 11 and incubated for 10 minutes 
at 4C to strip away membrane-associated proteins. Membranes, along with tightly-associated 
membrane proteins, were peleted at 55000 RPM for 1 hour. Samples were subsequently prepared 
for SDS-PAGE analysis. For Digitonin fractionation, samples were lysed in sucrose bufer. Once 
the supernatant (cytosolic fraction) was set aside, the pelet was washed 2x with sucrose bufer, 




minute incubation in the bufer, samples were spun down at 55000 RPM for 1 hour. This was 
repeated for al indicated concentrations of detergent. For Fig. 3A, based on our fractionation 
protocol, we calculated that the input was about 60% cytosol and 40% membrane. We only 
colected the non-nuclei, non-mitochondria membrane (i.e. 20% of remaining membranes). For 
our westerns in Fig. 3A we used 10 µl of input and ~3x-purified cytosol and ~5x-purified 
membrane. Combining the data from the cytosol and membrane fractions and considering eror in 
our experimental approach proteasome signal from our input is likely coming from both the 
cytosol and a larger fraction from the membrane preparations. Because our input includes al the 
celular material and the fractionation removes the nuclei and mitochondria we believe, if any, a 
very smal amount of proteasome signal in our input can account for that which is coming from 
these organeles. 
2.12 TX-114 phase extraction 
Protocol was adapted from (Park et al. 2013). Briefly, primary neuronal cultures were treated with 
1% precondensed TX-114. Samples were dounce homogenized, spun at 4°C, and incubated at 
30°C. Samples were centrifuged for 3 minutes at room temperature. Supernatant was retained as 
the DT-free fraction and resulting pelet was kept as the DT-rich fraction. 
2.13 Concanavalin-A plama membrane isolation 
Protocol was adapted from (Lee et al. 2012). Briefly, 0.25 mg biotinylated Concanavalin-A 
(ConA) was first coupled to 1 mL of streptavidin-coated agarose beads. Nuclei were peleted from 
hypotonicaly lysed DIV 16 cultured cortical neurons, as described above, and the supernatant 
containing plasma membranes and cytosol were applied to 150ul of ConA beads. After thorough 
washing in lysis bufer containing 0.025% Nonidet-P40, samples were prepared for SDS-PAGE 




2.14 DNA constructs 
The ful-length mouse tagged GPM6A, tagged GPM6B, tagged β5 constructs were acquired from 
Origene. Al vectors obtained from commercial sources are verified and tested for the appropriate 
expression of the inserts using primary antibodies or epitope-tag antibodies against the expressed 
proteins. While we keep stocks of each validated plasmid, we periodicaly sequence these 
plasmids to confirm their authenticity. Al plasmids used in this study are amplified and purified 
using standard kits from commercial vendors.  
2.15 shRNA knockdown 
Four unique shRNA constructs were obtained each against GPM6A, GPM6B, and PLP from 
Origene. These were validated HuSH 29mer shRNA constructs expressing GFP. Each construct 
was transfected into neurons using previously described and standard protocols. Each construct 
was transfected at 100 ng and 500 ng/wel. In addition, the constructs were co-transfected in 
combination to knockdown either two, or al three genes.  
2.16 Human subjects 
Fetal brain tissue was obtained at Johns Hopkins University. Primary cultures of fetal cortical 
tissues were prepared. The use of fetal brain tissue was approved by the Johns Hopkins 
University institutional review board (IRB). Informed consent was obtained from al subjects. 
The authors did not have access to any identifying personal information.  
2.17 Co-immunoprecipitations 
Transfected HEK293 cels were colected and homogenized in IP Bufer (1% NP-40, 2mM 
MgCl2, 300mM NaCl, 2mM CaCl2, 50mM HEPES, 10% Glycerol) bufer. For 
immunoprecipitations, lysates were incubated with FLAG-M2 agarose beads (Sigma-Aldrich). 




2.18 Proteasome purification and assessment of catalytic activity 
For proteasome purification, cels were treated and then immediately put on ice before 
purifications were performed as previously described (Besche and Goldberg 2012). Briefly, 
proteasomes were purified out of neuronal cytosol and detergent-extracted neuronal plasma 
membranes using the 20S proteasome purification kit (Enzo Life Sciences) or the 26S proteasome 
purification kit (UBPBio). For western blots, samples were denatured at 65 °C for 5 minutes in 
SDS sample bufer, resolved by SDS PAGE, transfered to nitrocelulose, and immunobloted. 
For catalytic activity assays, 1/6th of the bead volume folowing proteasome purification was 
resuspended in activity assay bufer (20 mM Tris-HCl, pH8.0, 5 mM ATP, 5 mM MgCl2, 1 mM 
DTT). 26S Proteasomal activity was assessed by the addition of 10 µM of SUC-LLVY-AMC 
(Enzo Life Sciences). The contribution of 20S proteasomal activity was assessed by the 
comparison of 26S proteasome activity to that of total proteasome activity (26S+20S), measured 
by the activity of samples containing SDS at a final concentration of 0.05%. 
2.19 Cel culture radiolabeling 
Chapter 3: Cortical neurons were cultured for 12 days in vitro. Radioactive labeling was done in 
Neurobasal growth media with B-27 supplement and without methionine or cysteine (Life 
Technologies, special order). 35S methionine/cysteine (EasyTag PerkinElmer) was incorporated 
during indicated times at 55 mCi in the met/cys free growth medium. Where indicated, MG-132 
(25 µM, Cel Signaling) and ATPgS (1 mM, Sigma) was added during the radioactive labeling 
window. For al labeling experiments, normal growth media on neurons was switched into 
labeling media supplemented with radioactive label for 10 minutes. Lysates were prepared in 
RIPA bufer (50 mM Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Sodium Deoxycholate, 
0.1% SDS, 5 mM EDTA, complete protease inhibitor cocktail tablet (Roche), 1 mM sodium 
orthovanadate, 1 mM β-glycerophosphate). SDS sample bufer was added and samples were 




loading samples onto large SDS-PAGE gels, coomassie stained to verify equal loading, and then 
gels were dried down on a large gel drier onto Whatman filter paper. Dried gels were exposed to 
phosphorimager screens and scanned with a Typhoon FLA5500 imager.  
Chapter 4: Cortical neurons were cultured for 12-16 days in vitro. Radioactive labeling was done 
in Neurobasal growth media with B-27 supplement and without methionine or cysteine (Life 
Technologies, special order). 35S-methionine/cysteine (EasyTag PerkinElmer) was incorporated 
during indicated times at 55 mCi in the met/cys free growth medium. Where indicated, MG-132 
(20 µM, Cel Signaling) was added during the radioactive labeling window. For al labeling 
experiments, normal growth media on neurons was switched into labeling media supplemented 
with radioactive label for 10 minutes. For stimulation experiments, neurons were membrane 
depolarized with 55 mM extracelular KCl by addition of prewarmed depolarization bufer (55 
mM KCl, 0.2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES pH7.5) or a control bufer 
(Depolarization bufer, substituting 55mM NaCl for 55mM KCl) in fresh neuronal growth media 
as previously described (Lin et al. 2008). Lysates were prepared directly in RIPA bufer (50 mM 
Tris pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Sodium Deoxycholate, 0.1% SDS, 5 mM 
EDTA, complete protease inhibitor cocktail tablet (Roche), 1 mM sodium orthovanadate, 1 mM 
β-glycerophosphate) with SDS sample bufer added. This was done to prevent any enzymatic 
activity as soon as possible. Samples were heated at 70 °C for 5 minutes prior to loading onto 
SDS-PAGE gels. Autoradiographs were done by loading samples onto large SDS-PAGE gels, 
coomassie stained to verify equal loading, and then gels were dried down on a large gel drier onto 
Whatman filter paper. Dried gels were exposed to phosphorimager screens and scanned with a 
Typhoon FLA5500 imager. A variety of other manipulations and pharmacological agents were 
used during the pulse-chase protocol as indicated in supplementary figure 1. Synaptic activity was 
blocked by the addition of Tetrodotoxin (1 �M, Tocris), CNQX(1 �M, Tocris), and AP5 (1 �M, 




�M), and chemical LTP (125 mM NaCl, 2.5 mM KCl, 2 mM CaCl2, 5 mM Hepes, 33 mM 
Glucose , 0.2 mM Glycine, 0.02 mM Bicuculine, and 0.003 mM Strychnine) protocols. Neurons 
were treated with ACSF, chemical LTP bufer, or glutamate for 10 minutes during radiolabeling. 
5% FES was added for 30 minutes prior to radiolabeling and during radiolabeling. Media 
exchange was done by simply replacing growth media with fresh neurobasal-b27 to account for 
the stress of replacing media. 
2.20 Peptide colection and quantification 
Chapter 3: Folowing incorporation of radioactive 35S methionine/cysteine, neurons were rapidly 
washed in PBS and fresh Neurobasal media without phenol red and with 2x B-27 supplement was 
added. At the two-minute time point, al of the media was colected and then spun through a 10 
kDa Amicon filter (Milipore) and the flow through was then spun through a 3 kDa Amicon filter 
(Milipore). The flow-through from this sequential filtering was then dialyzed using dialysis 
tubing with a 100-500 Da cutof (Spectrum Labs) into either 1x PBS (Gibco) or 20 mM 
Ammonium Bicarbonate (Sigma). Folowing four days of dialysis, samples were lyophilized and 
resuspended in MiliQ water for downstream calcium imaging. Quantification of peptides was 
done by counting the amount of radioactivity in each sample by liquid scintilation (Walac 1410). 
Proteinase K control experiments were done by treating the media with 100 µg/mL proteinase K 
overnight in 2M Urea and 10mM BME, prior to re-dialyzing the proteolyzed media into 2M Urea 
for two days, and then gradualy reducing the Urea concentration down into NaCl and then into 
Ammonium Bicarbonate. Resuspended peptides were quantified prior to applications using 
LavaPep Fluorescent Peptide Quantification Kit (LP022010, Gel Company). 
Chapter 4: Radiolabeled peptide colections were done as previously described (Ramachandran 
and Margolis 2017). Briefly, neurons growing in their endogenous medium were treated with 
either a control or stimulation bufer. This was removed and replaced with pre-warmed 




with either control or stimulation bufers. Folowing 10 minutes of radiolabeling and stimulation, 
neurons were quickly washed with pre-warmed PBS and then 10mL of fresh Neurobasal/B27 was 
added. 50�l samples were immediately taken from the extracelular space. Samples were then 
quantified by liquid scintilation. 
2.21 Biotin-epoxomicin 
Biotin-epoxomicin is de-novo synthesized and purchased from Leiden University Institute of 
Chemistry. They are fuly equipped with synthetic capabilities in organic chemistry. Mass 
spectrometry and NMR verify al batches produced by his lab for quality and purity. Al batches 
used have had >99% purity. To further minimize batch variation, we test al batches in biological 
experiments (dose-titration for peptide release, NMP inhibition and cel viability responses). 
Biotin-epoxomicin was added to neuronal cultures at 25 µM immediately after labeling. 
Folowing peptide release assays, treated cels were lysed in a sucrose homogenization bufer 
(0.32 M sucrose, 5 mM HEPES, 0.1 mM EDTA, 0.25 mM DTT). Membranes were separated 
from the cytosol by high-speed centrifugation at 55,000 RPM for 1 hour. Fractions were 
solubilized in SDS sample bufer prior to loading on SDS-PAGE gels for western analysis. EM 
processing was done after 5 minutes of treatment with Biotin-Epoxomicin. 
2.22 Calcium imaging 
Calcium imaging was performed as previously described (Kim et al. 2014). Briefly, for the 
Biotin-Epoxomicin experiments, cultured embryonic cortical neurons were transfected with 1 µg 
of a mammalian expression construct encoding GCaMP3 at DIV10 and imaged at DIV 12-14. 
Bicuculine treatment was administered as a 1 µM stimulation in calcium imaging bufer in a 
perfusion setup. Once the bicuculine stimulation was washed out, biotin-epoxomicin (25 µM) 
was co-administered with 1 µM Bicuculine in calcium imaging bufer. Each treatment was 
monitored for three minutes prior to washout. Coverslips were not imaged twice due to Biotin-




process by stimulating with 55 mM KCl and washing out and assessing for a proper calcium 
signal. Quantification was done by picking multiple regions of interests in primary and secondary 
dendrites across multiple coverslips over diferent imaging days. Data was analyzed using the 
Time Series Analyzer V3.0 ImageJ plugin and the ROI manager. Data were pooled for al the 
ROIs to generate a single N value. Brains from P0-P3 mouse pups (Cre-GCaMP3; Nestin-Cre 
ER) were dissected and plated in Neurobasal-A with B-27 supplement for two weeks. At DIV7, 
4-hydroxytamoxifen (4-HT, concentration) was added to induce GCaMP expression. Neurons 
were imaged in a calcium-imaging bufer (130 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 0.6 mM 
MgCl2, 10 mM Hepes, 10 mM glucose, 1.2 mM NaHCO3 pH 7.45). Peptides were colected, 
filtered, and dialyzed and then lyophilized prior to resuspension in 1 mL of MiliQ water and 
addition onto GCaMP-encoding neurons. 5 µl of resuspended peptides were suficient to induce 
the described calcium-induced efects. Peptides treated with Proteinase K were spun through a 10 
kDa MW cutof filter prior to addition onto neurons in order to remove Proteinase K. 
Pharmacological inhibitors were perfused in at the indicated times at the folowing 
concentrations: BAPTA (2 µM), Thapsigargin (5 µM), Tetrodotoxin (1 µM), Nifedipine (1 µM), 
APV (2 µM).  
2.23 Mass Spectrometry 
Chapter 3: Mass spectrometry for proteasomes isolated from cytosolic and membrane fractions 
was performed at MS Bioworks, LLC. 
Chapter 4: The fractionated peptides were analyzed on an Orbitrap Fusion Lumos Tribrid Mass 
Spectrometer coupled with the UltiMateTM RSLCnano nano-flow liquid chromatography system 
(Thermo Fisher Scientific). The peptides from each fraction were reconstituted in 0.1% formic 
acid and loaded on a Acclaim PepMap100 Nano-Trap Column (100 µm × 2 cm, Thermo Fisher 
Scientific) packed with 5 µm C18 particles at a flow rate of 5 µl per minute. Peptides were 




acid in 95% acetonitrile) over 95 minutes on an EASY-Spray column (50 cm x 75 µm ID, 
Thermo Fisher Scientific)packed with 2 µm C18 particles, which was fited with an EASY-Spray 
ion source that was operated at a voltage of 2.0 kV.  
Mass spectrometry analysis was caried out in a data-dependent manner with a ful scan in the 
mass-to-charge ratio (m/z) range of 350 to 1550 in the “Top Speed” seting, three seconds per 
cycle. MS1 and MS2 were acquired for the precursor ion detection and peptide fragmentation ion 
detection, respectively. MS1 scans were measured at a resolution of 120,000 at an m/z of 200. 
MS2 scan were acquired by fragmenting precursor ions using the higher-energy colisional 
dissociation (HCD) method and detected at a mass resolution of 50,000, at an m/z of 200. 
Automatic gain control for MS1 was set to one milion ions and for MS2 was set to 0.05 milion 
ions. A maximum ion injection time was set to 50 ms for MS1 and 100 ms for MS2. MS1 was 
acquired in profile mode and MS2 was acquired in centroid mode. Higher-energy colisional 
dissociation was set to 35 for MS2. Dynamic exclusion was set to 30 seconds, and singly-charged 
ions were rejected. Internal calibration was caried out using the lock mass option (m/z 
445.1200025) from ambient air. 
2.24 Statistics 
No statistical methods were used to predetermine sample size. The experiments were not 
randomized. Al statistical analyses were performed using Origin Prism and Graphpad software, 
accounting for appropriate distribution and variance to ensure proper statistical parameters were 
applied. Experimental sample sizes were chosen according to norms within the field. The 
observed magnitude of diferences, together with the low replicate variance, permits high power 
of analysis based on the sample size chosen. For quantification of proteasomal localization by 
EM analysis, images were acquired by an independent assistant in the Johns Hopkins imaging 
core not involved in the experimentation and counts were then objectively talied by a second 




figure legends for the respective EM experiments. For remaining experiments investigators were 
not blinded to alocation during experiments and outcome assessment. 
Statistical analysis using Student’s t tests, 1-way ANOVAs and the appropriate post hoc tests 
were performed as described in each figure legend. P values ≤ 0.05 were considered significant 
2.25 Ribosome peleting 
Ribosome-nascent chain complexes were isolated according to wel established 
protocols(Brandman et al. 2012; Dutler, Pechmann, and Frydman 2013). Folowing various 
treatments and radiolabeling, neurons were lysed in a bufer containing either 100ug/mL 
Cycloheximide or Puromycin (25 mM HEPES pH7.5, 10mM MgCl2, 20mM KCl, 50mM NaCl, 
2mM ATP, 10u SuperASE-In, 20uM MG-132, 1.5% Triton X-100, protease inhibitors). Lysates 
were cleared by centrifugation at 10,000 RPM for 10 minutes, and the supernatant was layered 
onto a 1M sucrose cushion. Ribosome-nascent chain complexes or empty ribosomes (folowing 
puromycin treatment) were peleted via centrifugation at 70,000 RPM in a Ti 70.3 rotor. 
Supernatants were discarded and ribosomal pelets were washed three times with lysis bufer. 
1/10 of the ribosomes were counted by liquid scintilation and the remainder was prepared in SDS 
loading bufer. 
2.26 Two-dimensional gels for nascent chain analysis 
2-dimensional gels to analyze the ribosome-nascent chain complex were performed as previously 
described(Ito et al. 2011). Briefly, folowing 30 seconds of radiolabel incorporation at room 
temperature, neurons were lysed in bufers containing either Cycloheximide or Puromycin. 
Folowing lysis, RNCs were isolated as described above. Isolated RNC complexes were 
resuspended in SDS loading bufer, and then loaded onto neutral pH SDS-PAGE gels to 
minimize in-gel tRNA hydrolysis. Each samples was run with a few microliters of prestained 
ladder to delineate the lanes. After running in a single dimension, lanes were cut out of the gel 




hydrolyzes the ester bond linking the tRNA to its nascent polypeptide, generating a population of 
radiolabeled proteins whose mass is reduced by the weight of the tRNA (~25 kDa). Folowing 
RNA hydrolysis, samples were run in a second dimension, and then transfered onto 
nitrocelulose membranes. After exposure for autoradiography, membranes were blocked in BSA 
and immunobloted using anti-ubiquitin antibodies. 
2.27 Protein extraction, digestion, and labeling 
After indicated treatments, the cels were lysed by adding in 6 M urea and 2 M thiourea bufer 
with protease inhibitor cocktail. The lysates were sonicated with 35% amplitude for 1 min. 
Protein lysates were centrifuged at 16,000 g at 4 °C to exclude cel debris (peleting at the 
botom), and protein concentration was estimated using a SDS-PAGE method. Briefly, protein 
lysate was loaded with BSA standard ranging from 0.33 µg to 9 µg on a 3-12% NuPAGE gradient 
gel and separated for about 0.5 cm. The gel was stained with Coloidal Coomassie G-250 
folowed by destaining with water. The band intensities were measured by ImageJ software. A 
total of 200 µg of each sample was reduced with 10 mM dithiothreitol at room temperature for 
one hour and alkylated with 30 mM iodoacetamide for 20 minutes in the dark. The protein 
samples were digested using endoproteinase LysC (1:100) at 37 °C for 3 hours folowed by 
sequencing-grade trypsin (1:50) at 37 °C overnight. After the digestion, the peptide samples were 
subjected to desalting and labeling with 10-plex TMT reagents according to the manufacturer’s 
instructions (Thermo Fisher Scientific) and the 9/10 channels (126, 127N, 127C, 128N, 128C, 
129N, 129C, 130N, 130C) were used for labeling. The labeling reaction was performed for 
one hour at room temperature, folowed by quenching with 100 mM Tris-HCl (pH 8.0). The 
digested and labeled peptides from al 10 channels were pooled.  
The peptides were fractionated by basic pH reversed-phase liquid chromatography (bRPLC) into 
96 fractions, folowed by concatenation into 24 fractions by combining every 24th fractions. 




binary pump, VWD detector, an autosampler, and an automatic fraction colector. In brief, 
lyophilized samples were reconstituted in solvent A (10 mM triethylammonium bicarbonate, pH 
8.5) and loaded onto XBridge C18, 5 µm 250 × 4.6 mm column (Waters, Milford, MA). Peptides 
were resolved using a gradient of 3 to 50% solvent B (10 mM triethylammonium bicarbonate in 
acetonitrile, pH 8.5) at a flow rate of 1 ml per min over 50 min colecting 96 fractions. 
Subsequently, the fractions were concatenated into 24 fractions folowed by vacuum drying using 
SpeedVac. The dried peptides were suspended in 0.1% formic acid. 
2.28 Proteasome purification and activity assays 
Proteasomes were purified from either neuronal plasma membranes or out of the cytosol as 
previously described (Ramachandran and Margolis 2017). Briefly, neurons treated with either 
control or depolarization bufer were separated into membrane and cytosolic fractions using 
ultracentrifugation as previously described. Proteasomes were subsequently immunoprecipitated 
using resin conjugated to an antibody against the β2 proteasome subunit (Enzo). 
Immunoprecipitated proteasomes were then incubated with Suc-LLVY-AMC (Enzo) to test for 
activity. 20S activity was monitored as previously described. 
2.29 Data analysis, Mass Spectrometry – Chapter 4 
Proteome Discoverer (v 2.1; Thermo Scientific) suite was used for quantitation and identification. 
During the preprocessing of MS/MS spectra, the top 10 peaks in each window of 100 m/z were 
selected for database search. The tandem mass spectrometry data were then searched using 
SEQUEST algorithms against mouse RefSeq protein database (version 84) with common 
contaminant proteins. The search parameters used were as folows: a) trypsin as a proteolytic 
enzyme (with up to two missed cleavages); b) peptide mass eror tolerance of 10 ppm; c) 
fragment mass eror tolerance of 0.02 Da; and d) carbamidomethylation of cysteine 
(+57.02146 Da) and TMT tags (+229.162932 Da) on lysine residues and peptide N-termini as a 




minimum peptide length was set to 6 amino acids. Peptides and proteins were filtered at a 1 % 
false-discovery rate (FDR) at the PSM level using percolator node and at the protein level using 
protein FDR validator node, respectively.  
The protein quantification was performed with folowing parameters and methods. The most 
confident centroid option was used for the integration mode while the reporter ion tolerance was 
set to 20 ppm. The MS order was set to MS2 and the activation type was set to HCD. Unique and 
razor peptides both were used for peptide quantification while protein groups were considered for 
peptide uniqueness. Reporter ion abundance was computed based on signal-to-noise ratio and the 
missing intensity values were replaced with the minimum value. The quantification value 
corections for isobaric tags and data normalization were disabled while the co-isolation threshold 
was set to 50%. The highest signal-to-noise ratio value from PSMs for a peptide was used to 
generate a peptide level abundance folowed by averaging peptide level signal-to-noise ratio 
values for a protein to generate a protein level abundance. 
Protein grouping was performed with strict parsimony principle to generate the final protein 
groups. Al proteins sharing the same set or subset of identified peptides were grouped while 
protein groups with no unique peptides were filtered out. The Proteome Discoverer iterated 
through al spectra and selected PSM with the highest number of unambiguous and unique 
peptides. 
2.30 TMT Diferential Expression 
The list of quantified proteins exported from Proteome Discoverer 2.1 was utilized as the input 
for our diferential expression analysis. The raw values were organized in a matrix where each 
column represented a sample and each row a protein. To normalize the raw expression values, we 
began by log2 transforming the matrix with a +1 for computation. Then we median polished the 




of the column median from each column. The resulting normalized expression values for each 
sample appeared normaly distributed and was comparable across samples. 
For the detection of diferential regulation, we folowed the recommendation outline in 
(Kammers et al. 2015). An empirical Bayes method was employed on the normalized matrix to 
detect diferences between the 3 samples of the biotin-epoxomicin treated group compared to the 
6 samples of the control and cycloheximide groups. The empirical Bayes method shrinks 
individual protein’s sample variance towards a pooled estimate, and creates a more stable and 
powerful inference in diferential protein abundance detection.  
The output of the diferential abundance analysis detected 1340 and 408 proteins to be 
diferentialy abundant at the 0.05 and 0.01 level respectively. However, due to the large number 
of proteins tested, we were more interested in q-values that adjust for multiple comparisons. 
Using a cutof of q < 0.1, which coresponds to a false discovery rate of 10%, we detect 190 
proteins to be diferentialy abundant in the 2 groups that we defined. Of those 190 proteins, 122 
were up-regulated. 
For the selection of the colors in the heatmap, we caried out feature-scaling of the normalized 
expression values on a gene-by-gene basis. For each gene, this process assigns the largest 
expression a value of 1, and the smalest expression a value of 0. The remaining values are scaled 
between 0 and 1 based on where they are relative to the largest and smalest expression values. 
For instance, a feature-scaled value of 0.5 represents an expression level that is halfway between 
the lowest expression and the highest expression observed for a gene. In other words, this 
sample’s expression is 50% of the maximum fold change away from the lowest and the highest 
expression values at this gene.  
2.31 Markov Chains to Model Radioisotope Release 
To model the radioisotope release curves that were experimentaly observed, we employed 




in 1-second increments, starting at the moment of washout until 1800 seconds (30 minutes) after. 
The transition process and probabilities between states is given in figure 2E. Each radioisotope is 
assumed to begin as a free isotope within the cel. 
A free isotope has at each second interval a pBackground chance of difusing across the cel 
membrane to become a free isotope extracelularly. In that same second interval, that isotope also 
has a pLoading chance of coming in contact with a ribosome and becoming a part of a nascent 
polypeptide. This leaves that for each interval, a free isotope has a 1-pLoading-pBackground 
chance of remaining as a free isotope.  
Once a radioisotope has progressed to the state of a nascent polypeptide, it has some probability 
pCTD of being released co-translationaly. If entering that release path, the time it takes for the 
release to be realized extracelularly requires a time that is distributed N(8, sd=2)/2.5. The N(8, 
sd=2) represents that on average cleave sites are every 8 or so amino acids, while 2.5 is the wel 
established rate which degradation occurs. If not entering this pathway, the nascent chain 
becomes a folding intermediate. The time required for this is dependent upon the length of the 
protein that this isotope is being incorporated into, the location at which it is being incorporated, 
and the rate of translation. To determine the length of the protein, we sampled a protein at random 
from the list of detected intracelular proteins under ful protein degradation inhibited conditions. 
The probability of sampling each protein is proportional to their relative abundance. Once the 
protein has been selected, we simulated the point of incorporation of the radioisotope to be 
uniform along the length of the ful protein. The time to progress from a nascent polypeptide to 
the folding intermediate is determined as the (# of AA in the protein after the incorporation 
point/5), with 5AA/s being the established rate translation. 
Upon becoming a folding intermediate, the radioisotope has a chance pFID of being degraded and 
released extracelularly. If entering this degradation path, the time before the radioisotope is 
realized extraceluarly is calculated as the #AA in the protein before the incorporation point 




2.5AA/second. If at this point, the radioisotope does not enter the degradation path, it wil initiate 
the process towards a folded protein. 
The time it takes for a folding intermediate to become a folded protein is based upon the power 
law (Lane and Pande 2013)and is calculated as a random variable folowing exp(5*log(#AA)-
27.7+Norm(0, sd=3). This coresponds to a folding time of approximately 30 seconds for a 50 
kDa protein. Once the protein is folded, it has a probability pFD of entering degradation in any 1-
second interval. If it does enter the pathway, we assume the time it takes for the isotope to be 
released extracelularly is determined mostly by the unfolding time, which we assumed 
conservatively to be equal to the folding time distribution. Otherwise, the protein remains folded 
with a probability of 1-pFD. We chose a pFD of 1e-5 for our model because it coresponded to a 
conservative representation that the half-life of a folded protein existing in a folded state is 
approximately 20 hours. 
2.32 Monte Carlo Inference for Model Parameters 
With this formulation of the Markov chain, there remains 4 variables that are not based upon 
previously established results: pLoading, pBackground, pCTD, and pFID. We employed Monte 
Carlo simulations in a 2-stage process to optimize those parameters to most closely miror the 
experimental observed release curves. Experimental release curves were estimated as folows. For 
each experimental condition, we have observations of released radioisotope at times 0, 60, 120, 
300, 600, and 1800 seconds after washout. The value of each time point was divided by the total 
amount of radioisotope within the cel at 0 seconds after washout to rescale the observations as a 
proportion. For any point in time between the 5 observed time points, the released proportion was 
assumed to folow a linear relationship.  
We first exploited the assumption that the dominant isotope release pathway should be difusion 
(between 0-600 seconds) in an experimental condition where al degradation of proteins is 




parameter space of al pairwise combinations of pLoading between 0.0035 and 0.0075 in 0.0001 
increments and pBackground between 0.00001 and 0.0004 in 0.00001 increments. For each of 
combination of pLoading and pBackground we used Monte Carlo simulations of 2500 Markov 
chains, each one starting as a free isotope and having transition probabilities given by the 
pairwise combination of pLoading and pBackground. The proportion of the 2500 initial 
radioisotopes that is released extracelularly at each second in time was recorded as the simulated 
release curve. The simulated release curves were compared to the experimental release curve 
when al protein degradation was inhibited to determine the optimal combination of pLoading and 
pBackground. The penalty measure is the sum of the squared distance between observed and 
simulated at each time point between 1 and 600 seconds. We chose not to evaluate the curves 
beyond 600 seconds because it appeared reasonable that difusion was the dominant form of 
isotope release prior to 600 seconds. For the time range between 600-1800 seconds, other release 
mechanisms like autophagy might confound our eforts. This process revealed pLoading and 
pBackground to be optimized at 0.0056 and 0.00017 respectively. 
After having optimized pLoading and pBackground, we continue on to find the pair of pCTD and 
pFID that best matches the experimental release curves under control conditions. We used a 
similar Monte Carlo simulation approach looking at al pairwise combinations of pCTD and pFID 
both between 0 and 0.7 in 0.001 increments. Using experimental data, we calculated that at the 
moment of washout, the ratio of free radioisotopes to isotopes in folded protein to isotopes in 
nascent polypeptides to be 300:20:1. As such, for each pairwise simulation, we initiated the initial 
state of the Markov chains to reflect that ratio. For each pairwise simulation, we simulated 
between 15,000 – 20,000 Markov chains, and tracked the progression of the isotopes for 1800 
seconds. The simulated proportion of radioisotopes at any point of time that is extracelular was 
calculated as our simulated release curve. We searched for the pair of pCTD and pFID that 




simulated curve and the observed control release curve. The optimal values for pCTD and pFID 
were observed to be 0.047 and 0.0 respectively. 
We conducted the same optimization process of pCTD and pFID under KCI stimulation to in a 
manner that mirored the above approach. We evaluated a parameter space for pCTD and pFID 
both between 0 and 0.2 in 0.05 increments. We searched for the pair that produced the minimum 
total squared eror at each time point from 1-600 seconds between the simulated curve and the 
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Proteasomes are heterogeneous multisubunit catalytic complexes that consist of a core 
20S stacked ring of a and β subunits with a a 7 β 7 β 7 a 7 architecture, and can be associated with 
19S regulatory cap-particles to form a 26S proteasome(Coux, Tanaka, and Goldberg 1996). 
Among the other 20S-containing proteasomes are 20S proteasomes capped with 11S or 
PA200(Coux, Tanaka, and Goldberg 1996). While capped 26S proteasomes mediate ATP-
dependent degradation of ubiquitinated proteins, uncapped 20S proteasomes do not require 
ubiquitin or ATP for their catalytic function(Ciechanover 1998; Ciechanover and Schwartz 1998; 
Ben-Nissan and Sharon 2014). Recent studies have shown that 20S proteasomes may have key 
biological functions separate from the canonical 26S ubiquitin-proteasome, particularly in 
clearing unstructured proteins and in degrading proteins during celular stress(Ben-Nissan and 
Sharon 2014). 
20S proteasomes are absolutely essential in mammalian cels. In lieu of genetic 
perturbation, proteasome function has been studied through the use of many diferent inhibitors 
such as MG-132, Lactacystin, Epoxomicin, and peptide boronates(Kisselev, van der Linden, and 
Overkleeft 2012). The use of these inhibitors has revealed diverse roles for the proteasome in 
many diferent tissues and contexts, driven by protein homeostasis through ubiquitin-dependent 
proteasomal degradation. Typicaly, these processes require proteasome function over hours to 
days (long-term). Indeed, proteasomes do play such long-term roles in important aspects of 
neuronal function such as synaptic remodeling and cel migration(Ehlers 2003; Wang et al. 2003). 
However, proteasome function is also required for activity-dependent neuronal processes over 
very short timescales (seconds to minutes), such as regulating the speed and intensity of neuronal 
transmission or the maintenance of long-term potentiation, a molecular underpinning of learning 
and memory(Karpova et al. 2006; Dong et al. 2008; Djakovic et al. 2009; Ehlers 2003; Bingol 
and Schuman 2006; Cai et al. 2010; Rineti and Schweizer 2010). Presumably, short-term 




landscape, so it was unclear how proteasomes could rapidly alter neuronal function. Thus, we 
reasoned that an unidentified function for proteasomes in the nervous system must exist. 
Changes in calcium dynamics and transients underlie many of these neuronal processes 
that occur over short timescales. Indeed, perturbation of proteasome activity has been shown to 
afect calcium dynamics in neurons(Rineti and Schweizer 2010; Wu, Hyrc, et al. 2009). 
Consistent with these findings, we observed that acute addition of the pan-proteasome inhibitor 
MG-132 onto neurons suppressed neuronal activity-induced calcium signaling (Figure 3.1). The 
efect on calcium dynamics that we observed occured within seconds of MG-132 addition, 
indicative of a signaling role for proteasomes independent of their proteostatic role. Studies 
addressing the role for proteasomes in the nervous system have used pan-proteasome inhibitors 
such as MG-132 or lactacystin or have focused on the 26S proteasome through altering the 
ubiquitination pathway(Bingol and Schuman 2006; Fonseca et al. 2006; Rineti and Schweizer 
2010). These approaches do not distinguish between uncapped 20S or capped-20S proteasomes. 
We considered that evaluating proteasomes in the nervous system, without bias for 20S or 20S-
containing proteasomes, would provide a means to identify unique proteasomes that could have 
acute signaling functions.  
20S proteasome subunits are localized to neuronal plasma membranes 
Previous studies have identified localization as a key feature in determining proteasome 
function(Pines and Lindon 2005). Distribution of the 26S proteasome in the nervous system has 
been measured using fluorescently-tagged 19S cap subunits or electron cryotomography (Cryo-
ET)(Asano et al. 2015; Patrick et al. 2003; Djakovic et al. 2009). While cryo-ET approaches are 
theoreticaly unbiased, the processing methods inherently select for analysis of larger complexes, 
and therefore are more likely to identify singly- and doubly-capped proteasomes. In order to take 




20S-containing) in the nervous system, we performed an immunogold electron microscopy 
(Immuno-EM) analysis of hippocampal slice preparations using antibodies raised against either 
the proteasome β2, β5 or β2 subunits (hence forth refered to as anti-β2, anti-β5, anti-β2). These 
are core 20S proteasome subunits common to al catalyticaly active proteasomes(Coux, Tanaka, 
and Goldberg 1996; Blomen et al. 2015). 
We first performed western blot analysis of mouse brain lysates to assess the antibodies 
used for our immuno-EM studies. Brains from P30 mice were lysed and prepared for SDS-
PAGE, and then immunobloted with anti-β2, anti-β5, or anti-β2. Each antibody recognized a 
single band by western analysis at the appropriate molecular weight (Figure 3.2a-e). We 
proceeded to perform immuno-EM from mouse hippocampal sections using these antibodies and 
appropriate gold-conjugated secondary antibodies. We did not detect any significant staining 
using secondary gold-conjugated antibodies alone (Figure 3.3a-c). We observed diverse 
subcelular and cytosolic distribution of gold particles coresponding to proteasome subunits, as 
previously reported(Coux, Tanaka, and Goldberg 1996) (Figure 3.2a-e and Figure 3.4a-c). 
Unexpectedly, we observed ~40% of al gold particles localized to neuronal plasma membranes 
(PM). Similar results were obtained using two additional antibodies raised against �2 and �5 
subunits, but directed against diferent epitopes (Figure 3.2b, d and Figure 3.4a, b). In contrast, 
we did not observe PM localization of gold particles when using antibodies raised against 19S 
cap proteins Rpt5 or S2 subunit (Figure 3.2f and Figure 3.4d). Immunostaining using these 19S 
antibodies show difuse cytosolic localization, consistent with prior studies(Djakovic et al. 
2009). 
Extending these findings, we performed immuno-EM analysis from mouse primary 
neuronal cultures, as these preparations are largely devoid of non-neuronal cel types and can 
provide higher resolution analysis(van Weering et al. 2010; Chen et al. 2015). No immunogold 




3.6a). For these experiments, using anti�β2 or anti��5 we observed ~40% of immunogold 
signal at neuronal PMs (Figure 3.5a and Figure 3.6b). Of those particles observed at neuronal 
PMs, 43 ± 1% overlaid PMs, 39 ± 0.9% were located at the intracelular face, and 18 ± 0.9% 
were at the extracelular face (Figure 3.5a). Using similar immuno-EM approaches, we did not 
observe PM localization of proteasomes in cultured non-neuronal HEK293 cels, which had 
particles localized to the cytoplasm (Figure 3.6c). Because conjugation of a primary antibody to 
a gold-particle tagged secondary antibody can result in the gold particle being localized up to 
~20 nm from the target antigen, we quantified the fine localization of gold particles near 
neuronal PMs and ploted each particle in relation to its distance from the PM. This was a linear 
measurement taken from the center of the PM to the centroid of the gold particle. A majority of 
particles overlaid the PM, with the particle density diminishing as a function of distance from the 
membrane (Figure 3.5b). Thus, the signal observed at plasma membranes coresponds to a 
unique pool of membrane-localized proteasome subunits rather than a reflection of intracelular 
proteasome subunits. Since core proteasome subunits are not known to be present in the cel 
separate from the macromolecular proteasome complex, these data likely reflected the 
membrane localization of intact proteasomes(Coux, Tanaka, and Goldberg 1996). 
Neuronal membrane proteasomes are exposed to the extracelular space 
Immuno-EM staining with a previously validated antibody raised against the 
cytoplasmic domain of the voltage-gated potassium channel, Kv1.3, only showed cytosolic 
labeling and labeling on the intracelular face of the PM as previously described(Gazula et al. 
2010) (Figure 3.7a). By immuno-EM analysis we see 20S proteasome staining on the 
extracelular face of the PM, which raises the possibility that proteasomes may be exposed to the 
extracelular space (Figure 3.2a-e, 3.5a and Figures 3.4a-c, 3.6b). We decided to use three 
additional approaches to substantiate these findings: one specificaly detecting proteasome 




(surface biotinylation & protease protection) (Figure 3.5c). First, we used antibody feeding onto 
live neuronal cultures(Kim et al. 2005; Hanley et al. 2002). No staining was observed using 
secondary alone controls (Figure 3.7b). Feeding a primary antibody against an N-terminal 
extracelular epitope of the GluR1 (N-GluR1) ionotropic receptor showed punctal staining as 
previously reported(Peebles et al. 2010). We did not observe staining feeding an antibody 
against intracelular protein MAP2 (Figure 3.5d). Consistent with proteasomes subunits being 
exposed to the extracelular space, feeding anti��5 we observed punctal localization of which 
20% overlapped with GluR1 (Figure 3.5d). Pretreatment of anti��5 with the �5 blocking 
peptide eliminated 84% of the signal (Figure 3.5d). 
To biochemicaly determine whether proteasomes were surface-exposed, we turned to 
previously described surface-biotinylation/purification approaches(Lin et al. 2009; Ehlers 2000) 
folowed by immunobloting with antibodies against 20S proteasome subunits, Rpt5, Actin, and 
GluR1. As expected, in our streptavidin puldown samples from surface-biotinylated neurons we 
did not detect cytosolic Actin and did detect GluR1 (Figure 3.5e). Consistent with proteasomes 
being extracelularly accessible, we detected core 20S proteasome subunits in our streptavidin 
puldown (Figure 3.5e). We did not detect significant puldown of Rpt5. Several measurements 
were taken to assure our results were not due to poor cel health or enhanced cel permeability 
(Figure 3.7c and 3.7d).  
As an orthogonal method of identifying surface exposed proteins, we used a protease 
protection assay, which relies on the proteolysis of extracelularly exposed epitopes of proteins 
upon treatment of live cels with an extracelular protease(Caterina, Hereld, and Devreotes 1995; 
Zhu et al. 2003). Cultured cortical neurons were treated with Proteinase K (PK) for varying 
times and then fractionated into either cytosolic or membrane fractions. By immunoblot analysis, 
we found that proteasome subunits fractionated to the membrane, similar to N-GluR1, and were 




from the cytosolic fraction, similar to Tubulin, were protected from protease cleavage(Wunder, 
Lippincot-Schwartz, and Lorenz 2010) (Figure 3.5f). Because PK, when added to live cels can 
only degrade proteins exposed to the extracelular space, we interpreted this observation to mean 
that proteasomes were surface-exposed and that the majority of proteasomes in our membrane 
preparations are from plasma membranes and not from other membrane organeles. This result 
was coroborated using Concanavalin-A (ConA), a lectin binding protein that binds glycosylated 
molecules, and has been used to enrich for plasma membranes(Lee et al. 2012) (Figure 3.7e). 
Taken together, these data support the existence of a surface exposed proteasome complex at the 
neuronal PM. For convenience, we wil henceforth refer to the proteasome localized to the 
neuronal plasma membrane as the neuronal membrane proteasome, or NMP. 
Neuronal membrane proteasomes are tightly associated with plasma membranes  
We wanted to further enhance our biochemical understanding of how proteasomes, as 
largely hydrophilic complexes, could be localized to the hydrophobic PM. Neuronal membranes 
were isolated and sequentialy extracted with increasing concentrations of digitonin to pul out 
increasingly hydrophobic proteins. Samples were prepared for western analysis (Figure 3.10a). 
Quantification of these immunoblots revealed that a significant percentage of alpha and beta 
subunits co-fractionated with cytosolic proteins (Tubulin) and hydrophobic membrane proteins 
(GluR1). These data are consistent with proteasomes fractionating in two diferent modes, one 
that is cytosolic and another that is membrane-bound, providing additional evidence for a unique 
pool of membrane-localized proteasomes in contrast to cytosolic proteasomes (Figure 3.10a). To 
determine whether NMPs were tightly or peripheraly associated with plasma membranes, we 
used sodium carbonate extraction. Neuronal cultures were separated into cytosolic, peripheraly-
associated (carbonate-soluble) and tightly-associated (carbonate-insoluble) membrane proteins 
fractions(Zhu et al. 2003). Calregulin(Smith and Koch 1989) was used as a marker of 




associated membrane proteins. Immunobloting these fractions showed that core 20S proteasome 
components were tightly-associated (carbonate-insoluble), while Rpt5 was peripheraly-
associated (carbonate-soluble) (Figure 3.10b).  
We considered there were two primary ways this could be possible: (1) the proteasome 
itself was hydrophobic in some way or (2) the proteasome was tightly associating with integral 
membrane proteins. In an atempt to distinguish between these possibilities, we performed Triton 
X-114 phase partitioning of cultured neurons to separate hydrophilic and hydrophobic 
proteins(Park et al. 2013). Immunobloting the Triton-rich and Triton-free fractions, we observed 
Actin fractionated into the Triton-free phase, multi-pass transmembrane protein GluR1 
fractionated into the Triton-rich phase, and EphB2, a single-pass transmembrane protein 
fractionated into both phases (Figure 3.10c). Proteasome subunits fractionated in both phases, 
with only ~15-25% of proteasome subunits fractionating in the Triton-rich phase (Figure 3.10c). 
Based on our immuno-EM, surface biotinylation and membrane fractionation data up to 40% of 
proteasome subunits were plasma membrane localized. We reasoned that the discrepancy 
between these analyses might be due to the fact that proteasomes were not suficiently 
hydrophobic to exist in the plasma membrane independent of auxiliary membrane proteins. 
Neuronal membrane proteasomes are largely a 20S proteasome and in complex with GPM6 
family glycoproteins 
To identify potential auxiliary membrane proteins associated with the NMP we purified 
proteasomes out of neurons using two diferent afinity methods(Besche et al. 2009). Cytosolic 
and membrane-extracted fractions from neuronal cultures were incubated with 20S-purification 
matrix (purifies any 20S-containing proteasome complex) or 26S purification matrix (only 
purifies cap containing proteasome complex). Immunoblot analysis revealed that both 20S and 




matrix was able to purify proteasomes out of the membrane (Figure 3.11a), suggesting to us that 
this is an approach for purifying the NMP. 
Using the 20S-purification matrix, we purified 20S proteasomes from the cytosol and 
membrane of neurons for in-depth mass spectrometry (MS) analysis. As expected, we identified 
al of the core 20S proteasome subunits in the purification from both membranes and cytosol 
(Table 1a). While we identified a variety of regulatory cap proteins to co-purify with the 
cytosolic proteasome, we identified very few to co-purify with the proteasome purified from 
membranes (Table 1a). These findings were validated by extensive western analysis (Figure 
3.8a-c).  
We sought to identify auxiliary membrane proteins in our MS data sets that may be 
capable of mediating proteasome association with the plasma membrane. We postulated that 
such a protein would specificaly associate with the NMP compared to the cytosolic proteasome, 
be highly expressed in the nervous system, and be transmembrane (Table 1b). Based on these 
criteria, we focused our eforts on the neuronal membrane glycoprotein GPM6A, a known 
member of the Proteolipid Protein family of multi-pass transmembrane glycoproteins(Werner et 
al. 2001; Fuchsova et al. 2009). To validate these mass spectrometry data, we turned to HEK293 
cels as a non-neuronal heterologous system that does not express the NMP (Figure 3.9a). 
Lysates from HEK293 cels previously transfected with expression plasmids encoding myc-
/FLAG-tagged GPM6A and GPM6B (myc/FLAG-GPM6A/B) were immunoprecipitated using 
an anti-FLAG antibody. Immunobloting using antibodies against myc and 20S proteasome 
subunits, we found that endogenous proteasome subunits from HEK293s co-immunoprecipitate 
with myc/FLAG-GPM6A/B (Figure 3.11b). While we interpret these data to mean that 
proteasomes can associate with GPM6 proteins, as demonstrated from our MS data from 
neurons, we wanted to know whether the GPM6 proteins could induce the proteasome to become 




that expression of GPM6A and GPM6B in HEK293s was suficient to induce surface expression 
of the endogenous HEK293 proteasome at the PM (Figure 3.11c). These results are not seen 
upon overexpressing GFP, single-pass transmembrane protein EphB2, or multi-pass 
transmembrane protein Channelrhodopsin 2 (Figure 3.11c). As a control for our surface 
biotinylation assay, we uniformly detected the plasma membrane protein, Transferin, verifying 
equal puldown eficiency (Figure 3.11c). Additionaly, overexpression of myc-tagged �5 
proteasome subunit together with myc/FLAG-GPM6A/B led to both myc-�5 and the 
endogenous subunits to become surface exposed (Figure 3.11c). These findings phenocopy the 
phenomenon we observe in primary cultured neurons, and indicate the GPM6A/B proteins are 
suficient to expose proteasomes to the extracelular space. Atempts to determine whether 
GPM6 family proteins were required for NMP expression were unsuccessful as shRNA 
mediated knockdown of GPM6A in neuronal cultures induced cel death suggesting GPM6 
proteins may be essential for viability (data not shown). 
GPM6A and GPM6B are primarily expressed in the nervous system(Zhang et al. 2014). 
Consistent with these data, using our surface biotinylation assay in whole mouse tissues, we 
determined that NMP expression was restricted to mouse neuronal tissues (Figure 3.11d). 
Similar results were observed using human brain tissue (Figure 3.9b). These were the first set of 
data to indicate some specific role for NMP in neuronal function and prompted us to determine 
whether NMP expression was regulated and changed over neuronal development. Using our 
surface biotinylation assay in slice preparations from mouse brain, we determined that NMP 
expression paraleled in vivo expression paterns of GluR1, whose expression functionaly 
corelates with critical stages in neuronal development(Lin et al. 2009) (Figure 3.11e). 
Performing the same experiments in neuronal cultures, we observed that the NMP was expressed 





Neuronal membrane proteasomes degrade intracelular proteins into extracelular peptides  
 To test whether the NMP was catalyticaly active, we purified proteasomes from both 
the cytosol and neuronal plasma membranes using a 20S purification matrix and incubated them 
with a substrate that fluoresces upon proteasomal chymotrypsin-like cleavage(Vilchez et al. 
2012). Addition of a low concentration of SDS to the reaction relieves the gating mechanism of 
the 20S proteasome without denaturing the 20S or 26S proteasome holocomplex(Ben-Nissan 
and Sharon 2014). Addition of SDS greatly stimulated the catalytic activity of membrane 
proteasomes and had litle efect on cytosolic proteasome activity (Figure 3.12a and Figure 
3.13a), consistent with a large fraction of NMPs being 20S and catalyticaly active. 
 Since the core 20S complex alone is ~11x15 nm, any orientation of the NMP at the 
neuronal PM, which is 6-10 nm across, would provide it access to both the intracelular and 
extracelular space. We hypothesized that in intact cels, a catalyticaly active NMP in such an 
orientation would be able to promote proteasome-dependent degradation of intracelular proteins 
into the extracelular space. To test this hypothesis, we used 35S-methionine/cysteine-
radiolabeling approaches to trace the fate of newly synthesized intracelular proteins(Schubert et 
al. 2000) (Figure 3.12b). After 10 minutes of radiolabel incorporation (Figure 3.12c), free 
radioactivity was washed away, and media was colected over a timecourse and analyzed by 
liquid scintilation to detect radiolabeled proteins. We observed rapid release of radioactivity 
into the culture medium under baseline conditions (Figure 3.12d). We observed a significant 
decrease in radioactive flux folowing addition of MG-132, without afecting radiolabeling 
eficiency (Figure 3.12c, d). Addition of ATP�S, a non-hydrolyzable ATP analog, had no efect 
on release of radioactive material (Figure 3.12d). This was consistent with the release of 
radioactivity being due to an uncapped 20S proteasome, which does not require ATP. To 
determine whether the released radiolabel was incorporated into protein peptides, diferent 




amino acids and dipeptides. Of the released radioactive material at the 2-minute colection time, 
82 ± 11% was made up of PK-sensitive molecules that ranged between 500 and 3000 Daltons in 
size (Figure 3.12e). Similar results were observed at a 30-minute colection time (Figure 3.13b). 
Since proteasome cleavage products are peptides between 500 and 3000 Da in size we conclude 
that a large fraction of radioactivity in the media was composed of protein peptides derived from 
a proteasome(Kisselev, Akopian, and Goldberg 1998) and not individual amino acids or smal 
molecules. To discriminate between cytosolic and membrane proteasomes in mediating the 
eflux of extracelular peptides, we took advantage of the temporal switch in NMP expression 
between DIV7 and DIV8, where both DIV7 and DIV8 neurons express cytosolic proteasomes 
but only DIV8 neurons express the NMP (Figure 3.9c, d). We observed that proteasome-
dependent release of radiolabeled peptides into the media was observed at DIV8, but not at 
DIV7(Figure 3.12f). Consistent with this being an NMP-mediated neuronal phenomenon, we did 
not observe proteasome-dependent release of radiolabeled peptides in heterologous HEK293 
cels that do not express the NMP (Figure 3.13c). Taken together, these data support our 
hypothesis that the NMP degrades intracelular proteins into extracelular peptides.  
Neuronal membrane proteasomes are required for release of extracelular peptides and modulate 
neuronal activity  
To specificaly determine the contribution of the NMP in the generation of these 
extracelular peptides, separately from that of the cytosolic proteasome, we identified a chemical 
tool that was selective to the NMP. We found that biotinylation of the non-reactive portion of 
epoxomicin, a highly potent and specific proteasome inhibitor, generates a cel-impermeable 
compound (biotin-epoxomicin) that maintains target specificity(Li et al. 2013). The epoxomicin 
of biotin-epoxomicin covalently ataches to the catalytic proteasome � subunits thus 
permanently tagginging � subunits with biotin. To test this, cultured neurons acutely treated 




fluorescent streptavidin. Biotin signal was only observed as two distinct bands in membranes 
from neurons treated with biotin-epoxomicin, denoting the covalent modification of the 
membrane proteasome � subunits (Figure 3.14a). 
Furthermore, Immuno-EM analysis of neuronal cultures treated with biotin-epoxomicin 
showed 91 ± 5% of biotin at plasma membranes (Figure 3.14b and Figure 3.15a). Any cytosolic 
labeling was likely due to the streptavidin-Au binding of endogenously biotinylated proteins, as 
we detected low-abundance cytosolic labeling in cultures not treated with biotin-epoxomicin 
(Figure 3.15a, b). Since biotin was directly labeled using streptavidin-Au, this analysis reduces 
the distance between the gold particle and the target antigen compared to conventional antibody-
based immuno-EM. These data show that NMPs overlay neuronal plasma membranes and are 
exposed to the extracelular space and provide further evidence that the NMP is catalyticaly 
active, since epoxomicin requires proteasome activity in order to bind to and inhibit the catalytic 
subunits(Meng et al. 1999b). Using this inhibitor, we sought to separate the role of the NMP 
from the role of the cytosolic proteasome in regulating extracelular peptide production. Acute 
application of biotin-epoxomicin to radiolabeled neurons inhibited radioactive peptide release 
into the extracelular space (Figure 3.14c). Using biotin-epoxomicin, we wanted to test our initial 
hypothesis that the NMP could mediate rapid neuronal signaling. 
To test whether the NMP was relevant to aspects of neuronal signaling, changes in 
intracelular calcium were measured since calcium serves as a rapid readout for many types of 
neuronal signaling(Patel et al. 2015). Calcium imaging was performed using GCaMP3-
transfected cultured neurons treated with perfusate containing GABAergic receptor antagonist 
bicuculine which, by relieving inhibition on neuronal circuits, induces regular firing of action 
potentials and calcium transients(Patel et al. 2015). Folowing 2 minutes of bicuculine 
stimulation, perfusate was switched to bufer containing both bicuculine and 25 �M biotin-




robust atenuation of the amplitude of bicuculine-induced calcium transients, similar to that 
which we observed upon acute addition of MG-132 (Figure 3.14d and e). Addition of biotin-
epoxomicin induced a large variability in the frequency of calcium transients: 47% of neurons 
displayed an increase in frequency, while the same treatment induced a potent abrogation of 
bicuculine-induced calcium signals in 38% of neurons (Figure 3.14f). Based on these data, an 
endogenous function of the NMP is to modulate the strength and speed of activity-dependent 
neuronal signaling through its proteolytic activity, possibly through the actions of the resulting 
extracelular peptides. 
Neuronal membrane proteasome-derived peptides are suficient to induce neuronal signaling 
To systematicaly test the efects of proteasome-directed peptide signaling, peptides were 
purified and then perfused onto GCaMP3-encoding neurons under various conditions. Neurons 
were ensured to be healthy at the end of every experiment by stimulating with 55 mM KCl, which 
consistently induced strong calcium signaling. The proteasome-directed peptides were purified 
and resuspended in calcium imaging bufer. Peptide concentration was determined to be ~50 
ng/mL and was added back at that concentration. Alone, purified peptides induced a robust 
degree of calcium signaling in naïve neurons (Figure 3.16a). This peptide-induced stimulation 
was eliminated if the peptide purification was done in the presence of PK (Figure 3.16b). These 
data suggest that the observed calcium-signaling efects were due to the actions of extracelular 
protein peptides, and not smal molecules or excitatory amino acids. Moreover, media colected in 
the presence of MG-132 did not possess the capacity to stimulate naïve neuronal cultures (Figure 
3.16c), indicating that the relevant bioactive peptides were derived from the proteasome. 
Moreover, in similar experiments, addition of random peptides to GCaMP3-encoding neurons did 
not possess the capacity to stimulate naïve neuronal cultures (Figure 3.17). We then determined 
that these peptides were inducing calcium flux from the outside of the cel in, rather than 




chelator BAPTA to the perfusate abrogated the peptide-induced calcium signal (Figure 3.16d), 
whereas depletion of ER calcium stores using thapsigargin did not reduce the maximum 
amplitude of the peptide-induced calcium signal (Figure 3.16e).  
 To identify which channels were relevant to peptide-induced calcium activity, we used 
diferent ion channel inhibitors to pharmacologicaly identify relevant pathways. Blocking fast 
voltage-gated sodium channels using Tetrodotoxin did not block the peptide-induced calcium 
signal, revealing that the influx of calcium was probably not due to action potential-induced 
signaling, and more likely directly due to effects on calcium channels (Figure 3.16f). Blockade of 
L-type calcium channel dependent influx using Nifedipine also did not modulate the peptide-
induced calcium signal (Figure 3.16g). However, inhibiting N-methyl-D-aspartate receptors 
(NMDARs) using 2-amino-5-phosphonopentanoic acid (APV) reduced the maximum amplitude 
of the peptide-induced calcium influx (Figure 3.16h). Together, these data suggest that the 
peptides derived from the neuronal membrane proteasome can modulate neuronal activity, at least 




We report on an unusual finding of a 20S proteasome that is tightly associated with the neuronal 
plasma membrane and exposed to the extracelular space. In this capacity, it can degrade 
intracelular proteins into bioactive extracelular peptides that induce calcium signaling through 
NMDA receptors. The model we prefer (discussed further below) based on these data are that a 
20S proteasome complex is coupled to the plasma membrane by GPM6 glycoproteins, and that 
the extracelular peptides generated are the means by which the NMP acutely regulates neuronal 
function. 
Proteasome association with neuronal plasma membranes and surface-exposure by GPM6 family 
glycoproteins 
 Identification of the GPM6 glycoprotein family as proteins that interact with proteasomes 
and are suficient to induce the expression of proteasomes at the plasma membrane provides some 
insight into how proteasomes, as hydrophilic protein complexes, could interact so tightly with the 
hydrophobic plasma membrane. However, we noticed that the magnitude to which GPM6-
induced membrane proteasome expression in heterologous cels did not match the magnitude of 
endogenous membrane proteasome expression in neurons. This suggests that there may in fact be 
other proteins that mediate the interaction of the NMP with the membrane, an area being actively 
investigated.  
 We postulate that the GPM6 glycoproteins may form a protein pore, perhaps through 
oligomeric interactions, which have been proposed previously(Werner et al. 2001; Sato et al. 
2011). In the right conformation, proteasomes binding to pore-containing membrane proteins 
could give proteasomes a hydrophilic binding surface to the hydrophobic plasma membrane, 
alowing the proteasome to gain access to the extracelular space. We propose a few models for 
how GPM6 proteins, or other membrane tethers may localize the proteasome to the plasma 
membrane (Figure 3.18). In each case, we posited that 1) proteasomes must be located at plasma 




GPM6, and 3) proteasomes must be able to degrade proteins from the intracelular to the 
extracelular space. Model 1 – Cytoplasmic docking: In this model, a proteasome located at the 
plasma membrane would be docked on or tethered to auxiliary membrane proteins on the 
cytoplasmic side of the membrane. Degraded proteins would be shed through a peptide pore 
formed by the auxiliary proteins. Model 2 – Extracelular docking: In this model, a proteasome 
located at the plasma membrane would be docked on or tethered to auxiliary membrane proteins 
on the extracelular side of the membrane. Proteins would be delivered through a protein pore 
formed by the auxiliary proteins. Model 3 – Intramembrane docking: In this model, a proteasome 
located at the plasma membrane would be tethered or anchored to auxiliary membrane proteins 
within the lipid bilayer. The cel biological conundrum of how a proteasome can interact with the 
plasma membrane may be the most significant question to address in order to gain a deeper 
understanding of NMP function. Because antibody feeding and protease protection require that 
large molecules gain access to the proteasome, we posit that model 1 is less likely, and either 
model 2 or model 3 wil prevail. While we find these models most consistent with our data, we 
certainly do not preclude other potential models. Ultimately, the nature of this seemingly 
transmembrane complex can only be validated by a structural approach. 
NMP composition and regulation 
 We made significant atempts to identify NMP interacting partners in an efort to 
determine whether the NMP was capped by the 19S, 11S, or PA200 subunits. Our data likely 
preclude the presence of the canonical 19S proteasome cap, or regulatory caps such as 11S or 
PA200(Besche and Goldberg 2012; Ben-Nissan and Sharon 2014; Tai and Schuman 2008a). 
While we identified a few 19S subunits co-fractionating with the NMP by mass spectrometry, we 
could not identify significant amount of key 19S subunits Rpt5 or S2. We also made the 
intriguing observation that immunoproteasome subunit PSMB8 uniquely co-fractionated with the 




for two primary reasons. First, while a few functions for 20S proteasomes have been ascribed, 
their function independent of the 19S cap largely remains a mystery, especialy in the nervous 
system(Tai and Schuman 2008a). Second, significant implications come from the idea that 20S 
proteasomes are primarily tasked with clearing misfolded or unstructured proteins(Ben-Nissan 
and Sharon 2014; Tsvetkov et al. 2008; Tsvetkov et al. 2009). A large source of disordered or 
unfolded proteins is derived from failed products of protein translation and misfolded or 
improperly folded proteins. These end-products of proteotoxic stress are halmarks of many 
neurodegenerative disorders(Schmidt and Finley 2014; Tai and Schuman 2008b), a fact which 
places the NMP at the heart of various disease states.  
NMP-directed peptide signaling modulates neuronal function 
 Unconventional secretion pathways have been implicated in release of celular protein 
cargos(Jiang et al. 2013; Lee et al. 2016). Moreover, many groups have demonstrated that 
inhibition of ubiquitin-dependent proteasome function afects synaptic signaling and 
transmission. Our data support a role for the existence of a specialized neuronal membrane 
proteasome that mediates neuronal function by “inside-out” signaling through the production of 
extracelular proteasome-derived peptides. While it remains possible, we have not detected any 
role for secretion pathways or ubiquitin in the release of these peptides (Ramachandran and 
Margolis, unpublished data).  
Proteasome-derived peptides, which when purified, rapidly and robustly stimulate 
neurons. Pharmacological dissection of the downstream pathways of peptide signaling revealed 
that NMP-derived peptides act in part by modulating NMDARs. The signaling through 
NMDARs only makes up ~50% of the total activity of the peptides. Other possible targets 
include: 1) Peptides interact with major histocompatibility immune complexes (MHC) that have 
recently been shown to play key roles in developmental and experience-dependent mechanisms in 




channels, thereby altering calcium-mediated signaling; and/or 3) peptides signal to neuronal or 
non-neuronal cels such as glial cels through yet to be identified receptors.  
It is wel-established that NMDARs are critical for neuronal activity-dependent signaling 
relevant to learning and memory(Xia et al. 1996; Nicol and Roche 2013; Malenka and Nicol 
1999). Given that cytosolic proteasomes have been shown to be regulated by neuronal activity, it 
wil be intriguing to beter understand whether the NMP and the resulting extracelular peptides 
are also modulated by changes in neuronal activity. It is also unclear how this signaling is 
specified within the brain, but we postulate that it relies on how the NMP recognizes and targets 
proteins for degradation. Therefore, it wil be critical to identify not only the sequences of the 
peptides, but also the substrates from which they are derived. These insights into substrate 
identity and targeting wil reveal how the NMP functions, but may begin to link proteostatic 





Figure 3.1. Proteasomes rapidly regulate neuronal calcium signaling 
Cortical neuronal cultures at 14 days in vitro were transfected using a plasmid that encodes for 
GCaMP3, a geneticaly encoded calcium indicator. Bicuculine, a GABA receptor antagonist 
that relieves inhibition on neuronal circuits and induces regular firing of action potentials, was 
added to naïve GCaMP3-encoding neurons. Calcium imaging was performed on transfected 
cultures. Traces of Bicuculine response before and after MG-132 addition are ploted. First 
black arowhead indicates when Bicuculine is perfused onto neurons, second arowhead 
indicates when MG-132 is spiked into perfusion. Lines above graph (Bicuculine – black, MG-
132 – Blue) indicate time window when drug is applied. Quantification of normalized 
fluorescence intensity (ΔF/F0) measurements of calcium signals over imaging timecourse is 
presented. Trace is accumulated data from representative neuron over 18 ROIs (regions of 
interest). Two independent neuronal cultures. 15 neurons quantified per culture. *P<0.01 (two-








Figure 4.1. Ephexin5 is upregulated in AS mouse hippocampal tissue and removal of 
Ephexin5 modulates Figure 3.2. 20S proteasome subunits are localized to neuronal plasma 
membranes 
(a-f) (left) Western blots of neuronal lysates probed using indicated antibodies. (a-f) (center) 
Electron micrographs of immunogold labeling (12 nm gold particles) from hippocampal slice 
preparations using antibodies raised against core catalytic β2 (a, b), β5 (c, d), �2 (e) 
proteasomal subunits and 19S cap proteasome subunit Rpt5 (f). Representative images shown. 
White boxes on EM show magnified region (displayed to the right). Several arows shown 
coresponding to immunogold label; cytosolic (white); membrane (black). (a-f) (Right) 
Quantification of gold particles from stated number of micrographs to get at least 300 gold 
particles: a) N=49; b) N=47; c) N=43; d) N=54; e) N=54; f) N=82. >300 gold-particles per 
antibody were counted. Slices were made from two separate 3-month old mice, >20 slices were 





Figure 3.3. Secondary-alone antibody controls do not detect signal by Immuno-EM  
(a) Immuno-EM analysis of hippocampal slice preparations using only a secondary gold-
conjugated anti-rabbit antibody in the absence of the primary antibody to detect non-specific 
background staining. Secondary alone controls for anti-goat (b) and anti-mouse (c) are shown. 
White arows indicate low background immuno-Gold particle staining observed, note low 
magnification (11000X). Slices were made from two separate 3 month old mice, >20 slices were 
generated for immuno-EM analysis, same metrics were used for secondary controls as for slices 





Figure 3.4. 20S proteasome subunits are localized to neuronal plasma membranes. Low 
magnification (63000X) image of immuno-electron micrographs performed using antibodies 
against β2 (a), β5 (b), α2 (c), and 19S cap proteasome subunit S2 (d). Labeled ultrastructures: 
Presynaptic regions (Pre), Postsynaptic regions (Post). Insets shown at higher magnification. 





Figure 3.5. Neuronal membrane proteasomes are exposed to the extracelular space 
(a) Electron micrographs of immunogold labeling (12 nm gold particles) from from DIV14 
primary mouse cortical cultures using anti-β2. Representative images shown. Inset shows 




Synaptic vesicles (SV). Arows coresponding to immunogold label; cytosolic (white); 
membrane (red-cytosolic face), (yelow-directly overlaying), (green-extracelular face). (N=84 
images, >300 gold-particles counted. Multiple punches from single DIV14 culture, >20 slices 
generated). (b) Quantification depicted for a subset of gold particles near membranes, with every 
tick mark representing 2 nm from the PM. Each dot represents a single gold particle. Numbers 
above dots represent the number of dots counted. (c) Schematic showing three diferent 
approaches taken to determine whether proteasomes were surface-exposed. (d) Antibody 
Feeding: Live primary mouse cortical neuronal cultures at DIV14 were incubated with 
antibodies against MAP2, N terminus of GluR1 (GluR1), or β5 proteasome subunits. 
Representative images shown. β5 proteasome antibody pre-incubated with the blocking peptide 
shown below. Quantification of percentage overlap between the signal from each antibody 
shown (N=2 independent neuronal cultures, n=15 neurons/culture). Significance is calculated 
between �5 staining alone and �5 antibody pre-incubated with blocking peptide. *P<0.01 (two-
tailed Student’s t-test). (e) Surface biotinylation: Proteins from surface biotinylated DIV14 
cortical neurons were precipitated on streptavidin afinity beads and subjected to 
immunobloting. Inputs (~3.5% of total) are shown to left of streptavidin puldown (Strep) 
(~11% of total). Quantification is of streptavidin signal normalized to input signal (N=4 
independent neuronal cultures). *P<0.01 (one-way ANOVA). (f) Protease Protection: PK was 
applied onto cultured cortical neurons at DIV14 for the indicated minutes. Cytosolic and 
membrane fractions were immunobloted with anti-GluR1 (GluR1), anti-α1-7, anti-β2, and anti-
Tubulin. Quantification is below. Significance for each timepoint against the zero minute 
timepoint is calculated (N=3 independent neuronal cultures). *P<0.01 (two-tailed Student’s t-







Figure 3.6. 20S proteasome subunits are localized to neuronal plasma membranes. (a) 
Immuno-EM analysis using only a secondary gold-conjugated anti-goat antibody in the absence 
of the primary antibody to detect non-specific background staining (63000X). Labeled 
ultrastructures: Presynaptic regions (Pre), Postsynaptic regions (Post), Microtubules (MT – 
black arowheads), and synaptic vesicles (SV - black arowheads). Single DIV14 culture, >20 
slices generated. Same metrics were used for secondary controls as for slices incubated with 
primary.(b) Low magnification (63000X) image of Immuno-EM performed using antibodies 
against the β5 and β2 proteasomal subunits. Arows corespond to immunogold label 
distinguished as cytosolic (white) or on membranes (cytosolic face - red, directly on - yelow, 
extracelular face- green). Labeled ultrastructures: Presynaptic regions (Pre), Postsynaptic 
regions (Post), Microtubules (MT – black arowheads), Mitochondria (Mito) and synaptic 
vesicles (SV - black arowheads). Multiple punches from single DIV14 culture, >20 slices 
generated. (c) Quantification of Immuno-EM analysis of HEK293 (HEK293) cels and cortical 
(Cortical) neurons for the β2 proteasome subunit. Percentage of gold particles in the cytosol 
(Cyto) and at plasma membranes (Mem) was quantified. *P<0.01 (two-tailed Student’s t-test). 
Data are presented as mean ± SEM. >300 gold-particles counted, multiple punches from single 





Figure 3.7. Neuronal membrane proteasomes are exposed to the extracelular space. (a) 
Immuno-electron micrographs performed using antibodies against the intracelular domain of 
Ion Channel Kv1.3 (63000X (left) and 43000X (right). Arows corespond to immunogold 
label distinguished as cytosolic (white). Note close proximity of gold particles to membranes. 
Similar results were observed and extensively quantified by Gazula et al, 2010. No membrane 
or extracelular staining was observed using this the antibody raised against Kv1.3. Slices were 
made from two separate 3 month old mice, >20 slices were generated for immuno-EM analysis. 
(b) The antibody feeding protocol (Figure 2D) was performed on primary neuronal cultures at 
DIV14 without primary antibodies, and stained using indicated secondary antibodies alone. 
Scale bar = 10 �M. Same metrics were used for secondary controls as for slices incubated with 




were either untreated (DIV 18), or treated with hydrogen peroxide (H2O2 - 1 mM), 
Staurosporine (Stauro - 1 µM), or MG-132 (10 µM) . Neurons were colected in sample bufer 
and immunobloted for caspase-3 cleavage to measure cel death. Quantification shown to the 
right (E). A separate batch of neurons were treated and incubated with propidium iodide (PI), an 
intercalating agent that can get into neurons undergoing celular death. Folowing PI addition, 
neurons were immediately imaged to determine whether treatments afected cel death. The 
percentage of nuclei that were PI positive were counted, compared to the total number of cel 
bodies, and quantification is shown (E). Note, in both cases our neuronal cultures are not dying. 
*P<0.01 (two-tailed Student’s t-test). Data are presented as mean ± SEM. (e) Neuronal cultures 
were lysed and plasma membranes were puled down on Concanavalin A-coupled agarose beads 






Figure 3.8. Neuronal membrane proteasomes are largely made of 20S core proteasome 
subunits. (a) Representative western blots of proteasomes purified out of DIV16 neuronal 
cultures using 20S purification matrices. Purification was done out of either neuronal cytosol 
(Cyto) or detergent-extracted neuronal plasma membranes (Mem). Inputs (5%) shown to the left. 
(b,c) Surface biotinylation: Biotinylated proteins from surface biotinylated DIV12 cortical 
neurons were precipitated on streptavidin afinity beads and subjected to immunobloting using 




Flowthrough (FT) that did not bind to streptavidin beads was loaded to the right of Streptavidin 
puldown. Note that the combined FT and Strep lanes are roughly equivalent to the Input. This is 
consistent with the proteasomes being both in the membrane and cytosol. Additionaly, surface 
biotinylation experiments were performed on neurons that had been treated with 1% 
Formaldehyde to covalently fix protein-protein interactions. Performing identical precipitation 
and preparation to (b), samples were immunobloted with indicated antibodies (c). Note that actin 
is puled down folowing fixation, unlike conditions without fixation, indicating that surface 
biotinylation of fixed samples may introduce artifacts of proteins that associate with membrane 
proteins but are not truly surface exposed. The precipitation of 19S cap proteins with our surface 
biotinylation under these conditions may indicate an artificial result or the existence of true 







Figure 3.9. Neuronal membrane proteasomes do not exist in heterologous cels and are 
developmentaly regulated in neuronal cultures. (a) Neuroblastoma-2A cels (N2A), HEK293 
cels (HEK), and primary cortical neuronal cultures at DIV 14 (Cort) were surface biotinylated. 
HEK293 cels were used as a heterologous system with non-neural origins and N2A cels were 
used as a heterologous system with neural origins. Biotinylated proteins were precipitated using 
streptavidin afinity beads and immunobloted using indicated antibodies. (b) Human brain tissue 
was obtained according to IRB protocol, and surface biotinylated. Proteins were purified on 
streptavidin-agarose beads and subsequently immunobloted using indicated antibodies. (c) 
Primary neuronal cultures from DIV 5 to DIV 8 were surface biotinylated. Biotinylated proteins 
were precipitated using streptavidin afinity beads and immunobloted using indicated antibodies. 




antibodies against MAP2 or β5 proteasome subunits. Representative images shown. Scale bar = 
10 �M. Quantification of immunocytochemistry is shown to the right for the total amount of 
proteasome signal observed at DIV 7 and DIV 8 (N=2 independent cultures, n=11 neurons 







Figure 3.10. Neuronal membrane proteasomes are tightly associated with plasma 
membranes  
(a) Primary mouse cortical neuronal cultures at DIV 14 were fractionated into cytosolic (Cyto) 
and membrane (Mem) components. Membranes were extracted with indicated sequentialy 
increasing concentrations of Digitonin. Samples were analyzed by immunobloting using 




levels for each antibody. While 0.25% digitonin extracted cytosolic protein Tubulin, higher 
concentrations (0.5%, 1.0%) of digitonin were required to extract known hydrophobic proteins 
such as GluR1. An explanation of percentages loaded on gel is explained in materials and 
methods. Significance is calculated by comparing signal from the 0.5% digitonin fraction to the 
0.25% digitonin fraction for each antibody (N=3 independent neuronal cultures quantified). 
*P<0.01 (one-way ANOVA). Data are presented as mean ± SEM. (b) Proteasome subunits are 
tightly bound to membranes. Neuronal cultures at DIV14 were fractionated into cytosolic, 
peripheraly-associated (Periph), and tightly-bound (Bound) proteins. Immunoblots of each 
fraction using indicated antibodies are shown. Quantification to right, data are presented as 
mean ± range (N=2 independent neuronal cultures). (c) Cultured neurons at DIV14 where phase 
separated with TX-114. Immunoblots shown using indicated antibodies. DT-free indicates 
aqueous phase, and DT-rich contains the TX-114 phase. Quantification to the right, data are 
presented as as mean ± range (N=2 independent neuronal cultures). Uncropped blots are shown 









Figure 3.11. Neuronal membrane proteasomes are largely a 20S proteasome and in complex 
with GPM6 family glycoproteins 
(a) Representative western blots of proteasomes purified out of neuronal cultures using capped-
26S (26S IP) or 20S purification matrices (20S IP). Purification was done out of either neuronal 
cytosol (Cyto Pure) or detergent-extracted neuronal plasma membranes (Mem Pure). (b) 
Immunoprecipitation with anti-Flag from HEK293 cel lysates previously transfected with 
plasmids containing Myc/Flag tagged GPM6A and GPM6B, folowed by immunobloting with 
Myc or proteasome antibodies (α1-7, β2, β5). Inputs (10% of total, left) and immunoprecipitated 
samples (75% of total, right) are shown. (c) Exogenous expression of GPM6A/B is suficient to 
induce surface expression of endogenous proteasomes in HEK293 cels. HEK293 cels were 
mock transfected (Blank) or transfected with plasmids containing GFP, EphB2, 
Channelrhodopsin-2 (ChRdp2), GPM6A/B, and GPM6A/B + Myc-tagged β5 (A/B +Myc-β5). 
Folowing transfection, cels were biotinylated and lysates prepared for streptavidin puldown 
and western analysis. Western blots for indicated proteins are shown at left (4% of total) and 
right (streptavidin puldowns, 32% of total). Quantification shown below is normalized to input 
signal. β5 western is overexposed in order to see Myc-tagged bands (two arows, right of 
immunoblot). Significance is calculated between A/B transfected samples, and al others (N=3 
independent cel cultures and transfections quantified). *P<0.01, one way ANOVA. Data are 
presented as mean ± SEM. (d) Surface-exposed proteasome expression is unique to nervous 
system tissues. Representative western blot of input (2% of total) lysates (left) and streptavidin 
puldown (4% of total, right) of biotinylated proteins folowing surface biotinylation of 
dissected tissues from a P3 mouse. Cortex (Ctx), Hippocampus (Hip), Olfactory bulb (Olf), 
Hind Brain (Brn), Heart (Ht), Lung (Lg), Kidney (Kid), Liver (Lv), Pancreas (Pnc). 
Immunoblots were performed using antibodies against indicated proteins. (e) Representative 




right) of biotinylated proteins folowing surface biotinylation of mouse cortex tissue dissected 





Figure 3.12. Neuronal membrane proteasomes degrade intracelular proteins into 
extracelular peptides 
(a) Purified 20S proteasomes from neuronal cytosol (Cyto) or membrane (Mem) were incubated 
with the fluorogenic proteasome peptide substrate SUC-LLVY-AMC. Fluorescence is released 
upon cleavage, endpoint fluorescence with and without incubation with SDS is quantified. 
Significance is shown between SDS-treated and untreated samples (N=3 replicate proteasome 
purifications from independent neuronal cultures quantified). (b) Schematic for colection and 
purification of extracelular peptides. Media from radiolabeled mouse cortical neuronal cultures 
is colected and purified. Media colected from neurons folowing radiolabeling was subjected to 
size exclusion purification, with or without Proteinase K (PK). (c) Representative autoradiograph 
of lysates from cortical neurons previously radiolabeled with 35S methionine/cysteine for 10 




treated neurons is shown at right. (d) Rapid eflux of radioactive material out of neuronal cultures 
into media depends upon proteasome function. Media colected from neurons folowing 
radiolabeling with or without MG-132 or ATPγS. Liquid scintilation quantification of media at 
indicated timepoints is shown normalized to control at the 10-minute timepoint; 2 minute 
timepoint shown separately on bar graph (right) (Media from N=3 independent cel cultures). 
Significance in line graph is shown for MG-132 treated neurons compared to vehicle alone at 
each time point. (e) Media colected from neurons folowing radiolabeling was subjected to size 
exclusion purification, with or without Proteinase K (PK). The percentage of total radioactivity 
eluting at diferent sizes is shown (N=3 independent cel cultures and purifications quantified). 
(e) Release of proteasome-derived peptides in the extracelular space corelates with NMP 
expression. Experiment performed as described in (d); media colected from either DIV 7 or DIV 
8 neurons, with MG-132 (MG-132) or without (Vehicle). (Media of N=3 independent cel 
cultures) *P<0.01 (a, e) two-tailed Student’s t-test, (e) significance of 500<35S Signal<3000Da 





Figure 3.13. Neuronal membrane proteasomes are catalyticaly active and degrade 
intracelular proteins into extracelular peptides. (a) Quantification of the 60-minute 
timecourse of the endpoint proteasome activity assay shown in Figure 4e. Note diference in 
activity from membrane proteasomes when SDS is added compared to cytosolic proteasomes. 
*P<0.01 (two-tailed Student’s t-test). Data are presented as mean ± SEM (Data from N=3 




incorporation, media was washed out and replaced with Neurobasal growth media. Media was 
colected at either the two-minute or 30 minute timepoint folowing washout. Colected medium 
was then run through a size-exclusion protocol. An aliquot from each fraction was taken and 
quantified by liquid scintilation. Samples are normalized to the total amount of radioactivity 
present in the input sample taken at the two-minute timepoint, folowing subtraction of the zero-
minute timepoint. We observed an increase in the fraction of radioactivity eluting below 500 Da 
and between 500 and 3000 Da at the 30 minute timepoint compared to the 2 minute timepoint, 
consistent with a sustained turnover of the intracelular pool of short-lived proteins into amino 
acids and short peptides. (c) Media from radiolabeled HEK293 cels is colected and purified, as 
described in Figure 4d, folowing vehicle treatment or MG-132 treatment. Data are presented as 






Figure 3.14. Neuronal membrane proteasomes are required for release of extracelular 
peptides and modulate neuronal activity 
(a,b) Biotin-epoxomicin does not cross neuronal membranes and covalently binds proteasome 
subunits. (a) Neurons treated with biotin-epoxomicin (Bio-Epox) were separated into cytosolic 
(Cyto) and membrane (Mem) fractions and analyzed by western using streptavidin conjugated to 
a fluorophore. Immunoblots using indicated antibodies shown below. (b) Immunogold labeling 
against biotin using streptavidin-Au (black arows) from neuronal cultures treated with Bio-Epox, 
with representative images shown (N=54, obtained from multiple punches of a single neuronal 
culture, >20 slices generated. Labeled ultrastructures: Presynaptic regions (Pre), Postsynaptic 
regions (Post), Microtubules (MT), and synaptic vesicles (SV). Quantification of particles in 
cytosol and on membrane (right); *P<0.01 (two-tailed Student’s t-test). (c) Media colected from 
radiolabeled neurons treated with Bio-Epox (Bio-Epox) or without (Vehicle). Liquid scintilation 




timepoint; 2 minute timepoint shown separately on bar graph. Significance in line graph is shown 
for Bio-Epox treated neurons compared to vehicle alone at each time point. (N=3 independent 
neuronal cultures quantified, *P<0.01, two-tailed Student’s t-test). (d) NMP inhibition modulates 
speed and intensity of neuronal calcium transients. Bicuculine added (downward black 
arowhead) to naïve GCaMP3-encoding neurons. Downward dark blue arowhead indicates 
timing of Bio-Epox addition. Representative images (left) and traces of Bicuculline response 
before and after Bio-Epox addition are ploted (right). Quantification of normalized fluorescence 
intensity (ΔF/F0) measurements of calcium signals over imaging timecourse are shown. (e) 
Average maximum amplitudes are ploted, and include analysis of calcium signaling after 
treatment with MG-132. Significance compared to Bicuculine stimulation alone. (f) Box-and-
whisker plot of al frequencies observed. *P<0.01, one-way ANOVA (E), two-tailed Student’s t-
test (f), Al data are presented as mean ± SEM (D-F, N=2 independent replicate cultures, n=24 
neurons per culture, with 18 ROIs (regions of interest) analyzed per neuron). Uncropped blots are 






Figure 3.15. Neuronal membrane proteasomes are required for release of extracelular 
peptides and modulate neuronal activity. (a) Low magnification image of immuno-electron 
micrographs performed using streptavidin conjugated to gold particles in cortical neurons treated 
with Biotin-Epoxomicin. Immunogold label shown by arows in cytosol (red) and on membrane 
(yelow). Labeled ultrastructures: Presynaptic regions (Pre), Postsynaptic regions (Post), 
Microtubules (MT). Obtained from multiple punches of a single neuronal culture, >20 slices 
generated. (b) Immuno-EM analysis using streptavidin conjugated to gold particles in the absence 
(Vehicle) of the Biotin-Epoxomicin to detect non-specific background staining. Cytosol labeling 









Figure 3.16. Neuronal membrane proteasome-derived peptides are suficient to induce 
neuronal signaling 
(a) Purified peptides were perfused onto GCaMP3-encoding mouse cortical cultured neurons. 
Doted lines indicate time of peptide addition and washout. K+ indicates the timing of 55 mM KCl 
addition to neurons to determine that they stil respond properly at the end of the experiment. 
Line graph shows increase in fluorescence over baseline during time of peptide addition, a 
decrease folowing washout and robust increase with KCl addition. Four sample traces from 
diferent neurons are ploted. (b, c) Similar to part (a), cultured neurons were incubated with 
either Peptides (PK) (peptides were pretreated with P K, PK was removed, and then samples 
dialyzed to remove smal molecules) or with Peptides (MG-132) (peptides purified from cels 
treated with MG-132). (d-h) Indicated drugs were perfused onto neuronal cultures during the 
times depicted by the dashed lines. Peptides were subsequently added as indicated and described 
in (a). Concentrations of drugs: BAPTA (2 �M), Thapsigargin (5 �M), Tetrodotoxin (1 �M), 
Nifedipine (1 �M), APV (2 �M). (i) Quantification of maximum intensity of change from each 
condition is ploted. *P<0.01 one-way ANOVA. Data are presented as mean ± SEM (N=3 
independent replicate cultures, n>15 neurons per treatment, with at least 10 ROIs analyzed per 





Figure 3.17. Neuronal membrane proteasome-derived peptides are suficient to induce 
neuronal signaling. Purified extracelular peptides were added to naïve GCaMP3-encoding 
neurons. Representative images (top), quantification of normalized fluorescence intensity 
measurements of calcium signals over imaging timecourse (botom). Scale bar = 40 �M. 
Arowheads depict peptide addition (white arowhead) and peptide washout (black arowhead). 
Peptides (PK): Peptides pretreated with Proteinase K; Peptides (MG-132): purified media from 
neurons radiolabeled in the presence of MG-132; Control peptide: random peptides. *P<0.01 
(one-way ANOVA). Data represent mean ± SEM (N=3 independent biological replicate cultures, 








Figure 3.18. Proposed theoretical models of NMP association with the plasma membrane 
Three models of how proteasomes can associate with plasma membranes are shown above. 















Activity-dependent degradation of the immediate-early nascentome by the 
neuronal membrane proteasome 
Modified from: 
Kapil V. Ramachandran, Jack M. Fu, Thomas B. Schafer, Chan-Hyun Na, and Seth S. 
Margolis. “Activity-dependent degradation of the nascentome by the neuronal membrane 






Neuronal activity-dependent processes have been shown by many laboratories to be 
dependent upon new protein synthesis and proteasome-dependent protein degradation (Schrat et 
al. 2004; Djakovic et al. 2009; Fonseca, Nagerl, and Bonhoefer 2006; Fonseca et al. 2006; 
Keleher, Govindarajan, and Tonegawa 2004). Inhibition of either of these pathways impairs 
neuronal signaling in a host of systems and paradigms. Consistent with a role for neural activity 
in regulating protein synthesis and degradation, the ribosome and proteasome independently 
localize to sites of synaptic activity and are important for activity-mediated synaptic remodeling 
(Ehlers 2003; Ostrof et al. 2017; Ostrof et al. 2002; Bingol and Schuman 2006; Tai et al. 2010; 
Tcherkezian et al. 2010). Additionaly, these two complexes are hypothesized to coordinate their 
functions to modulate neuronal signaling (Fonseca et al. 2006; Klein, Castilo, and Jordan 2015; 
Deglincerti et al. 2015; Schwanhausser et al. 2013). However, the biochemical evidence for the 
existence and mechanism of this coordination remains to be elucidated. 
We considered that such a mechanism might simultaneously engage the actions of both 
the ribosome and proteasome in neurons, emulating a protein quality control mechanism to 
maintain neuronal protein homeostasis. This would manifest as co-translational degradation, 
which is the direct proteasome-mediated degradation of a nascent polypeptide while stil 
associated with the ribosome(Inada 2017; Dutler, Pechmann, and Frydman 2013; Kramer et al. 
2009; Wheatley, Grisolia, and Hernandez-Yago 1982). Co-translational degradation remains an 
elusive phenomenon. In the 1970s and 80s, classic experiments in monitoring protein fate 
reported a significant portion of proteins underwent rapid degradation either during or 
immediately folowing their synthesis (Robertson and Wheatley 1979; Wheatley, Giddings, and 
Inglis 1980; Wheatley, Grisolia, and Hernandez-Yago 1982; Wheatley and Inglis 1980). Over the 
next 30 years, further investigation of these observations in yeast and in vitro revealed that some 
proteins undergoing synthesis are degraded co-translationaly (Benoist and Grand-Peret 1997; 




2005). However, how these events are regulated remains unknown, the extent to which these 
events occur is debated, and have never been monitored in neurons. In contrast, significant 
evidence has emerged for co-translational ubiquitylation, a process where a nascent chain is 
ubiquitylated while stil ribosome-associated, but then is removed from the ribosome and 
subsequently degraded by proteasomes. A plethora of evidence for such quality control 
mechanisms in yeast and heterologous cels has emerged over the past 40 years (Anton and 
Yewdel 2014; Brandman et al. 2012; Comyn, Chan, and Mayor 2014; Dimitrova et al. 2009; 
Dutler, Pechmann, and Frydman 2013; Fletcher et al. 2014; Ha et al. 2016; Ha, Ju, and Xie 2014; 
Inada 2017; Kirstein-Miles et al. 2013; Turner and Varshavsky 2000; von der Malsburg, Shao, 
and Hegde 2015; Yonashiro et al. 2016; Shao, von der Malsburg, and Hegde 2013). Most notably, 
there is a significant body of literature on co-translational ubiquitylation mechanisms through 
Listerin1 (Ltn1, an E3 ubiquitin-ligase) and the ribosome quality-control complex (Brandman et 
al. 2012; Yonashiro et al. 2016; Shao, von der Malsburg, and Hegde 2013; von der Malsburg, 
Shao, and Hegde 2015; Duttler, Pechmann, and Frydman 2013; Wang, Durfee, and Huibregtse 
2013). These ubiquitylated nascent chains are subsequently removed and sent to the proteasome 
for degradation. However, despite Ltn1’s involvement in neurodegeneration, the vast majority of 
these biochemical experiments have been done in yeast or non-neuronal cels (Bengtson and 
Joazeiro 2010; Chu et al. 2009; Yonashiro et al. 2016; Brandman et al. 2012; von der Malsburg, 
Shao, and Hegde 2015). The contribution of co-translational protein homeostasis mechanisms in 
neurons, which must maintain a delicately balanced proteome, remains largely unexplored. 
Many of these mechanisms, especialy co-translational ubiquitylation, rely on the concerted 
actions of the ubiquitin-proteasome system (Ben-Nissan and Sharon 2014; Ciechanover 1998; 
Colins and Goldberg 2017; Coux, Tanaka, and Goldberg 1996). In this paradigm, ubiquitylated 
proteins are delivered to and degraded by the 26S proteasome, a large multisubunit protease with 




stacked subunit configuration that contains the catalytic domains required to cleave protein 
substrates (Ciechanover 1998). The other is the 19S cap complex, containing multiple subunits 
which recognize ubiquitylated substrates and ATPases which unfold proteins (de Poot, Tian, and 
Finley 2017; Finley, Ciechanover, and Varshavsky 2004; Schmidt and Finley 2014). These 19S 
ATPases are generaly required since the 20S core proteasome can only degrade already unfolded 
proteins, or those with large unstructured domains such as intrinsicaly disordered proteins 
(Tsvetkov et al. 2008; Tsvetkov, Reuven, and Shaul 2009; Ben-Nissan and Sharon 2014; Coux, 
Tanaka, and Goldberg 1996). While the majority of studies on proteasome-dependent degradation 
have been atributed to the actions of the 26S, roles for the 20S proteasome are emerging. 
Recently, we discovered an uncapped 20S proteasome complex tightly associated with the 
neuronal plasma membrane, where it degrades intracelular proteins into extracelular peptides 
(Ramachandran and Margolis 2017). The mechanisms for substrate delivery to this neuronal 
membrane proteasome (NMP) remained unknown, but we presumed they must be unfolded to 
some extent since the NMP is a 20S proteasome (Ramachandran and Margolis 2017). Protein 
synthesis produces a significant source of unfolded proteins, initialy as nascent polypeptides and 
then as folding intermediates (Dutler, Pechmann, and Frydman 2013; Balchin, Hayer-Hartl, and 
Hartl 2016; Pechmann, Wilmund, and Frydman 2013; Sontag, Samant, and Frydman 2017). We 
hypothesized that coordination between translation and degradation in the nervous system was 
manifested through the NMP, possibly mediated by neuronal activity. We began by asking 
whether neuronal activity modulates NMP function, initialy testing whether it was required for 
NMP-dependent production of extracelular peptides (Ramachandran and Margolis 2017). We 
added tetrodotoxin (TTX) to our neuronal culture, which binds voltage-gated sodium channels 
and blocks firing of spontaneous action potentials within our cultures. We found that TTX 
strongly abrogated extracelular peptide release, previously defined as being NMP-dependent 




study activity-dependent mechanisms of NMP function in detail. 
 In this manuscript, we made the observation that that elevated neuronal activity leads to an 
increase in NMP-dependent peptide production, coincident with a ~40% decrease in newly 
synthesized proteins. We then used Monte Carlo simulations of Markov models to monitor the 
fates of proteins inside the cel and trace their fate as they were being degraded into the 
extracelular space. This predicted that nascent polypeptides, and not ful-length proteins or 
folding intermediates, provided the substrates for NMP to generate extracelular peptides. We 
experimentaly validated these in silico findings and found that tRNA-bound nascent 
polypeptides were direct co-translational targets of the NMP. In an efort to identify specific 
NMP substrates, we found that neuronal activity controled the NMP-mediated degradation of a 
large class of substrates including the immediate-early gene products. These data define an 
activity-dependent mechanism of neuronal co-translational degradation and identify the very first 





Neuronal stimulation induces NMP-dependent degradation of newly synthesized proteins into 
extracelular peptides 
To extend our observed findings in Figure 4.1 and determine whether neuronal activity 
induces NMP function, we monitored NMP-dependent production of extracelular peptides under 
states of neuronal stimulation. We first used KCl-induced membrane depolarization as a classic 
and efective tool to induce elevated activity of the majority of neurons in culture (Lin et al. 2008; 
West et al. 2001; Xia et al. 1996). Primary mouse cortical neuronal cultures at days in vitro (DIV) 
10-14 were treated with either a stimulation bufer (KCl) or a control bufer (NaCl). These 
neurons were concomitantly radiolabeled with 35S-methionine/cysteine for 10 minutes, without 
any prior metabolic deprivation (Vabulas and Hartl 2005; Ramachandran and Margolis 2017). 
Folowing concomitant radiolabeling and neuronal stimulation, we washed away both free isotope 
and stimulation bufer. This media was replaced with fresh conditioned media containing either a 
pan-proteasome inhibitor (MG-132), an NMP-specific inhibitor (biotin-epoxomicin), or control 
(DMSO) (Meng et al. 1999b; Li et al. 2013; Meng et al. 1999a; Sin et al. 1999; Ramachandran 
and Margolis 2017). Immediately folowing washout, samples were taken from the extracelular 
medium over time and analyzed by liquid scintilation. We have previously shown that this 
method preferentialy monitors the release of extracelular NMP-derived peptides over smal 
molecules or free isotope (Ramachandran and Margolis 2017). We observed a significant MG-
132 and biotin-epoxomicin-sensitive increase in radiolabeled extracelular peptides released from 
neurons that had been stimulated, compared to controls (Figure 4.2). These data were consistent 
with the released material being comprised of protein peptides derived from the NMP 
(Ramachandran and Margolis 2017). 
Our working hypothesis was that the observed stimulation-induced NMP-dependent 
increase in extracelular peptide production would be reflected in enhanced NMP-mediated 




pool of proteins made during elevated neuronal activity using SDS-PAGE and autoradiography. 
Neurons were treated with the radiolabeling protocols described above. Al samples were 
coomassie stained after SDS-PAGE to ensure equal sample loading (Figure 4.3A). By 
densitometry analysis of these autoradiographs, we noticed a decrease in radioactive intracelular 
protein signal from neurons that had been radiolabeled during stimulation (Figure 4.2B). This 
efect was induced by a variety of wel-characterized stimulation protocols that give rise to 
activity-dependent neuronal signaling, but not by serum containing growth factors (Figure 4.3B-
D)(Lin et al. 2008; Scheetz, Nairn, and Constantine-Paton 2000; Marin et al. 1997; Fortin et al. 
2010). Treating these neurons with MG-132 or biotin-epoxomicin during radiolabeling blocked 
the stimulation-induced loss of radiolabeled protein signal (Figure 4.2B). We interpret this to 
mean that neuronal activity enhances NMP-mediated degradation of intracelular proteins made 
during stimulation. This enhanced degradation of intracelular substrates was not due to increased 
intrinsic catalytic activity of the NMP (Figure 4.3E). 
Our experiments thus far monitored the NMP-mediated and activity-dependent turnover 
of proteins made during stimulation. Given that certain protein populations have been shown to 
be more susceptible to degradation than others (Wheatley, Giddings, and Inglis 1980; McShane et 
al. 2016; Ha et al. 2016), we asked whether the degradation kinetics for proteins synthesized 
during stimulation were diferent than those for proteins made prior to or folowing stimulation. 
Surprisingly, by changing our radiolabeling protocols, we did not observe the same magnitude of 
stimulation-induced degradation of proteins from neurons that had been radiolabeled prior to the 
onset of stimulation, even after sustained stimulation (Figure 4.2C). Consistent with this, we also 
did not detect a stimulation-induced increase in extracelular radioactive peptide eflux when 
neurons were radiolabeled prior to, instead of during stimulation (Figure 4.2D). Additionaly, we 
observed no change in intracelular radiolabeled protein signal from neurons that had been 




stimulation does not simply promote the turnover of al proteins, but specificaly enhances the 
NMP-mediated turnover of newly synthesized proteins made during neuronal stimulation. These 
observations raised a fundamental question – why were proteins made during stimulation, as 
compared to al other proteins, being turned over by the NMP? We hypothesized that the answer 
to this was linked to the properties of the substrates it was targeting. 
Monte Carlo simulation of Markov chains favors degradation of nascent polypeptides as the 
source for NMP-derived extracelular peptides 
Our understanding of NMP function was that it directly degrades intracelular proteins 
into peptides in the extracelular space (Ramachandran and Margolis 2017). This predicts that 
degradation kinetics of intracelular NMP substrates are directly coupled to the release kinetics of 
the extracelular peptides (Ramachandran and Margolis 2017). The data thus far relied on 35S-
methionine/cysteine addition to neuronal cultures and tracing the fates of the proteins in which 
radioactive isotopes were incorporated. Folowing charging onto a tRNA, isotopes go through 
two major steps on their way to being incorporated into a folded protein: First, they must be 
incorporated into the growing nascent polypeptide which is associated with the ribosome during 
protein synthesis. Subsequently, this polypeptide must go through the complex task of folding 
before achieving its proper folded conformation, some of which is achieved while stil ribosome-
associated (Gloge et al. 2014; Kramer et al. 2009; Hartl, Bracher, and Hayer-Hartl 2011; 
Pechmann, Wilmund, and Frydman 2013). Very generaly, polypeptides progressing from one 
stage to the next adopt increasing conformational stability with a coresponding increase in their 
half-lives (Alberts B 2002). We sought to understand whether our data revealed any selectivity by 
which population of polypeptides (i.e. nascent polypeptide, folding intermediate, or folded 
protein) were being targeted for degradation by the NMP. 




radioisotopes over a time course that mirors our experimental peptide release data. Each Markov 
chain folows the trajectory of a single radioisotope that begins as a free radioisotope inside the 
cel, folowing 10 minutes of simulated isotope incorporation (Figure 4.4A). The radioisotope can 
progress from the initial free state to become incorporated into a nascent polypeptide, and then 
into a folding intermediate, and finaly into a folded protein. In each of these four possible states 
of incorporation, the radioisotope has some probability of extracelular release (Figure 4.4A). The 
transition probabilities from one state into the next and the release mechanisms at each state are 
modeled after wel-established kinetic parameters (e.g. rates of protein translation, degradation, 
and protein folding) and take into account the distribution of protein sizes in neurons (Figure 4.4C 
and 4.5A)(Lane and Pande 2013; Pande 2014; Balchin, Hayer-Hartl, and Hartl 2016; Hartl, 
Bracher, and Hayer-Hartl 2011; Wu et al. 2016). By representing a single experiment as a 
colection of Markov chains, we could model the proportion of radioisotopes that are either inside 
or outside of the cel at any point in time. These simulated values for extracelular radioisotope 
release were evaluated against our experimentaly observed release curve. We took the difusion 
of free isotope into account by optimizing our model against radioisotope release when al 
proteasomes are inhibited by MG-132 (Figure 4.5B). The precise methods used to generate the 
model parameters are described in detail in materials and methods. 
While our model was simple, we atempted to account for as many factors as reasonable 
using biologicaly determined parameters. When the model was biased towards turnover of 
nascent polypeptides, we observed that the shape of the in silico release curve closely mirors the 
shape of the experimental release curves (Figure 4.4B). The direct degradation of nascent 
polypeptides by a proteasome is the operational definition of co-translational degradation(Inada 
2017; Dutler, Pechmann, and Frydman 2013; Kramer et al. 2009; Wheatley, Grisolia, and 
Hernandez-Yago 1982), which is how we wil refer to this process. In contrast, by shifting the 




shape. Although this curve can match the experimental release curve at 5 minutes and beyond, 
these data considerably underestimate values for any time span less than 5 minutes (Figure 4.4C). 
More dramaticaly, biasing the model towards turnover of folded proteins generated a continualy 
gradual and linear release curve. This indicated a rate far too slow to account for the rapid release 
and subsequent taper of experimentaly released radioisotopes (Figure 4.4D).  
The shapes of the release curves for co-translational degradation and folding intermediate 
degradation more closely approximated our experimental data than those for folded protein 
degradation. To further refine our analysis, we used Monte Carlo simulations to optimize which 
combinations of the probabilities for co-translational and for folding intermediate degradation 
best give rise to the observed release data (Figure 4.6A). We sampled a large parameter space of 
possible pairwise probabilities, and for each combination of co-translational and folding-
intermediate degradation probability, we simulated a large number of Markov chains and 
calculated each predicted release curve. By minimizing the eror of the predicted curves against 
the experimental data, we could identify a set of probabilities that most closely mirored our 
experimental data. We began performing calculations using the release data from control-treated 
neurons. In this condition, the eror between the simulated and observed data was minimized at 
values coresponding to 0% folding intermediate degradation probability, and a probability of 
4.7% that a nascent polypeptide would be targeted to co-translational degradation in a one second 
time window (Figure 4.6A, 4.5A). These values favoring degradation of nascent polypeptides 
give rise to a simulated release curve that exhibits the rapid logarithmic rise and gradual taper of 
released radioisotopes with minimal discrepancy to the experimental release curve (Figure 4.6B). 
By increasing the co-translational degradation probability from 4.7% to 16.5%, we minimized 
eror against the experimental KCl stimulation data more eficiently than by modifying the 
probability of folding intermediate degradation (Figure 4.6B, 4.7). This also simulated decreased 




4.2B, 4.4E). We conclude from these models that the most likely explanation for our 
experimental release data is that neuronal stimulation enhances the rate of co-translational 
degradation. We next sought to experimentaly test this prediction made by the Markov model.  
Co-translational degradation requires translation elongation (Inada 2017; Dutler, 
Pechmann, and Frydman 2013; Kramer et al. 2009; Wheatley, Grisolia, and Hernandez-Yago 
1982). One of the halmarks of co-translational degradation is its sensitivity to the translation 
elongation inhibitor puromycin (Nathans 1964). Puromycin is an aminoacyl-tRNA structural 
analog that engages into the peptidyl transferase center of the ribosome and covalently modifies 
the growing polypeptide (Figure 4.6C)(Nathans 1964; Nathans and Neidle 1963; Wang, Durfee, 
and Huibregtse 2013; Shao, von der Malsburg, and Hegde 2013). This specificaly disrupts 
translation elongation by dissociating the growing nascent polypeptide from the ribosome. 
Treatment of neurons with puromycin folowing concomitant radiolabeling and neuronal 
stimulation resulted in a significant reduction of NMP peptide release from both KCl-stimulated 
and control neurons (Figure 4.6D). These data support the prediction made by our modeling data 
that translation elongation was required for the production of NMP-derived extracelular peptides. 
Colectively, these data provide evidence that nascent polypeptides were co-translationaly 
degraded by the NMP into extracelular peptides. 
Neuronal stimulation induces NMP-mediated co-translational degradation of ribosome-associated 
nascent polypeptides  
During translation elongation, nascent polypeptides are bound to a tRNA within the 
ribosome. This complex is colectively refered to as a ribosome-nascent chain complex 
(RNC)(Dutler, Pechmann, and Frydman 2013). However, multiple groups have reported 
conditions where nascent polypeptides are separated from the RNC prior to their completion and 




Huibregtse 2013; Dutler, Pechmann, and Frydman 2013). To determine whether the NMP was 
targeting nascent polypeptides while stil associated with the RNC, we performed ribosome 
peleting assays to isolate RNCs (Brandman et al. 2012). Briefly, 35S-cysteine/methionine 
radiolabel was added to neuronal cultures in the presence of proteasome inhibitors for only 30 
seconds. This shortened protocol preferentialy labels nascent polypeptides before they finish 
synthesis into ful-length proteins (Dutler, Pechmann, and Frydman 2013; Ito et al. 2011). 
Immediately folowing radiolabeling, neurons were lysed either in the presence of cycloheximide 
(CHX) and proteasome inhibitors to freeze translation and degradation, or with puromycin and 
proteasome inhibitors to release the nascent polypeptide from the ribosome and freeze 
degradation (Figure 4.8A - model). RNCs were subsequently peleted as previously described, 
with equal ribosome loading across samples (Figure 4.9A). By liquid scintilation analysis of 
CHX-treated samples, we noticed a decrease in radioactive signal in RNC pelets from neurons 
that had been radiolabeled during stimulation compared to controls (Figure 4.9A). Consistent 
with the radioactivity solely coming from the nascent polypeptide, treatment with puromycin 
resulted in a complete loss of radioactivity in the RNC pelet (Figure 4.9A). Treating neurons 
with MG-132 or biotin-epoxomicin during radiolabeling blocked the stimulation-induced 
reduction in radioactive signal in the RNC pelet (Figure 4.9A). We believed that this 
proteasome-mediated turnover of nascent polypeptides was neuronal-specific, as we did not 
observe an increase in radiolabeled signal from RNCs isolated from MG-132 treated HEK293 
cels (which do not express the NMP (Ramachandran and Margolis 2017) (Figure 4.9B). 
Notably, we observed a ~20% increase in radiolabeled signal in RNCs isolated from neurons that 
had been treated with proteasome inhibitors (Figure 4.8A).  
To extend these analyses and specificaly monitor nascent polypeptides separately from 
the RNC complex, we leveraged previously described two-dimensional gel electrophoresis (2D-




length proteins (Ito et al. 2011). Briefly, peleted RNCs from neurons radiolabeled for 30 seconds 
were separated in the first dimension by SDS-PAGE (Figure 4.8B). Next, individual gel lanes 
were treated with base to hydrolyze tRNAs from their bound nascent polypeptides, and 
subsequently separated by SDS-PAGE in the second dimension (Figure 4.8B). Separating nascent 
polypeptides from their tRNAs shifts their molecular weight, changing the migration of patern of 
these nascent polypeptides in the second dimension. Nascent polypeptides hydrolyzed from their 
tRNAs ran as a fast-migrating band, in stark contrast to a slow-migrating band consisting of 
polypeptides that were not bound to tRNA in the first dimension. This tRNA-free population was 
comprised of ful-length proteins (e.g. ribosomal proteins) and nascent polypeptides separated 
from their tRNAs during processing in the first dimension (Figure 4.8B). In our analysis, we 
found puromycin-sensitive radiolabeled signal in both the fast- and slow-migrating bands, 
consistent with the entire radioactive signal associated with the RNC complex being derived from 
the nascent polypeptide (Figure 4.8C). 
Using this approach, we analyzed isolated RNCs from radiolabeled neurons folowing 
KCl stimulation. We observed approximately a 40% reduction in radiolabel signal intensity of 
both the fast- (tRNA-hydrolyzed polypeptide) and slow-migrating bands from KCl-stimulated 
versus control samples (Figure 4.8C). Consistent with our quantification of scintilation counts in 
RNCs, the stimulation-induced loss of radiolabel signal was entirely recovered by treating 
neurons with MG-132 or biotin-epoxomicin as described above (Figure 4.8C, 4.9C). 
Immunobloting these samples using an antibody against ubiquitin revealed detectable signal in 
the slower migrating band of the 2D-gel which was undetectable in the faster migrating nascent 
polypeptide band (Figure 4.8D). Importantly, we detected ubiquitin immunoblot signal from 
puromycin-treated samples in the slower migrating band (Figure 4.8D). Therefore, based on these 
data, we suggest that the nascent chain is not ubiquitylated at suficient levels to explain the 




likely RNC-associated, are targeted for degradation. We concluded from these data that neuronal 
stimulation induces NMP-mediated co-translational degradation of ribosome-associated nascent 
polypeptides in a ubiquitin-independent manner. These data were consistent with the NMP 
operating as a 20S proteasome, which degrades unfolded polypeptides in an ubiquitin-
independent manner (Ben-Nissan and Sharon 2014; Coux, Tanaka, and Goldberg 1996). 
Identification of activity-dependent nascent NMP substrates 
 During neuronal stimulation, were al nascent polypeptides similarly susceptible to co-
translational degradation or was there some selectivity in which nascent polypeptides were being 
targeted? To specify these principles of co-translational degradation through the NMP in an 
unbiased manner, we turned to global proteomic analysis. A variety of methods have been 
developed to analyze newly synthesized polypeptides, typicaly by introducing chemicaly 
modifiable noncanonical or unnatural amino acids (Aakalu et al. 2001; Dieterich et al. 2010; 
Dieterich et al. 2006; Landgraf et al. 2015). These are typicaly methionine analogs that are 
incorporated into newly synthesized polypeptides, and serve as a handle to isolate the 
polypeptides they modify (Aakalu et al. 2001; Dieterich et al. 2010; Dieterich et al. 2006; 
Landgraf et al. 2015). While these are powerful tools, two issues confounded our use of such 
approaches. First, decades of work into the stability of nascent chains and newly synthesized 
polypeptides has shown that proteins made with non-natural amino acids have a higher propensity 
to be turned over by the proteasome during or immediately folowing their synthesis [(Benaroudj 
et al. 2001; Rock et al. 2014; Rock et al. 1994; Wheatley, Giddings, and Inglis 1980; Wheatley 
2011; Wheatley, Grisolia, and Hernandez-Yago 1982; Prouty and Goldberg 1972; Goldberg and 
Dice 1974; Prouty, Karnovsky, and Goldberg 1975; Etlinger and Goldberg 1977)]. This method 
would likely bias our analysis of newly synthesized proteasome substrates, and provide an 
artificial overestimate of this population. Second, the met-tRNA that charges these amino acids 




acids, cels must be incubated in methionine-free media. Additionaly, the charging of 
noncanonical amino acids on met-tRNA is slower, and the eficiency of chemical modification 
and purifications are imperfect (Hartman, Josephson, and Szostak 2006). To overcome these 
limitations, studies utilizing these techniques usualy incubated cels for at least one hour in 
media containing noncanonical amino acids to maximize labeling. These timescales were 
incongruent with the timescales at which we were conducting our experiments.  
 Because of the combination of these variables, we chose not to use noncanonical or 
unnatural amino acids to identify co-translationaly degraded substrates of the NMP. Instead, we 
leveraged unbiased and high-coverage mass spectrometry-based quantitative proteomic analysis 
using tandem mass tag (TMT) technology (Figure 4.10A). Primary mouse cortical neuronal 
cultures were incubated with bicuculine for one hour and treated with vehicle (DMSO), biotin-
epoxomicin, or biotin-epoxomicin+ Cycloheximide (CHX) in the last 10 minutes of the 1-hour 
stimulation. We chose bicuculine for our activity-inducing paradigm for these experiments since 
it provided us with more dynamic control of the timing of our experiments. Importantly, 
bicuculine stimulation recapitulates the earlier observations made using KCl-stimulation (Figure 
S2D). Folowing these treatments in biological triplicates, proteins were extracted from the 
samples and derivatized using TMT tags folowing enzymatic digestion (Figure 5A). In order to 
increase protein coverage, reduce artifacts from ratio compression, and increase our signal/noise 
ratio, peptides from al treatment groups fractionated ofline before mass spectrometry (MS) 
analysis. We performed MS/MS analysis on each of the 24 fractions, with 2-hour runs per 
fraction in an Orbitrap Fusion Lumos mass spectrometer (Figure 4.10A). An additional 
fragmentation event with high-energy colisional detection was used for quantification, which 
increases the accuracy of estimates of protein levels. Protein identification and TMT-based 
quantitation was conducted using Proteome Discoverer 2.1, applying a false discovery rate of 1% 




normalization to account for the population variance was performed as described in materials and 
methods. Statisticaly significant diferences were determined after taking multiple comparisons 
testing into account. Overal, the combined analysis of the replicates across treatment groups 
yielded 141,295 peptides that were mapped to 8,223 proteins (Figure 4.10B). The reproducibility 
across biological replicates was robust, with coeficients of variation of <10% observed for >99% 
of the proteins. We defined a co-translationaly degraded substrate of the NMP as one with higher 
protein levels in bicuculine/biotin-epoxomicin-treated neurons as compared to both bicuculine 
and bicuculine/biotin-epoxomicin/CHX. Statisticaly significant diferences between biotin-
epoxomicin treated samples compared to the other groups were observed for 1,339 proteins at 
p<0.05, and 408 for p<0.01 (Table 4.1). However, we found it necessary to take multiple 
comparisons testing into account, increasing the stringency and robustness of this data set. This 
analysis yielded a list of 191 diferentialy expressed proteins, of which 122 were up-regulated, 
and therefore considered co-translationaly degraded NMP substrates (Figure 4.10B,C, Table 
4.2). 
 In our MS data, we identified NMP substrates that were previously described as 
ubiquitin-proteasome system (UPS) targets, such as Odc1 and Rgs4 (Figure 4.10D)(Hoyt, Zhang, 
and Cofino 2003; Zhang, Pickart, and Cofino 2003; Asher et al. 2005; Davydov and Varshavsky 
2000; Lee et al. 2005; Bodenstein, Sunahara, and Neubig 2007). Further analysis of our MS data 
also revealed a set of substrates not previously shown to be turned over by proteasomes, such as 
Bex2, Ubc, and Snurf (Figure 4.10D). However, by and large, the levels of many previously 
characterized UPS targets such as Shank, GKAP, PSD95, Ube3A and ApoER2 did not change in 
this assay (Figure 4.10D) (Ehlers 2003; Gao et al. 2017; Coledge et al. 2003; Lee et al. 2008; 
Hung et al. 2010; Shin et al. 2012). Further analysis of this dataset revealed an unusual 
enrichment of the immediate-early gene (IEG) products in our MS data as NMP substrates. These 




1995; Ito et al. 2005; Carle et al. 2007; Adler et al. 2010; Bae et al. 2002; Mabb et al. 2014; 
Speckmann et al. 2016; Peebles et al. 2010). Specificaly, we found that c-Fos, Fosb, Npas4, and 
Egr1 were significantly upregulated in response to biotin-epoxomicin treatment (Figure 4.10D). 
These IEG proteins have characteristicaly low expression in unstimulated neurons and are 
induced by prolonged neuronal stimulation We initialy atributed the upregulation observed in 
our MS data to canonical activity-induced mechanisms of IEG expression. However, by 
immunoblot analysis, bicuculine stimulation for one hour does not lead to significant increase in 
IEG protein expression (Figure 4.12A). In contrast, folowing two hours of bicuculine 
stimulation, we observed the canonical induction of IEG protein expression that was dependent 
on neuronal activity, transcription, and translation (Figure 4.12A) Based on these data, we 
suspected that our MS data revealed a unique mechanism of IEG protein regulation through the 
NMP, temporaly distinct and prior to the canonical activity-dependent mechanisms of IEG 
protein expression.  
 To independently validate our MS data, we used similar treatment conditions as in our 
MS analysis and analyzed IEG protein levels by immunoblot analysis. Neurons were stimulated 
with bicuculine for one hour, and treated with either MG-132 or biotin-epoxomicin for the final 
10 minutes. The addition of either MG-132 or biotin-epoxomicin in the presence of bicuculine 
led to an accumulation of IEG proteins, but no change in the protein levels of UPS targets such as 
PSD95 or Ube3A (Figure 4.11A). This increase in IEG protein levels was blocked by co-
incubation with Cycloheximide, but transcriptional inhibitor actinomycin D had no efect (Figure 
4.11A). While we did not detect a change in Arc levels in the MS analysis, we did observe 
significant changes by immunoblot. This likely reflects the diferences in detection sensitivity 
between the two methods. Notably, in the absence of bicuculine stimulation, MG-132 and biotin-
epoxomicin treatment also led to a smal, but reproducible increase in IEG products (Figure 




that the efect depends on translation and baseline activity present in neuronal cultures (Figure 
4.12B). In al of these experiments, the efects on IEG protein expression due to treatment with 
MG-132 and biotin-epoxomicin were nearly identical, suggesting that the majority of changes we 
observe are due to the NMP, and not the cytosolic proteasome (Figures 4.11A and 4.12A). 
Together, we interpreted these data to mean that neuronal activity was required for and induces 
NMP-mediated degradation of IEG proteins.  
 Taking these experimental data together with the Markov modeling and validation, we 
hypothesized that the NMP exclusively mediates co-translational degradation of IEGs, and not 
ful-length proteins. The data above demonstrating NMP-mediated IEG protein turnover do not 
distinguish between co-translational degradation and ful-length protein degradation. To monitor 
turnover only of the ful-length protein population, we took advantage of the robust induction of 
IEG protein expression folowing two hours of bicuculine stimulation (Figure 4.12A). Folowing 
stimulation, we washed out the bicuculine to monitor the turnover of these IEG proteins for one 
hour. Neurons were incubated with Cycloheximide after the washout to prevent any further 
protein expression, alowing us to monitor the fate of these IEG protein products that had 
completed synthesis. As expected, we observed robust induction of immediate-early gene 
products folowing two hours of bicuculine stimulation that was largely turned over in one hour 
in the absence of sustained translation (Figure 4.11B).This turnover was inhibited by the addition 
of MG-132, consistent with data from many groups demonstrating that IEG proteins are targeted 
by the ubiquitin-proteasome pathway (Figure 4.11B) (Adler et al., 2010; Bae et al., 2002; Carle et 
al., 2007; Ito et al., 2005; Mabb et al., 2014; Peebles et al., 2010; Speckmann et al., 2016; 
Tsurumi et al., 1995). In contrast, biotin-epoxomicin does not prevent the turnover of these ful-
length IEG products (Figure 4.11B). These data were the clearest demonstration that the NMP co-
translationaly degrades nascent polypeptides during states of activity, but is not capable of 




During elevated states of neural activity, protein synthesis and protein degradation are 
independently essential for regulating the expression level of proteins important for promoting, 
enhancing and maintaining neuronal activity-dependent processes . Our experiments unify these 
observations and elucidate an activity-dependent coordination of protein synthesis and protein 
degradation through the NMP. This resulted in NMP-dependent degradation of nascent 
polypeptides being synthesized during neuronal stimulation. We identified immediate-early gene 
products as among the many activity-dependent substrates of the NMP. Taken together, our 
studies define a protein homeostasis program that involves the coordination of protein synthesis 
and NMP-mediated degradation in the nervous system.  
Ubiquitin-independent co-translational degradation 
Protein turnover and degradation kinetics have been studied extensively over the past few 
decades (Prouty and Goldberg 1972; Prouty, Karnovsky, and Goldberg 1975; Dutler, Pechmann, 
and Frydman 2013; Schubert et al. 2000; Vabulas and Hartl 2005; Zhao, Garcia, and Goldberg 
2016; Schwanhausser et al. 2013; McShane et al. 2016; Wheatley, Giddings, and Inglis 1980; 
Wheatley, Grisolia, and Hernandez-Yago 1982). The majority of these studies have used isotope 
pulse labeling of proteins made over at least one hour, and then have monitored the fate of those 
synthesized proteins. Cumulatively, they have concluded that protein turnover is most wel-
explained by two-state degradation kinetics, which predicts that some proteins degrade at the 
same rate over many hours, while others have both fast (within 2 hours) and slow (>8 hour) 
kinetics(McShane et al. 2016). These radioisotope pulse labeling approaches use long labeling 
times that are more biased towards monitoring folded ful-length proteins. Short labeling times 
have been shown to preferentialy monitor polypeptides on the ribosome or folding intermediates. 
Indeed, by reducing the radiolabel pulse time to within a few minutes (timeframes much more 
similar to our analysis), other classic studies on protein turnover have shown that immediately 




and Goldberg 1975; Wheatley, Giddings, and Inglis 1980; Wheatley, Grisolia, and Hernandez-
Yago 1982). Whether these studies define co-translational degradation has not been fuly 
elucidated and certainly, such mechanistic studies have not been caried out in the nervous 
system. Our use of short radiolabeling protocols alowed us to capture a coordination of protein 
synthesis and protein degradation. This led to the preferential NMP-dependent degradation of 
polypeptides being synthesized during neuronal stimulation (i.e. the activity-dependent 
nascentome).  
The NMP has previously been described to be a 20S proteasome complex and despite 
extensive efort, no cap to recognize a ubiquitylated substrate has yet been identified on the NMP 
(Ramachandran and Margolis 2017). Given that the 20S requires an unfolded substrate, it is 
logical that this NMP-dependent program of co-translational degradation would be ubiquitin-
independent. Consistent with NMP degradation mechanisms operating independently of 
ubiquitylation pathways, we do not detect in our MS analysis changes in the levels of previously 
wel-characterized ubiquitylated substrates (Shank, GKAP, and AKAP79/150) of the UPS. These 
proteins are likely primarily degraded by the UPS pathways as ful-length proteins and not 
nascent polypeptides by the NMP. The mechanisms that discriminate substrate selectivity to the 
UPS pathway versus NMP degradation are unknown and critical to identify. In addition, the 
kinetics of our Markov modeling analysis, which predicted that the NMP degrades unfolded 
nascent polypeptides and not ful-length proteins, are also consistent with this NMP-dependent 
program being ubiquitin-independent. If nascent polypeptides were being ubiquitylated, our 
model would predict a delay in release curves coresponding to ubiqutiylation and 
deubiquitylation prior to degradation. The experimental release curves we observe are far too 
rapid to incorporate these additional steps. 
Based on our Markov modeling, we predicted that a nascent polypeptide has a probability 




consistent with experimentaly observations made in Figure 1C, comparing the intracelular 
radiolabeled proteins in the input (taken immediately after radiolabeling) with the 30 minute 
chase under baseline conditions. The biochemical approaches we used in Figures 4.2, 4.4, and 4.8 
are similar to those used in other systems analyzing nascent polypeptides – for example, nascent 
chains in yeast have been shown to be co-translationaly ubiquitylated and degraded. The fraction 
of nascent polypeptides being targeted for degradation in these experiments were estimated to 
comprise about 1-5% of the total translated proteome at any given time(Dutler, Pechmann, and 
Frydman 2013). Though these are two diferent modes of protein degradation (i.e. ubiquitin-
independent vs ubiquitin-dependent) they do suggest consistent instability of the nascentome 
across species and systems. How robust this process is across other cel systems, and whether 
they are handled by 20S or 26S proteasomes, remains to be determined. 
While our model predicted an increase in nascent chain degradation (16.5%) under 
stimulation conditions, this data is much more chalenging to properly model, as evidenced by the 
larger uncertainty between the predicted and experimental release data. The predicted 16.5% 
intracelular degradation also underestimates what we observe in the experimental data (Figure 
4.2B). These discrepancies are likely due to an inability to accurately model how synthesis and 
degradation change under stimulation conditions. Multiple groups have now shown changing 
translation dynamics during neuronal stimulation, and further work wil be required to integrate 
these data into NMP biology and our analyses. Mechanistic insight into activity-dependent co-
translational degradation wil be critical for understanding the roles and function for NMP-
mediated degradation.  
Nascent polypeptides, including the immediate-early gene products, as NMP substrates 
 The concept that proteasome-mediated protein degradation responds to neuronal activity 




neuronal activity. However, these studies relied on pan-proteasome inhibitors over the course of 
hours to days, typicaly focused on homeostatic plasticity. Such sustained proteasome inhibition 
leads to induction of stress pathways and initiation of the ER stress response, which includes a 
global shutdown of translation(Ding et al. 2006; Wu, Volta, et al. 2009; Obeng et al. 2006). This 
likely explains why groups have not observed the phenomena we report in this manuscript. By 
using short windows of inhibition and narowing in on a specific pool of proteins (e.g. those made 
during neuronal stimulation), we have unveiled an unconventional modality of activity-dependent 
degradation of many substrates including IEG products.  
 Over the past 30 years, many groups have focused their eforts on studying the role of 
immediate-early genes (IEGs) in experience-induced changes in neuronal activity. Several groups 
have gone on to show that proteasome inhibition using MG-132 can lead to an elevated 
expression of 2-3 fold of the products of IEGs in neurons, such as Arc, c-Fos, and Npas4 (Adler 
et al., 2010; Bae et al., 2002; Carle et al., 2007; Ito et al., 2005; Mabb et al., 2014; Peebles et al., 
2010; Speckmann et al., 2016; Tsurumi et al., 1995). However, these studies have not explicitly 
discriminated between those IEGs being synthesized and those which have already been 
synthesized. In fact, the vast majority focus on those already synthesized and monitor their 
turnover through the UPS pathway, typicaly by focusing on the E3 ubiquitin ligases that target 
these IEGs. Our finding that MG-132 blocks the degradation of ful-length IEG products (Figure 
4.11B) is consistent with previous data that ful-length IEGs are degraded by the cytosolic 
proteasome. Since biotin-epoxomicin has no efect on the turnover of these ful-length IEG 
products (Figure 4.11B), we do not believe the NMP targets these ful-length products. This is 
consistent with the notion that the NMP does not degrade proteins made prior to stimulation 
(Figure 4.2C) and with the Markov modeling that the NMP does not target ful-length and folded 
proteins (Figures 4.4 and 4.6). In contrast, by adding biotin-epoxomicin during stimulation 




process of being synthesized are degraded by the NMP (Figure 4.11A). This is also consistent 
with the phenomenon observed in Figure 1B and with the predictions made by the Markov 
modeling. We find it interesting to mention that IEGs and other NMP substrates (such as Rgs4) 
contain intrinsicaly disordered domains. Whether these properties contribute to their 
susceptibility to co-translational degradation by the NMP remains to be explored. 
 For decades immediate early genes have been defined by their rapid response to neuronal 
activity at the level of gene transcription. While this is known to eventualy lead to translation and 
expression of a IEG proteins product, the relationship between gene expression and timing of 
protein production has not indicated a direct 1:1 corelation (Haider and Pal 2013; Maier, Guel, 
and Serano 2009). Our study indicates that transcription is not required for the NMP mediated 
turnover of IEG protein products. These data suggested to us that mRNA for several IEGs must 
be available for IEG products to be continuously targeted by the NMP. It is wel known that 
induced mRNAs can remain in the cel for hours to days(Schwanhausser et al. 2013; 
Schwanhausser et al. 2011). Many studies monitoring the impact of neuronal activity on IEG 
gene transcription use a strategy of quieting the neurons with activity blockers, largely to remove 
any residualy expressed mRNA. This condition does not mimic the in vivo environment which 
expresses mRNA for many IEGs at appreciable levels. Our studies do not quiet neurons prior to 
stimulation. Based on our data that inhibiting the NMP of neurons at baselines induces activity-
dependent increases in IEG protein products, we believe that our cultures do exhibit substantial 
neuronal activity at baselines. This change in IEG protein levels likely reflects the translation of a 
smal but available pool of IEG mRNAs that in response to stimulation, are rapidly co-
translationaly degraded by the NMP. We speculate that transcriptional induction serves to 
overwhelm the co-translational degradation system, and leads to the generation of ful-length 
IEGs that go on to cary out specific functions. The observed transcription-independent coupling 




whether this mechanism gives rise to the discrepancy between the transcriptome and the 
proteome. In summary, our data codify the principles of co-translational degradation through the 





Figure 4.1: Suppression of neuronal activity reduces peptide eflux. Cultured cortical neurons 
at days in vitro (DIV) 14 were incubated with Tetrodotoxin (TTX - dashed lines, 1hr) or without 
(Control - solid line). 35S-methionine/cysteine radiolabel was incorporated for 10 minutes. 
Radiolabel was washed out, and fresh media +/- TTX was added. Samples were taken at indicated 
timepoints over a 10 minute timecourse and counted by liquid scintilation. Data are mean and 
s.e.m. of n = 3 experiments from independent neuronal cultures. Line graph, *p < 0.01 (Students 
t-test) for control compared to TTX treatment at each time point. 
  







































Figure 4.2. Neuronal stimulation induces NMP-dependent degradation of newly synthesized 
proteins into extracelular peptides. 
(A) Concomitant radiolabeling during neuronal stimulation induces NMP-mediated radiolabeled 
peptide release. Media colected from neurons concomitantly radiolabeled and treated with 
control (Con) or KCl stimulation bufer with or without MG-132 or biotin-epoxomicin (Bio-
Epox). Liquid scintillation data for media at the indicated time points are shown normalized to 
control at the 5-minute time point. Data are mean and s.e.m. of n = 3 experiments from 
independent neuronal cultures. Line graph, *p < 0.01 (two-way ANOVA) for Control compared 
to KCl treatment at each time point. Line graph, ‡p < 0.01 (two-way ANOVA) for Untreated 
compared to MG-132 treatment at each time point. Line graph, §p < 0.01 (two-way ANOVA) for 
Untreated compared to Bio-Epox treatment at each time point. 
(B) Neuronal stimulation induces NMP-mediated degradation of intracelular proteins made 
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during stimulation. Left, representative autoradiograph of lysates from cortical neurons 
radiolabeled with 35S-methionine/cysteine during either control (C) or KCl (K) stimulation and 
treated with MG-132 or biotin-epoxomicin (Bio-Epox). Right, quantification of densitometry 
signal normalized to control alone. Data are mean and s.e.m. of n = 3 experiments from 
independent neuronal cultures. Bar graph, *p < 0.01 (two-way ANOVA) compared to control, ‡p 
< 0.01 (one-way ANOVA) for Untreated compared to MG-132 treatment, §p < 0.01 (two-way 
ANOVA) for Untreated compared to Bio-Epox treatment. 
(C) Neuronal stimulation does not induce NMP-mediated degradation of proteins made prior to 
stimulation. Left, Representative autoradiograph of lysates from cortical neurons previously 
radiolabeled and then chased into either control (C) or KCl (K) stimulation bufers for indicated 
times. Input shows sample colected immediately folowing labeling. Right, quantification of 
densitometry signal normalized to control alone. Data are mean and s.e.m. of n = 3 experiments 
from independent neuronal cultures. Statisticaly significant diferences between samples was not 
observed (two-way ANOVA). 
(D) Radiolabeling immediately prior to neuronal stimulation does not induce NMP-mediated 
radiolabeled peptide release. Experiments done as described in (A), note neurons were 
radiolabeled prior to instead of during stimulation as in (A). Data are mean and s.e.m. of n = 3 
experiments from independent neuronal cultures. Statisticaly significant diferences between 





Figure 4.3: Neuronal stimulation reduces radiolabel incorporation into proteins in a 
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(A) Gels for Figures 1B and 1C were stained with coomassie dye and dried down onto whatman 
filter paper. Note equal loading across conditions. 
(B) Cortical neurons at Days in vito 15 were radiolabeled during either ACSF treatment (C) or 
chemical LTP induction (L) (as described in Materials and methods). MG-132 was added to 
indicated neurons during stimulation. Autoradiographs quantified by densitometry shown to right. 
Data are mean and s.e.m. of n = 2 experiments from independent neuronal cultures. Bar graph, *p 
< 0.01 (two-way ANOVA) for treatments compared to controls. 
(C) Neurons were treated with either a Media exchange (M), Glutamate (G), or 5% Fetal Equine 
Serum (S) and radiolabeled for 10 minutes. Autoradiographs quantified by densitometry shown 
to right. Data are mean and s.e.m. of n = 2 experiments from independent neuronal cultures. Bar 
graph, *p < 0.01 (two-way ANOVA) for treatments compared to controls. 
(D) Neurons were treated with bicuculine (B) or water (C) for one hour. MG-132 and radiolabel 
were added during the final 10 minutes of bicuculine stimulation. Autoradiographs quantified by 
densitometry shown to right. Data are mean and s.e.m. of n = 2 experiments from independent 
neuronal cultures. Bar graph, *p < 0.01 (two-way ANOVA) for treatments compared to controls. 
(E) Neurons stimulated with Control (C) or KCl (K) bufers were separated into Cytosolic (Cyto) 
and Membrane (Mem) fractions. Proteasomes were purified from each of these samples. Purified 
proteasomes were incubated for 30 minutes with Suc-LLVY-AMC, a smal-molecule proteasome 
substrate that releases fluorescence when cleaved. Raw fluorescence units are shown. Data are 
mean and s.e.m. of n = 2 experiments from independent neuronal cultures. Bar graph, data were 
not statisticaly significantly diferent across samples (two-way ANOVA). 
(F) Neurons stimulated with either Control (C) or KCl (K) bufers were incubated with 35S 
methionine/cysteine radiolabel. Radiolabel was either incorporated at the same time as the 
stimulation (during), or as soon as the stimulation was washed out into media (folowing). For 




during radiolabeling.  Data are mean and s.e.m. of n = 3 experiments from independent neuronal 







for diferent kinetic parameters based on either calculated or wel-established data are shown to 
the left. Simulated Markov chains (50,000 simulations) to analyze intracelular and extracelular 
radioisotope composition. The probability for each plot is shown artificialy biased towards either 
Nascent polypeptide (B), Folding intermediate (C), or Folded protein (D). Top, the simulated 
graphs ilustrate the resulting shapes of isotope release curves for a given bias. Each graph 
represents the proportion of total isotopes at any given second resulting from degradation of 
nascent polypeptides (Purple), Folding intermediates (Red), or Folded proteins (Blue). Difusion 
of free isotope (Grey) was taken into account and constant across conditions. Botom, the 





Figure 4.5: Optimization of parameters for Markov chain modeling 
(A) Probabilities of unfolding were optimized based on previous work calculating average half 
lives of protein substrates (McShane et al. 2016). Certain protein substrates are much more likely 
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data. We first calculated protein half lives based on diferent values of probability of unfolding 
and subsequent degradation, ploted above. We then took the approximate half lives of proteins as 
determined by previous studies that rigorously determine protein half life (McShane et al. 2016). 
To be on the extremely conservative end of protein half life estimation, we assumed an average 
and aggregate half life of 20 hours, as indicated by the red line. This was despite an aggregate 
average of 40-50 hours based on prior work. 
(B) The eror of our predicted in silico Markov chains across the 2D parameter space of 
probability of background release of radioisotopes (pBackground) versus the probability of 
loading onto a ribosome (pLoading). This optimization was done under degradation inhibition, to 
ensure that the observed release is theoreticaly dominated by the difusion of radioisotope. The 
red dot denotes the location of the minimum. The figure on the right is a zoomed in view of the 
region around the minimum that has up to 10x the eror, and indicates that the minimum is very 
dramatic. The optimal pBackground and pLoading are 0.00017 and 0.0056 respectively. 
(C) Parameter space of probabilities of co-translational degradation and folding intermediate 
degradation to optimize values against experimental data. Eror minimization for folding 








Figure 4.6. Nascent polypeptides are likely the source for NMP-derived extracelular 
peptides. 
(A) Parameter space of probabilities of co-translational degradation and folding intermediate 
degradation to optimize values against experimental data. Optimized values in the indicated 
parameter space are shown zoomed in to the bottom right. Eror minimization for co-translational 
degradation probability as a 2-dimensional zoomed in representation shown to the botom left. 
Note the minimized eror for pCTD (probability co-translational degradation) is non-zero and a 




(B) Graph of in silico release data using parameters optimized by minimizing eror of 
probabilities against experimental isotope release data. Calculated release data for untreated 
(Control) is shown to the left. Calculated release data for neurons stimulated with KCl is shown 
to right. Insets show zoomed in time-course for the first 300 seconds, similar to experimental 
release data shown in Figure 1. Experimental data are shown in black dots, overlaid with 
simulated release curves.  
(C) Schematic of experiments with Puromycin. Translating ribosomes shown in grey on mRNA. 
AUG start site shown just prior to tRNA (smal structure with codon recognition loops, in 
ribosome P site) and growing radioactive polypeptide (growing red line out of translating 
ribosomes). Puromycin (hexagon) modifies and releases the nascent polypeptide (red) from 
actively translating ribosomes.  
(D) Concomitant radiolabeling during neuronal stimulation induces NMP-mediated radiolabeled 
peptide release that is sensitive to Puromycin treatment. Media colected from neurons 
concomitantly radiolabeled and treated with control (Con) or KCl stimulation bufer. Puromycin 
(Puro) or Vehicle added folowing washout of stimulation and radiolabel. Liquid scintilation data 
for media at the indicated time points are shown normalized to control at the 5-minute time point. 
Data are mean and s.e.m. of n = 3 experiments from independent neuronal cultures. Line graph, 
*p < 0.01 (two-way ANOVA) compared to control, #p < 0.01 (two-way ANOVA) for Untreated 





Figure 4.7: Parameter space of probabilities of co-translational degradation and folding 
intermediate degradation to optimize values against experimental KCl stimulation data 
The eror of our predicted in silico Markov chains across the 2D parameter space of probability of 
co-translational degradation pCTD versus the probability of folding intermediate degradation 
pFID. This optimization was caried out under KCI stimulation, and the optimal values of pCTD 
and pFID were estimated as 0.165 and 0 respectively. The plot on the top right depict the 
minimum (relative) eror achievable given diferent values of pCTD – indicating a sharp rise in 
eror as pCTD deviates in either direction from the optimized value of 0.165. Similarly, the plot 
on the botom right depicts the minimum eror achievable given diferent values of pFID – 




















































































discriminate ribosome-associated nascent chains. Lysates were layered over a sucrose cushion, 
and ribosome-nascent chain complexes (RNCs) were peleted. CHX induces ribosome staling 
with tRNA-bound nascent chains (red) stil associated with the Ribosome, while Puro dissociates 
the nascent chain from the Ribosome. Released Puromycylated nascent chains found in 
supernatant. Right, RNC complexes quantified by liquid scintilation. Graph shows quantification 
of ribosome scintilation counts, normalized against control alone. Data are mean and s.e.m. of n 
= 3 experiments from independent neuronal cultures. Bar graph, *p < 0.01 (two-way ANOVA) 
for samples compared to controls, #p < 0.01 (two-way ANOVA) for samples compared to KCl 
treatment at each time point. Al puromycin treatments were statisticaly significantly lower than 
controls, but not significant amongst each other.  
(B) Experimental strategy to separate tRNA-bound nascent polypeptides from RNCs and ful-
length proteins. Uncoupled indicate those nascent chains that hydrolyze during separation in first 
dimension (1D) SDS-PAGE. Lanes are cut out, treated with base at high temperature to hydrolyze 
the tRNA (doted lines), and run in a second dimension (2D). Slower migrating signal contains 
ribosomal proteins, ful-length proteins, and those uncoupled from the tRNA in the first 
dimension. Faster migrating signal contains those nascent chains hydrolyzed from their tRNAs in 
the base hydrolysis step after the first dimension of SDS-PAGE. 
(C) Elongating nascent polypeptides during KCl stimulation are degraded by the NMP. 
Representative autoradiographs of peleted RNCs from (A) processed by 2D SDS-PAGE. 
Stimulation condition - either Control (C) or KCl (K) in top right corner, treatment condition – 
either Vehicle (Veh) or MG-132 in botom left. Translation inhibitors – either cycloheximide 
(CHX) or pruomycin (Puro) added during lysis shown above autoradiographs. 







Figure 4.9: Neuronal stimulation induces NMP-mediated co-translational degradation of 
ribosome-associated nascent polypeptides. 
(A) Ribosome nascent chain (RNC) complexes were peleted from neurons stimulated with either 
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Samples were immunobloted using antibodies against Ribosomal S6 protein. Immunoblots of 
inputs are shown above those for peleted RNC (Ribo pelet). 
(B) Peleted RNCs from HEK293 cels, treated with Vehicle or MG-132. Samples analyzed by 
liquid scintilation. Scintilation counts normalized to vehicle-treated samples shown, average of 
n = 3 biological replicates ploted as mean and s.e.m.  
(C) Peleted RNCs from Control or KCl stimulated neurons treated with or without vehicle, MG-





cortical neurons were treated with indicated drugs over shown timeline. Bicuculine (Bic), biotin-
epoxomicin (Bio-Epox), cycloheximide (CHX). Folowing protein extraction and trypsinization, 
biological triplicates for each treatment conditions were labeled with tandem mass tags (TMT 
tags), indicated by the colors. Peptides were pooled together, fractionated ofline using basic 
reverse-phase liquid chromatography (bRPLC), and then analyzed by MS/MS methods. 
(B) Scaterplot of normalized log2 bicuculine/Bio-Epox treated compared to both bicuculine 
alone and bicuculine/Bio-Epox/cycloheximide, versus q-values (p-values after multiple 
comparisons testing). Representative examples of NMP-targets are highlighted in orange, 
compared to those targets that do not change by MS analysis with biotin-epoxomicin treatment 
shown in blue. 
(C) Heat map of proteins diferentialy expressed in bicuculine/Bio-Epox treated compared to 
bicuculine and bicuculine/Bio-Epox/cycloheximide. Coloring indicated percentage of maximum 
fold change, refer to Methods for details on heat map generation. Top 60 statisticaly significant 
targets are shown. 
(D) Individual targets are shown, with replicates in scaterplot format. Mean and s.e.m are 
graphed for each condition. ***p < 0.001, q < 0.1 (two-way ANOVA (p), adjusted for multiple 
corections (q) for biotin-epoxomicin (BEp) treatment compared to other samples). NMP targets 
previously shown to be UPS targets in top row, orange. NMP targets previously uncharacterized 
with regards to degradation shown in second row, orange. Lower two rows in blue show 





during CHX Chase. Each set was also treated with either MG-132 (MG), biotin-epoxomicin 
(BEp), or DMSO (Veh) during chase. Neuronal lysates were immunobloted using antibodies 
against indicated proteins. For (A) and (B), protein names in orange classified as NMP targets in 
mass spectrometry data set (Fig 5), protein names in blue are not NMP targets based on MS data 
set. Representative immunoblots shown. Data are mean and s.e.m. of n = 3 experiments from 






proteins. Protein names in orange classified as NMP targets in mass spectrometry data set (Fig 3), 
protein names in blue not NMP targets based on MS data set. Representative immunoblots 
shown. Significance table presented in supplement. For (A) and (B), protein names in orange 
classified as NMP targets in mass spectrometry data set (Figure 5), protein names in blue are not 
NMP targets based on MS data set. Representative immunoblots shown. Data are mean and s.e.m. 
of n = 3 experiments from independent neuronal cultures. Significance table presented in 





























Peptides derived from the NMP can interact with activated neurons and may 







NMP-generated peptides interact with stimulated neurons 
Over the course of identifying the NMP complex and NMP-dependent peptide 
communication, we have done a huge number of experiments to try and gain further mechanistic 
insight into the function for this system. We thought that some of the most important would be to 
identify where and how the peptides were binding and interacting with neurons. Part of this was 
addressed using calcium imaging, where we found that NMP-derived peptides induced calcium 
signaling in both neurons and glial cels. Presumably, this calcium signal originates from cel-
surface receptors on neurons and/or glial cels that bound these peptides and led to a secondary 
efect of opening calcium channels. We considered that in order for this to be true, we should be 
able to detect peptides bound to the surface of neurons or glial cels. 
To test this directly, we first purified the peptides away from the cel culture media and 
then chemicaly modified them using biotin. NHS-Biotin selectively modifies exposed amines on 
peptides, such as N-termini or lysines. Folowing dialysis to remove the NHS-Biotin tag, we 
quantified the amount of biotin signal on the peptides and found a significant amount of biotin-
modified peptides. This signal was greatly reduced in peptides purified from MG-132 treated 
neurons or from media that had previously been treated with Proteinase K. Folowing isolation 
and modification of these peptides, we applied them onto neurons that had been fixed, and 
visualized them using streptavidin-AF647 secondaries. We observed very litle binding of 
peptides onto neurons under baseline conditions (Figure 5.1a). However, when we used the same 
protocol on neurons that had been stimulated with KCl for one minutes, we observed a significant 
amount of binding (Figure 5.1a). This was reduced back to background levels when we treated 
the modified peptide mixture with Proteinase K (figure 5.1a). Notably, we did not observe 
nuclear staining, leading us to propose that the majority of the observed staining was at the cel 




Next, we modified our stimulation protocols to refine the role for neuronal activity in 
determining the interaction of these peptides with neurons. Instead of stimulating neurons en 
masse with KCl, we chose to use optogenetic methods to only stimulate a smal subset of 
neurons. We transfected channelrhodopsin-2 into cortical neuronal cultures, which only labeled 
1-2% of the total neurons in the culture. This sparse labeling and stimulation method would alow 
us to determine whether the stimulated neuron would be stained by the labeled NMP-mediated 
peptides, compared to unstimulated but adjacent cels. Folowing a 7Hz stimulation for one 
minute, neurons were fixed and stained using biotin-peptides and streptavidin as described before. 
Intriguingly, we observed biotin-peptide staining of both the ChR2-encoding neurons as wel as a 
smal percentage of neurons adjacent to the ChR2+ cels (Figure 5.1b). However, the majority of 
the cels surounding the neurons remained unlabeled. We interpret these data to mean that the 
ChR2+ neuron, as wel as the neurons innervated by the ChR2+ neurons, were stimulated and 
these biotin-peptides served as markers of neuronal stimulation. These data need to substantiated 
by additional experiments using TTX to inhibit neuronal transmission. This would substantiate 
the hypothesis that the staining observed in neurons adjacent to the ChR2+ neurons is because 
these cels are innervated by the ChR2+ cel. Of course, this also raises a fundamental question 
about how and why these peptides are selectively interacting with stimulated neurons over 
unstimulated cels. As we gain insight into what the peptides and receptors are, the answers to 
these questions should begin to be revealed over time. 
Dysregulation of the NMP in AD and NMP-generated peptides protect against Abeta-induced 
toxicity in neurons 
As previously discussed, proteasome-mediated protein degradation lies at the crux of a 
variety of neurodegenerative states. We wanted to distinguish changes in the NMP versus bulk 
proteasomes in neurodegenerative disease. To determine whether the NMP was dysregulated, 




biotinylation assay. We used diferent models to induce Abeta-mediated efects, including Abeta 
1-42 incubation in cultured neurons as wel as monitoring the NMP in AD mouse models and in 
postmortem human brain samples. First, to determine the efects of Ab on cultured neurons, we 
treated DIV16 mouse cortical neurons with oligomerized soluble Ab1-42. Folowing overnight 
treatment, neurons were surface biotinylated and analyzed for NMP expression. Compared to 
Abetascrambled controls, we observed a greater than 50% decrease in NMP expression in 
Abeta1-42 treated neurons (Figure 5.2a). We next decided to move our findings to mouse models 
of Alzheimer’s, where proteasome expression and activity has been shown to be dysregulated. 
Transgenic mice overexpressing human amyloid precursor protein (hAPP) with familial AD 
mutations result in high levels of Ab production in the brain (Cisse et al. 2011; Sel, Schafer, and 
Margolis 2017). Consistent with our findings that exogenous addition of Aβ leads to decreased 
levels of the NMP, we observed a similar magnitude decrease of the NMP from hippocampi of 
hAPP mice compared to WT litermate controls. Finaly, we extended these findings to human 
patients. We obtained tissue from the cortex of AD patients at advanced Braak stages. When we 
conducted this analysis, we were blinded to the patient samples. Once again consistent with our 
previous data, we observed a significant downregulation of the NMP in AD patient samples 
compared to unafected individuals (Figure 5.2b). Cumulatively, we believe that these data 
provide compeling evidence that the NMP is dysregulated in AD.  
The consequences of losing the NMP in the membrane could either be 1) an elevation in 
NMP substrate or set of substrates or 2) a significant reduction in NMP-mediated peptides. We 
chose to test the peptide hypothesis, simply because it would be far easier to test the peptide 
hypothesis versus the substrate hypothesis. Considering we could purify NMP-generated 
peptides, we first tested whether these peptides could relieve the deleterious efects of abeta. In 
order for abeta to enact its efects, multiple groups have shown that it binds to the cel surface of 




al., 2000). Therefore as a first pass experiment, we incubated neurons with fluorescently labeled 
abeta, which binds to neurons as an initiating event that cascades into neurodegeneration. We 
observed punctate staining as previously shown, largely due to interactions with synaptic 
molecules. We next perfused in peptides in a dose-dependent fashion, with the middle 
concentration being the endogenous concentration (50ng/mL). We observed a dose-dependent 
reduction in abeta signal on neurons in response to NMP-derived peptides (Figure 5.3a). 
Pretreatment of NMP-derived peptides with proteinase K eliminated the capacity to reduce abeta-
neuron interactions (Figure 5.3a). These data indicate that NMP-derived peptides either 1) 
directly compete with Abeta binding at the receptor level or 2) bind Abeta directly, thereby 
sequestering the Abeta and reducing the interactions with surface receptors on neurons. 
While the mechanism by which NMP-derived peptides reduces the interactions between 
Abeta and neurons remains to be elucidated, we wanted to determine whether this would be 
suficient to aleviate molecular aspects of neurodegeneration. A variety of pathways have been 
shown to be downstream of abeta binding, prior to neuronal death. As an example, Creb has 
shown to be de-phosphorylated, while c-Jun and Erk1/2 are phosphorylated in response to 
abeta(Vitolo et al. 2002; Morishima et al. 2001; Chong et al. 2006). This change in Erk1/2 
phosphorylation also induces a change in cleaved caspase 3 levels. Finaly, the surface levels of 
EphB2 have been reproducibly downregulated in response to Abeta. We tested al of these efects 
in our model in the presence of either NMP-derived peptides or those pretreated with Abeta or 
Abeta scrambled. As a control, we pretreated peptides with proteinase K. In these control 
experiments, we reproduced the efects of Abeta on CREB, Erk1/2, c-Jun, Caspase-3, and surface 
EphB2 (Figure 5.3b). By every measure, we observed that the addition of NMP-derived peptides 
protected against the deleterious efects of Abeta compared to addition of PK-NMP peptides 
(Figure 5.3b). Taken together with the fluorescent Abeta binding experiments, we believe that 
these data indicate that NMP-derived peptides can compete against the efects of abeta. Overal, 




and potentialy other disorders of protein aggregation. In pathological states such as in AD, the 
levels of the NMP are significantly downregulated. This leads to a downregulation of the 
protective peptides, alowing abeta to enact its deleterious efects. While these data are highly 
preliminary and only a speculative hypothesis, we believe that delving into the mechanisms of 







(b) Channelrhodopsin (ChR2) transfected neurons were stimulated at the indicated frequency 
for one minute, fixed, and stained with an anti-GFP antibody that is reactive against ChR2 
protein (Green) and labeled SNAPPs (Magenta). Pretreatment of SNAPPs with Proteinase K 










Figure 5.2. Dysregulation of NMP localization under pathological states such as in AD 
(a) A variety of celular processes are required for expression of the neuronal membrane 
proteasome. Indicated drugs were added between to DIV12 neurons overnight, and then 
processed for surface biotinylation. Div 12 (12), Actinomycin D(ActD), Cyclohexamide (CHX), 
2 hydroxy-myristic acid (2HMA), Autocamtide (CamT), CNQX/APV/TTX (CAT)., B-ZIP, and 
Abeta1-42 (Ab1-42). Inhibitors are discussed further in the methods. 
(b) Postmortem patient brains were subjected to surface biotinylation and analyzed for NMP 
expression. Samples were unblinded folowing analysis and samples obtained from AD patients 
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Figure 5.3. Stimulation-induced NMP-dependent peptides (SNAPPs) protect against Ab1-42 
binding and downstream molecular cascades 
(a) DIV16 primary cortical neurons were treated with indicated concentrations of fluorescently 
labeled Ab1-42 for four hours and then indicated concentrations of SNAPPs for an additional 
two hours. Neurons were washed and then fixed and stained to assess Ab1-42 binding. Images to 
right are magnified from zoomed out image to left. Puncta indicate sites of Ab1-42 binding. 
(b) Representative western blots from primary cultured neurons treated with 1µM Ab1-42  or 
Ab42-1 for 24 hours, and 250ng SNAPPs for the final four hours. SNAPPs (PK) were pretreated 
with Proteinase K to remove al peptide material. Inputs and streptavidin puldowns to the right 






























First, we identify a 20S plasma membrane bound proteasome that is unique to neurons in 
the mammalian nervous system. Based on our studies we conclude that the protein synthesis and 
NMP protein degradation machinery are cooperating to mediate neuronal activity-induced 
degradation of newly synthesized proteins. This process subsequently generates signaling 
peptides important for maintaining and enhancing neuronal activity dependent processes.  
6.1 Implications of 20S membrane proteasomes and ubiquitin-independent degradation 
Since the discovery of the proteasome and ubiquitin-dependent degradation, the vast 
majority of studies studying this have focused on 26S proteasome-mediated and ubiquitin 
dependent degradation. There are notable exceptions to this phenomenon. The majority of these 
studies have focused on specific substrates, largely under the class of intrinsicaly disordered 
proteins (IDPs)(Asher et al. 2005; Tsvetkov et al. 2008; Tsvetkov, Reuven, and Shaul 2009). 
These IDP proteins are characterized by large domains that are dificult to predict structuraly or 
have high regions of disorder. Such proteins have been shown to undergo ubiquitin-independent 
degradation in vitro and to bind to the 20S proteasome(Tsurumi et al. 1995; Benaroudj et al. 
2001; Zhang, Pickart, and Cofino 2003). However, the relevance for these mechanisms in vivo 
have been chalenging to demonstrate since the role for 20S proteasomes, separately from 26S, 
has been impossible to test until now. 
We have shown that neuronal plasma membrane proteasomes, by al measures, lack 19S 
subunits or any other cap structure. We believe that this likely indicates that the NMP is a 20S 
proteasome. Consistent with this, we have shown that treating neurons with the E1 inhibitor 
MLN-7243 has no efect on the activity-dependent degradation of substrates such as c-Fos or 
Npas4(Hyer et al. 2018). Therefore, we believe that the mechanism we reveal here of ubiquitin-
independent degradation through 20S proteasomes may be a more generalizable phenomenon. 
While the precise mechanisms may be diferent, it is entirely possible that 20S proteasomes can 
degrade substrates in other cels. Whether those mechanisms are co-translational, as the one 




demonstrating that co-translational degradation through 20S proteasomes can be reconstituted in 
vitro in rabbit reticulocyte lysate might suggest that the phenomenon is more generalizable. The 
plasma membrane tethering the NMP may simply provide a platform and a docking region for the 
ribosome to deliver substrates co-translationaly. A good analogy to this process is with another 
membrane, at the endoplasmic reticulum(Brehme et al. 2014). Even more generaly, the balance 
between 20S and 26S proteasomes in vivo needs to be clearly demonstrated in other systems. The 
NMP system is ideal because the 20S localization is distinct and uniquely separable. Recent 
studies indicate that the 20S at membranes is where al of the 20S is localized, and almost al of 
the proteasomes in the cytosol are 26S or capped by other structures(Erokhov et al. 2017). 
The question of the whether the NMP is capped by any structures is stil an open one. 
While we have not observed any of the canonical capping structures on the NMP, there are a 
variety of possibilities of how the NMP can be capped. First, there could be non-canonical caps 
such as lipid-based caps that have been previously proposed(Newman et al. 1996; Furuike et al. 
2003; van Meer, Voelker, and Feigenson 2008). Lipid caps pose an especialy interesting 
possibility since the NMP is localized to the plasma membrane. In vitro, proteasomes have been 
shown to orient perpendicularly to membranes specificaly enriched in phosphatidylinositol (PI), 
a key signaling phospholipid that is notably enriched in the nervous system over other tissues 
(Newman et al. 1996; Furuike et al. 2003; van Meer, Voelker, and Feigenson 2008). Other non-
canonical caps could include binding partners of the NMP, which actualy act as caps. Whether 
proteins such as GPM6 or other binding partners could serve such a role needs to be clearly 
demonstrated. Ultimately, rigorous biochemical approaches together with structural approaches 
wil be able to clarify these questions.  
In addition to the function of proteasomes and the NMP under normal conditions, the role 
for proteasomes in pathological states has been under recent and heavy investigation. Certainly, a 
large amount of evidence has been generated regarding the role for ubiquitin in amyloidogenic 




2017; Bence, Sampat, and Kopito 2001; Bennet et al. 2007; Hipp et al. 2012; Iwata et al. 2005). 
In addition, proteasome dysfunction has also been corelated with a large variety of 
neurodegenerative and neurodevelopmental diseases. In some cases such as with Angelman 
Syndrome, mutations in Ube3A (an E3 Ubiquitin ligase) can be causative and central to the 
etiology of the disease(Albrecht et al. 1997; Sel and Margolis 2015). In the case of mutant 
huntingtin, polyQ expanded Huntingtin can inhibit the proteasome but also can enact a large 
variety of other efects(Hipp et al. 2012; Iwata et al. 2005; Bence, Sampat, and Kopito 2001; 
Ortega, Diaz-Hernandez, and Lucas 2007; Wade et al. 2014). A similar principle to Huntingtin 
holds for the mechanisms underlying Abeta-induced efects in AD. Of those mechanisms which 
perturb the proteasome degradation system under pathological states, most are atributed to 
dysregulation of the ubiquitin-proteasome system. However, our discovery of the 20S NMP 
necessitates a re-evaluation of these interpretations, and a diferentiation of what system is indeed 
dysregulated. As an example, we show that the NMP is selectively dysregulated in AD, in 
contrast to the total or cytosolic proteasome. In further support of NMP-dependent mechanisms in 
disease states, we found that the NMP-derived peptides have unique functions in modulating AD 
phenotypes in cultured neurons. Not only did the peptides seemingly outcompete Abeta binding 
to neurons, but they also seemed to aleviate the initiating molecular events characteristic of 
Abeta-induced neurodegeneration. Further work wil be necessary to identify how precisely these 
peptides compete with Abeta. Specificaly, Abeta could either be bound and sequestered by these 
peptides in its monomeric form, or Abeta could be directly competed for at its binding sites. 
Finaly, more generaly, both protein synthesis and protein degradation play critical roles in a 
variety of disease states. Since NMP-mediated degradation couples these two major systems, any 
system that perturbs either protein synthesis or protein degradation could afect NMP-mediated 
co-translational degradation. Therefore, a ful evaluation of NMP-dependent efects in many 




6.2 Coordination between protein translation and degradation 
Based on our studies we conclude that the translation and degradation machinery are 
cooperating to mediate neuronal activity-induced degradation of newly synthesized proteins. This 
is, at least in part, mediated through a neuronal membrane proteasome in order to produce 
signaling peptides important for maintaining and enhancing neuronal activity dependent 
processes. Several groups have demonstrated stimulation-induced enhancement of proteasomal 
degradation(Ehlers 2003; Patrick et al. 2003; Bingol and Schuman 2006). Consistent with these 
findings, we observe that stimulation enhances the rate of proteasomal turnover of proteins 
labeled under baseline conditions. This previously defined experimental approach assesses the 
role of proteasomal degradation similar to work previously done in the immune system. We 
believed that studying the coordination of these two processes would be highly relevant for 
neuronal function, as this cooperation has recently been demonstrated to underlie various forms 
of synaptic plasticity. This change in our protocol alowed us to capture a robust coordination of 
the protein synthesis and degradation machinery and thus provided biochemical evidence for this 
previously hypothesized coordination. Based on our data we believe that neuronal activity does 
not simply promote global protein degradation, but rather promotes protein degradation 
exclusively of newly synthesized proteins. Moreover, our data are consistent with and provide 
insight into why acute proteasomal inhibition increases the expression level of proteins whose 
translation is dependent upon neuronal stimulation, i.e. immediate early genes(Mabb et al. 2014; 
Xia et al. 1996; Lin et al. 2008). Our hypothesis that the NMP degrades newly synthesized 
proteins was refined by our observations that ribosome-associated tRNA-bound nascent chains 
were targeted to the NMP in response to neuronal activity. This degradation of nascent chains 
seemed to occur independent of ubiquitylation. In addition, the degradation was selective for the 
nascent polypeptides, instead of the fuly folded proteins. Substrates were only targeted during 




 The role for the NMP in mediating neuronal function is likely driven through the 
production of extracelular proteasome-derived signaling peptides. Addition of purified 
proteasome-derived peptides had the opposite efect of inhibiting the NMP, driving neuronal 
stimulation. These data demonstrate that the peptides themselves are capable of inducing 
neuronal signaling, and likely serve as the means by which the NMP enacts its celular 
functions. Our findings reveal that the proteasome does not simply act as a disposal mechanism, 
but can operate as a direct signaling complex, giving degraded proteins new life in the form of 
biologicaly meaningful peptides. Indeed, our studies harken back to seminal studies in the 
immune system that found tissue-specific proteasomes degrade proteins to make peptides that 
are essential for immune signaling (Rock et al., 1994; Schubert et al., 2000). These findings add 
to the growing interest in the molecular overlap between the immune system and nervous 
system. More broadly, the concept that tissue-specific proteasomes exist as direct signaling 
complexes may be a principle found in other celular systems and is likely a new dogma in 
celular signaling. Equaly intriguing is the possibility that proteasomes are capable of 
associating with the peptide presentation machinery in the immune system, potentialy lending 
credence to the hypothesis that NMP-derived peptides associate with MHC complexes in the 
nervous system(Rock et al. 1994; Huh et al. 2000; Shatz 2009; Freudenburg et al. 2013; Anton 
and Yewdel 2014; Winter et al. 2017). We believe that given the role for the NMP in 
generating peptides, understanding the mechanisms by which the NMP is expressed at the 
plasma membrane and the dynamics of this complex at the membrane wil be critical for parsing 
out the role of peptides in neuronal signaling. While the mechanisms in the immune system and 
nervous system have many similarities, there are already key diferences based on our 
knowledge of the two mechanisms. First, the immune mechanism relies on the loading of 
immunoproteasome-generated peptides onto functional TAP transporters(Murata, Takahama, 
and Tanaka 2008; Freudenburg et al. 2013; Basler, Kirk, and Groetrup 2013). These TAPs load 




plasma membrane. This is a purely constitutive process that by al measures relies on 
ubiquitylation, like of folded proteins. It is not clear if the mechanism occurs using nascent 
polypeptides or with folded proteins. In the neuronal mechanism, the proteasome is itself 
extracelular exposed, generating the polypeptides directly into the extracelular space. TAP-
mediated loading is likely not at play in neurons. The process is also entirely regulated by 
neuronal activity, so not constitutive in the same sense. Finaly, the neuronal mechanism 
degrades specificaly and only the nascent chain, and not ful length proteins, independent of 
ubiquitylation.  
 One fundamental question is where NMP-mediated degradation of nascent chains occurs. 
The substrates that we have identified are not only transcription factors that are largely expressed 
at the soma, but also proteins that show synaptic expression. Our immunocytochemistry and 
immunogold EM data against the NMP are not consistent with somatic localization, but only with 
dendritic, synaptic, and axonal localization. Therefore, this raises the question about whether the 
transcripts encoding NMP targets are localized to dendritic and synaptic regions. These questions 
wil be critical to address moving forward. Moreover, there are clear outstanding questions about 
how activity initiates the translation and degradation of NMP substrates. A few studies have 
reported that neuronal activity can activate staled ribosomes in neurons(Graber et al. 2013). An 
additional mechanism involves the translation of RNAs that are held in ribonucleoprotein 
granules. Recent evidence suggests that some of the transcripts within these granules are 
translated upon neuronal activity(Proter and Parker 2016). These diferent mechanisms may 
contribute to how certain RNAs are localized to distal compartments and how they are 
diferentialy translated and degraded.  
 On the note of how the coordination and degradation are regulated, additional questions 
remain on how the ribosome itself, or at least the tRNA-bound nascent chain, is targeted to the 




do the ribosomes dock to the NMP? One would predict the presence of an adaptor protein or 
complex that mediates this process. A good analogy to this process would be signal recognition 
particle (SRP)-mediated insertion of nascent chains into the ER membrane. This process is 
established as how membrane proteins are inserted into the ER membrane to insert polytopic 
membrane proteins. The other possibility is that the ribosome does not directly associate with the 
NMP, and rather the nascent chain is delivered through chaperones or other indirect mechanisms. 
In addition, is the ribosome itself targeted or is there some sequence determinant of the RNAs 
targeted to NMP-mediated co-translational degradation? Based on our data that nascent chains of 
Fos and other targets can be degraded co-translationaly in vitro, we predict that there is some 
sequence or structural determinants within the RNA itself. There may also be some exposed or 
disordered domain that drives co-translational degradation through 20S proteasomes. The rabbit 
reticulocyte translation experiments rely on SDS-activated 20S proteasomes, which is obviously 
not physiological. Therefore, there must be some other mechanism to open the gates on the 20S 
proteasome, potentialy through the previously discussed alternative capping mechanisms. 
6.3 NMP-mediated peptides and neuronal function 
Multiple studies have posited the coordination of protein synthesis and protein 
degradation based on inhibitor studies in electrophysiology experiments. In large part, groups 
have determined that this coordination underlies aspects of synaptic tagging, as wel as LTP and 
LTD. However, this is one of the first to our knowledge that demonstrates a compeling 
biochemical coordination at the level of the substrates. It wil be critical to determine whether 
activity-dependent coordination of translation and NMP degradation underlies previously 
observed electrophysiological studies. Perhaps the most interesting question wil be whether the 
NMP-derived peptides or the degradation of nascent substrates is the relevant component for 
establishing the physiological function of this degradation mechanism. The answer to this 
question wil also reveal why such a mechanism exists - if the peptides are relevant for the 




molecules, whereas if the degradation is the largely relevant component, then NMP-mediated 
degradation may serve to reduce the biochemical noise of the system. Regardless of the precise 
mechanism, the function of NMP-mediated degradation wil be important to reveal and 
discriminate from al proteasomes. 
We believe that neuronal activity-induced proteasomal degradation of a large fraction of 
newly synthesized proteins is for the express purpose of generating a new class of extracelular 
signaling peptides which are important for neuronal activity dependent processes. NMP-derived 
peptides are a new modality for neuronal communication. While the mechanisms by which NMP-
derived peptides enact their signaling capacity are unknown, several possibilities include: 1) 
NMP-derived peptides interact with major histocompatibility immune complexes (MHC) that 
have recently been shown to play key roles in developmental and experience-dependent 
mechanisms in the nervous system; 2) NMP-derived peptides directly modulate ion channels 
altering calcium-mediated signaling; or 3) NMP-derived peptides signal to surounding non-
neuronal cels such as glial cels through yet to be identified receptors. Probing these possibilities, 
and others, wil likely be an important new area of investigation. Despite this immediate 
knowledge, the use of labeled NMP-derived peptides to bind to and trace activated neurons 
within a circuit wil likely have utility to neuronal circuit mapping in vivo and in vitro. While it is 
unclear how NMP-derived peptides mediate their signaling function, our data demonstrate that 
the mechanism by which they are released is through the NMP. Genetic and biochemical 
experiments to determine the receptors to which these peptides bind to and interact with wil be 
critical to elucidate the function of this mechanism. 
Many groups have demonstrated that acute and rapid inhibition of the proteasome has 
profound efects on synaptic signaling and transmission. These efects range from changes in 
transmission at the Drosophila neuromuscular synapse, regulation of activity-dependent spine 
dynamics, and an essential role in maintenance of LTP and LTD(Campbel and Holt 2001; Rineti 




2006; Keleher, Govindarajan, and Tonegawa 2004; Klein, Castilo, and Jordan 2015). We see a 
similar rapid and acute role for the NMP in mediating peptide release and in modulation of 
activity-dependent calcium signaling. Neuronal calcium signaling is tightly regulated whereby 
even smal changes in amplitude or frequency result in significant efects on nervous system 
function. Previous studies indicate that bicuculine-mediated neuronal stimulation synchronizes 
calcium transients within a neural network(Patel et al. 2015). These alterations in the dynamics of 
calcium transients have been shown to have an electrophysiological basis. While bicuculine also 
promotes proteasomal degradation, the role of the proteasome in activity-dependent calcium 
signaling has not been wel studied(Djakovic et al. 2009; Wu, Hyrc, et al. 2009). Our study is the 
first to identify a critical role for the proteasome in the form of the NMP in mediating 
Bicuculine-induced changes in calcium signaling. Our data also indicate that resting calcium 
levels are unafected by NMP inhibition, suggesting that it is only the activity-dependent aspects 
of calcium signaling that are altered with inhibition of the NMP. This is consistent with data from 
prior studies that observe no appreciable rapid efect on calcium levels with inhibition of total 
proteasomes. Taken together, neuronal stimulation drives proteasomal degradation of newly 
translated proteins through the NMP. This leads to the production of NMP-derived peptides 
which, by interacting with nearby activated neurons, promote feedforward regulation of neural 
network activity. The role and function of the NMP and NMP-derived peptides remain an open 
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